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Congenital heart disease is the most common birth defect with an estimated incidence of six 
per 1000 live born children.1 Several mechanisms may underlie congenital heart malformations, 
like: genetic mutations, maternal disease, environmental influences or combinations of these 
events. Therefore, it is not surprising that embryonic and fetal cardiovascular development 
has already been a major focus of study for years. The increasing knowledge of normal as 
well as abnormal development provides vital information for better prenatal counselling of 
parents and future (in-utero) therapeutic interventions in case of congenital heart 
malformations. 
1.1 eMBRYoNic DeVeLoPMeNT
After conception, the 2-cell staged embryo rapidly goes through subsequent developmental 
stages. Around the seventh day of development, the 150 micrometer sized embryo invades 
into the uterine epithelium. In the second week by the so-called gastrulation process the third 
germ layer of the embryo, the intraembryonic mesoderm, is formed. This process turns the 
bilaminar disk into a trilaminar embryo with three basic germ layers i.e. the ectoderm, 
endoderm and mesoderm. Each germ layer will give rise to specific structures of the embryonic 
body. The ectoderm differentiates to form the central nervous system and the epidermis. The 
endoderm provides the gastrointestinal and respiratory tract and is responsible for development 
of many endocrine glands and organs, such as the liver and pancreas. The mesoderm 
transitionally differentiates into the following four compartments known as: axial, paraxial, 
intermediate and lateral plate mesoderm. The axial mesoderm gives rise to the notochord, 
which is responsible for formation of the intervertebral disks. From the paraxial mesoderm 
the somites will give rise to the axial skeleton, skeletal musculature and the dermis. Furthermore, 
the branchial arches will develop from this compartment, which will form the facial muscle 
and cartilage. The intermediate mesoderm develops into the urogenital system comprising the 
kidneys and gonads. Finally, the lateral plate mesoderm is involved in the formation of the 
body wall, viscera and the circulatory system including the heart.2      
1.2 eARLY cARDiAc DeVeLoPMeNT
In human, the development of the heart starts around day 19 (≈mouse 7.0 days post conception 
(dpc)) in the lateral plate mesoderm region, which is divided into splanchnic and somatic 
mesoderm. This region is already characterised by the upregulation of certain genes revealing 
early cardiac specification i.e. Nkx2.5 (Drosophilas tinman)3,4 and GATA4.5 The splanchnic 




shaped heart primordium6,7 or primary heart tube with a venous and an arterial pole. In human 
at day 23 (≈mouse 8.25 dpc) the heart tube will loop to the right under influence of genes like 
Nodal,8 Lefty29 and Pitx-2c10 involved in left and right specification (Figure 1). At subsequent 
stages septation, outgrowth and remodelling of the individual heart chambers will eventually 
lead to a four-chambered mature heart. 
 
1.3 THe “BUiLDiNG BLocKs” oF THe HeART
Throughout the years extensive discussion has taken place about the exact origin of the 
cardiomyocytes of the developing heart. Around 1968 Manasek concluded that the coelomic 
epithelium was the only source of cardiomyocytes based on electron microscopy of developing 
avian hearts.11 However, in the same period others suggested that cardiomyocytes also derive 
from the mesenchyme located in the cardiac jelly and in the regions posterior to the primitive 
atrium.12 In 1973 Viragh and Challice found electron microscopic evidence that part of the 
myocardial wall of the sinus venosus originates from the loose mesenchyme of the septum 
transversum. They postulated that these mesenchymal cells aggregate along the sinus venosus 
wall and make contact with the pre-existing cardiac muscle and suggested that similar processes 
occur at the arterial pole of the heart near the truncus arteriosus.13 
Figure 1. Early cardiogenesis and formation of the heart tube. Schematic representation of the two cardiac 
mesodermal primordia located in the lateral plate mesoderm (a), which will fuse to form a straight heart tube (b) with 
a primitive arterial pole (AP) and venous pole (VP). Subsequently, this heart tube will loop in a dextral manner as 
depicted in (c). ANT indicates anterior; DL, dextral-looping; POST, posterior. Figures adapted from Gittenberger-
de Groot AC and Poelmann RE.229
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1.3.1 First and second Heart Field
In more recent years with sophisticated research techniques, several studies confirmed that 
not all cardiomyocytes have the same developmental origin. In lineage tracing studies 
individual (groups of) cells, derived from the lateral plate mesoderm could be followed during 
cardiogenesis, which has led to the concept of the so-called heart fields (Figure 2). A heart 
field can be defined as a discrete embryonic region, which contains cells that contribute to the 
formation of the heart. However discussion remains whether or not the contribution of a heart 
field should be considered as a continuum of splanchnic mesoderm. Fact is that the building 
of the heart occurs in a spatio-temporal fashion. Currently, the splanchnic mesoderm is 
established to be the first (primary) heart field, from which the cells derive that give rise to 
the so-called primary heart tube.14 Several myocardial transcription factors can already be 
detected in the primary heart field ensuring the ability of these cells to differentiate into 
cardiomyocytes.15
As from 8 dpc in mouse16 and stage HH14 in chick17,18 additional cardiomyocytes are 
incorporated to the arterial and venous pole of the primary heart tube, which are essential for 
further cardiac development. These cardiomyocytes are derived from a specific area of the 
splanchnic mesoderm known as the second heart field (SHF) or second lineage. Recent studies 
on the LIM homeodomain transcription factor Isl1 showed that Isl1 is highly expressed in 
splanchnic mesodermal cells. Lineage tracing of these Isl1 expressing cells demonstrated that 
they substantially contribute to the embryonic heart at both the arterial and venous pole, where 
after Isl1 expression is down-regulated and cardiomyocyte markers become up-regulated. 
Moreover, Isl1 mutant embryos showed severe hypoplasia and / or absence of the in- and 
outflow tract of the developing heart.19
     
1.3.2 Anterior and secondary Heart Field
Detailed studies in chick18,20 and mouse16 concerning the origin and fate of the SHF 
cardiomyocytes at the arterial pole of the heart resulted in two distinctive areas the so-called 
anterior and secondary heart field. The anterior heart field is located anterior to the primary 
heart tube in the pharyngeal mesoderm that extends into the pharyngeal arches. Cardiomyocytes 
which derive from the anterior heart field contribute to the formation of the entire outflow 
tract of the heart.16,20 The secondary heart field is located immediately adjacent and posterior 
to the outflow tract region behind the heart tube. The contribution of cells from the secondary 
heart field is only limited to the distal part of the outflow tract and partially overlaps with the 
cardiomyocytes derived from the anterior heart field (Figure 2).19 
1.3.3 The Posterior Heart Field
The SHF also contributes cardiomyocytes to the venous pole of the primary heart tube as 




SHF cardiomyocytes at the arterial pole of the heart. In this thesis the mesodermal region 
responsible for the contribution of cardiomyocytes to the venous pole of the primary heart 
tube is studied, and will be referred to as the: posterior heart field (PHF; Figure 2).
 
Figure 2. Heart fields in cardiogenesis. This schematic drawing represents the individual contribution of the heart 
fields during cardiogenesis. The first heart field gives rise to the primary heart tube and solely contains the myocardium 
that contributes to the future left ventricle (LV), atrioventricular canal (AVC) and parts of the atria. In contrast to the 
Isl-1 negative myocardium of the first heart field, the second heart field adds Isl-1 positive cardiomyocytes to the 
primary heart tube at the arterial as well as the venous pole of the developing heart. The contribution of the second 
heart field to the arterial pole is divided in two separate areas i.e. the anterior heart field, which adds cardiomyocytes 
to the right ventricle (RV) and proximal part of the outflow tract (OFT) and the secondary heart field that mainly 
contributes to the distal part of the OFT (DOT). The contribution of the second heart field to the venous pole is 
referred to as the posterior heart field. Along development the cardiac neural crest cells migrate from the neural plate 
at the arterial as well as the venous pole into the heart. CCS indicates cardiac conduction system; CV, cardinal veins; 
DAW, dorsal atrial wall; DMP, dorsal mesenchymal protrusion; ggL, cardiac ganglia; IAS, inter-atrial septum; PAA, 
pharyngeal arch arteries; PEO, pro-epicardial organ; POT, proximal part of outflow tract; PV, pulmonary vein; SAN, 
sinoatrial node. Figures adapted and expanded from Gittenberger-de Groot AC and Poelmann RE.229
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1.3.4 epicardium and epicardium Derived cells (ePDcs)
The primary heart tube initially is not covered by epicardial cells. These epicardial cells derive 
during development from a villous structure that occurs near the venous pole of the heart, the 
pro-epicardial organ (PEO; Figure 3a). Notably, the epicardium covering the arterial pole of 
the heart seems to have a distinct origin.21 In mouse embryos of 9.0 - 10.0 dpc the epicardial 
cells start to migrate from the PEO over the complete outer layer of the developing heart.22 
The adhesion and migration of the epicardial cells seems to be regulated by several factors 
including: RXRalpha,23 fibroblast growth factor (FGF),24 vascular cell adhesion molecule-1 
(VCAM-1),25 Tbx526 and alpha4 integrin.27,28  
After spreading of the epicardium, these cells migrate to the subendcoardial layer. Subsequently, 
so-called EPDCs are generated by a process known as Epithelial-to-Mesenchymal 
Transformation (EMT). EPDCs then invade into the myocardium, the subendocardial space 
and AV cushion tissue, where they contribute in formation of smooth muscle cells, the 
adventitial layer of the coronary vasculature and in the AV valves (Figure 3a and b).29 
Furthermore, a role for EPDCs has been demonstrated in development of the peripheral 
conduction system (Purkinje fibers).22,30
Thus far, there is no substantiated evidence that EPDC’s can differentiate into endothelial 
cells31 or myocardium.32,33
1.3.5 Neural crest cells
Neural crest cells (NCCs) contribute to many organs en tissues during embryonic development. 
In the early 1980 experiments by Kirby et al. demonstrated that a specific region of the dorsal 
neural tube, between the mid-otic placode and third somite (caudal rhombencephalic segment), 
provides cells to the developing heart and vessels. Initial experiments showed that these NCCs 
only contributed to the arterial pole of the heart.34,35 Later on, more elaborated cell tracing 
studies confirmed the contribution of NCCs to the arterial pole and also identified an important 
subpopulation of NCCs migrating to the developing venous pole of the heart (Figure 2).36 
At the arterial pole NCCs are involved in formation of the pharyngeal arch arteries and 
remodeling of the outflow tract i.e. formation of the aorticopulmonary septum,37 the semilunar 
valves38 and the myocardialization of the outflow tract septum.39,40 Furthermore, these cells 
contribute in the formation of the neurons and ganglia of the cardiac autonomous nerve 
system.41 At the venous pole of the heart NCCs are closely involved in development of the 
base of the atrial septum and an important role of NCCs has been postulated in the anlage of 
the cardiac conduction system (CCS).36,42,43 Eventhough, the exact role of NCCs in CCS 
development remains uncertain, the fact that almost all NCCs located near the developing 




Figure 3. The role of the epicardium and Epicardium Derived Cells (EPDCs) in cardiogenesis. (a) The epicardium 
derives from the pro-epicardial organ (PEO), a cauli-flower like structure, near the sinus venosus (SV) of the heart. 
As from 9.5 dpc in mouse, the epicardial cells start to spread from the PEO to cover the complete heart tube. 
Subsequently, epithelial-to-mesenchymal (EMT) will occur by which the EPDCs are formed. The EPDCs have an 
important role in several processes within cardiogenesis, like formation of the myocardial architecture, the coronary 
arteries and peripheral conduction system (Purkinje fibers). Furthermore, EPDCs have an imperative role in formation 
of the annulus fibrosus and atrioventricular (AV) valve apparatus as schematically depicted in (b). A indicates atrium; 
Cu, AV cushion tissue; EC, endothelial cell; Fb, fibroblast; OT, outflow tract; S, AV sulcus; SMC, smooth muscle 
cell; V, ventricle. Figure (a): adapted from Winter EM et al.31 Figure (b): adapted from Kolditz DP et al.92 
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1.4 THE CARDIAC CONDUCTION SYSTEM (CCS)
The CCS is a specialized network that initiates and closely coordinates the heart beat. Thereby, 
it facilitates an accurate controlled blood flow from the venous to the arterial pole of the heart, 
where it subsequently continues into the pulmonary and systemic circulation. The CCS can 
be divided in different parts, each of them characterized by its specific function in heart beat: 
The sinoatrial node (SAN), the AV node (AVN) and the His-Purkinje system (HPS; Figure 4). 
The SAN, located in the lateral wall of the superior caval vein where it enters the right atrium, 
is the location where the action potential is initiated by a group of spontaneously depolarizing 
pacemaker cells. From there the action potential stimulates the atrial part of the heart and 
eventually reaches to the second nodal region, the AVN. Based on its anatomical location and 
electrophysiological properties the AVN can be considered as “the guardian” of ventricular 
electrical activation. Anatomically, the half-oval shaped AVN is positioned against the central 
fibrous body in the so-called triangle of Koch. 
Figure 4. Schematic representation of the cardiac conduction system and impulse propagation through the 
mature heart. AVN indicates atrioventricular node; CS, ostium of coronary sinus; ICV, inferior caval vein; LA, left 
atrium; LBB, left bundle branch; LV, left ventricle; PV, pulmonary vein; RA, right atrium; RBB, right bundle branch; 
RV, right ventricle; SAN, sinoatrial node; SCV, superior caval vein; VS, (inter-) ventricular septum; asterisk, the 
Moderator band / trabecula septo-marginalis; Color codes: Blue lines between SAN and AVN represent the presumptive 




This virtual triangular-shaped region is bordered by three structures in the right atrium: the 
coronary sinus ostium, the tendon of Todaro and the lower side attachment of the septal leaflet 
of the tricuspid valve.44 The AVN is continuous with the bundle of His that forms the only 
myocardial continuity between the atria and ventricles. The remainder of the atria and ventricles 
are electrophysiologically separated by a layer of non-conducting fibrous tissue, the annulus 
fibrosus (1.5.1. “Annulus fibrosus: The isolating system”).45 The AVN controls the rate at 
which the action potential passes from the atria to the ventricles. In general conduction through 
the AVN is slow so that it creates a delay between atrial and ventricular systole i.e. contraction. 
In this manner it enables the atria to empty into the ventricles before the ventricular systole 
is induced. Furthermore, the AVN encloses a specific subset of cardiac ion channels, which 
enables the possibility to generate action potentials, i.e. allows it to function as the primary 
pacemaker in case of hampered SAN function,46 thus providing an “escape” rhythm (Chapter 
1.4.3-c “The Atrioventricular node”). The HPS is a specialized rapid conducting network, 
which enables a fast and simultaneous contraction of the ventricles. The HPS can be subdivided 
in several components: (1) the Bundle of His (i.e. common / AV bundle or penetrating bundle), 
which runs through the isolating annulus fibrosus in an anterior direction ending on the top 
of the interventricular septum; (2) the bundle branches i.e. the left bundle branch (LBB) and 
right bundle branch (RBB), which are connected to the bundle of His. Anatomically, these 
bundle branches run alongside the interventricular septum towards the apex of the heart, the 
RBB partially via the trabecula septo-marginalis in the right ventricle; the LBB shows a more 
fan-shaped appearance over the interventricular septum in the left ventricle. Subsequently, the 
Purkinje fibers sprout from the bundle branches, connecting to individual cardiomyocytes to 
ensure a rapid electrical activation of the ventricles.47  
1.4.1 The origin and development of the ccs
For many years the origin of the CCS has been studied. Initial debates focused on the origin 
of the cells, which contribute to the formation of this “specialized” network. Some postulated 
that the CCS had a neurogenic origin (the NCC lineage)43 whereas others suggested a 
myocardial origin.48 Lineage tracing studies however, demonstrated that the myocardium is 
the main source from which the CCS develops,48 whereas the NCCs appeared to have a more 
inductive role.42 Moreover, the cardiomyocytes of the CCS and those of the working 
myocardium (myocardium that is not part of the CCS) share the same four basic characteristics: 
1. contraction, 2. auto-rhythmicity, 3. intercellular conduction and 4. electromechanical 
coupling, which also suggests a myocardial origin of CCS cells.49 
Since it is established that the CCS is a myocardium derived structure, many researchers started 
to focus on the origin of the cardiomyocytes that contribute to formation of this system. 
In general two different approaches have been put forward: (1) “the recruitment model” puts 
forward that the CCS derives from a pool of multipotent undifferentiated cardiomyogenic 
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cells,50-52 (2) “the specification and ballooning model” suggests that a population of 
differentiated pre-specified conduction cells located in the embryonic primary heart tube will 
develop into the CCS;53 In this model the expression of specific genes / transcription factors 
in the primary heart tube myocardium prevents the differentiation of the pre-specified 
cardiomyocytes to a working myocardium phenotype. The individual heart chambers 
subsequently balloon-out of the primary heart tube,54,55 after which the myocardium of the 
primary heart tube is restricted to specific areas (i.e. the sinu-atrial region, the AV region, the 
primary fold and the outflow tract area) in between the working myocardium. These areas 
will, under the control of several transcription factors, contribute to the developing CCS.56 
Interestingly, in early years, based on strictly histological criteria, the so-called “ring theory” 
has been proposed. This theory suggested that the precursors of the CCS could be identified 
by several rings of tissue that, after looping of the heart had been initiated, could be 
distinguished from the surrounding working myocardium by specific cellular characteristics.57 
This theory has been the subject of vivid discussions in the past decades and is regarded highly 
controversial nowadays. However, it is interesting to note that after looping of the heart has 
occurred, several zones of tissue (so-called transitional zones) that overlap with the areas 
mentioned under “the specification and ballooning model” can be distinguished based on 
expression patterns of several markers involved in CCS development.58-61 Furthermore, these 
transitional zones largely correspond to the areas described in the “ring theory” including the 
sinu-atrial transition, the AV transition, the primary fold area and the ventriculo-arterial 
transitional zone (Figure 5).62  
The development of the CCS can be studied either morphologically or electrophysiologically, 
the latter will be discussed in Chapter 1.4.2 “Action potential generation and propagation 
in the developing heart.” Initial histological studies on CCS development demonstrated that 
cardiomyocytes of the CCS are characterized by reduced numbers of myofibrils and a high 
accumulation of glycogen as compared to the working myocardium in both human and 
animal.63,64 
During the years increasing numbers of CCS specific markers have become available, which 
enabled detailed morphological analysis of the developing CCS at subsequent stages of 
development: HNK-1,58 mink-LacZ,61 CCS-lacZ,59,60 cGATA-6-lacZ,65cardiac troponin 
i-lacZ,66 GATA-1, HCN467 and homeodomain transcription factors Nkx2.5,68,69 Hop,70 Id2,71 
and T-box the transcription factors: Tbx2,72 Tbx373 and Tbx5.71 The individual role and 
temporarily expression of these marker genes during CCS development has recently been 
reviewed.74 Based on the expression patterns during embryonic development of  the different 
markers known to date, the embryonic CCS seems to be more extensive as compared to the 




In this thesis the expression of the homeodomain transcription factor Shox2 (Chapter 2 and 
3) and transmembrane protein podoplanin (Chapter 4 and 5) are described and added to the 
list of CCS developmental markers. 
1.4.2 Action potential generation and propagation in the developing heart
The primary heart tube starts beating far before a specialized CCS can be recognized. At this 
stage the complete inflow tract in the tubular heart is able to generate action potentials, although 
optical mapping studies demonstrated in more detail that they mainly evoke from the dorsal 
side (initially more frequently left-sided) of the heart tube near the putative location of the 
sinus venosus.75,76 The action potential subsequently spreads anteriorly and activates the heart 
tube towards the outflow tract region. At these stages no differences in conduction velocity 
in the heart tube can be discriminated75,77,78 and action potential propagation is relatively slow 
due to poor intercellular coupling of the cardiomyocytes (Figure 6a).78
Figure 5. From primitive heart tube to a four-chambered heart including the transitional zones. (a) Represent 
the early embryonic body in which the splanchnic mesoderm is indicated along side the primitive streak, which will 
fuse to form a horseshoe-shaped heart primordium that subsequently transforms into the primitive heart tube. This 
primary heart tube depicted in (b) solely contains the myocardium of the future left ventricle (LV), AV canal and part 
of the atrium. At these stages two transitional zones can already be discriminated, at the venous pole (VP) the 
atrioventricular transitional zone (AVR) and the primary fold (PF) at the arterial pole (AP) of the heart. Subsequently, 
the heart will loop in a dextral manner, resulting in a looped heart tube as depicted in (c). Due to the addition of 
second heart field derived cardiomyocytes at the VP the atria (A) and sinus venosus area will appear, which include 
another transitional zone the sinu-atrial ring (SAR). The addition of second heart field derived cardiomyocytes at the 
AP will contribute to formation of the right ventricle (RV) that initiates from a groove in the PF. Furthermore, the 
myocardium of the outflow tract (OT) is added, which includes the ventriculo-arterial (VAR) transitional zone. 
Subsequently, by looping and septation a four chamber heart will appear in which the 4 transitional zones still can 
be recognized. Parts of these transitional zones show overlap with the mature CCS. Ao indicates aorta; AVN, 
atrioventricular node; CS, ostium of coronary sinus; ICV, inferior caval vein; LA, left atrium; PA, pulmonary artery; 
PV, pulmonary vein; SAN, sinoatrial node; SCV, superior caval vein; VS, ventricular septum. Figures adapted and 
expanded from Gittenberger-de Groot et al.62
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In the next step of heart development the primary heart tube starts to loop (Figure 6 b and c). 
At this looped stage, major changes occur in electrophysiological development. Initially, the 
entire sinus venosus myocardium has the potential to generate the action potential.79 At the 
venous pole the SAN primordium gradually can be recognized near the right horn of the sinus 
venosus, which from then on will be the leading location to evoke the cardiac action potential 
(human ≈embryonic day 35; mouse ≈10 dpc; chick ≈HH 14-17). Primitive embryonic ECG 
recordings77,78,80 as wells optical mapping studies81 showed that fast and slow conducting areas 
can be discriminated in the looped heart. The slow conducting areas are located in the inflow 
tract (IFT), the AV canal (AVC) and outflow tract of the heart (OFT) separating the fast 
conducting future chamber myocardium,78 thus mainly corresponding to the so-called 
“transitional zones” mentioned in Chapter 1.4.1 “The origin and development of the CCS.” 
The areas of fast and slow conduction also can be confirmed morphologically by the specific 
expression pattern of ion channels important for the intercellular transfer of action potentials.82-84 
The presence of slow conducting myocardium in the AVC seem to be interesting, since this 
part of the heart (between future atria and ventricles) eventually will become the AVN area 
with similar slow or delaying conduction properties. The combination of electrophysiological 
Figure 6. Development of the action potential in the embryonic and fetal heart. (a) In the primary heart tube the 
cardiac impulse is generated near the venous pole (VP) of the heart and subsequently travels towards the arterial pole 
(AP) so that the heart tube contracts in a peristaltoid manner. In the looped-heart stage (b) and (c) the impulse is 
generated in the sinoatrial node, located near the entrance of the superior cardinal vein and the right atrium, from 
where it subsequently activates the atrial myocardium (A), the atrioventricular canal (AVC), the ventricular 
myocardium (V) and outflow tract (OFT). At these stages slow conducting zones are already present near the inflow 
tract (not depicted in this figure), the AVC and OFT. Furthermore, in (c) the ventricular part of the heart is still activated 
in a base-to-apex manner. (d) Represents the ventricular activation pattern in a mature apex-to-base manner, which 
is closely related to a functional cardiac conductions system and isolation of the AV junction. LA indicates left atrium; 
LV, left ventricle; RA, right atrium; RV, right ventricle; asterisk, location of impulse initiation by the sinoatrial 




as well as morphological changes (i.e. formation of the AV-cushions) increase the pump 
efficiency of the looped heart, which results in a powerful blood flow from inflow towards 
outflow tract.
As cardiac development continues a switch in the activation pattern of the ventricles will take 
place (Figure 6d). Whereas ventricular activation initially occurs in a base-to-apex manner, 
during further development, a mature apex-to-base activation pattern arises,78,85,86 which ensures 
effective pumping of the four-chambered heart. Basically, two important processes in cardiac 
development have been related to the appearance of an apex-to-base activation of the ventricles: 
(1) the maturated and electrophysiological functional HPS,85,87-91 (2) The interruption of the 
AV myocardial continuity (except for the AV conduction axis) in the AVC region by the 
formation of the isolating annulus fibrosus (Chapter 1.5.1 “Annulus fibrosus: The isolating 
system”).86,92 93 
In the early fetal four-chambered heart, the electrophysiological properties highly resemble 
those observed in mature hearts. The action potentials arise from the SAN and subsequently 
activate the atria, the AVN and HPS leading to a ventricular apex-to-base activation pattern.  
1.4.3 individual components of the ccs
1.4.3-a  The sinoatrial node (sAN) 
The SAN, the pacemaker of the heart was first identified in 1906 by the Scottisch anatomist 
Sir Arthur Keith (1866 - 1955) and one of his students Martin Flack (1882 - 1931) in a mole 
heart. The nodal structure that they observed in the right auricle of the heart near the location 
where the vena cava enters the right atrium was called: the sino-auricular node.94
During the years, multiple studies have shown that the SAN can be recognized in human as 
from the fifth week of development.49 In mouse the first signs of the SAN primordium can be 
observed around 10.5 dpc, which was suggested to derive from an area of loose mesenchymal 
cells near the right atrium.63 The development of the SAN and role of the PHF in formation 
of this structure are the topic of Chapter 2-5 of this thesis. The anatomical “mature shape” 
of the SAN differs between several species.95-97 In human and mouse the SAN appears to be 
comma-shaped with a “head” at the border of the superior caval vein and the right atrium and 
a “tail” along the terminal crest,64,97,98 the adult derivative of the embryonic right venous valve 
that is an anatomical boundary between the right atrial appendage and the smooth walled sinus 
venosus part of the right atrium.
In the mature SAN, the myocardial cells show similar histological characteristics observed in 
the remainder of the CCS.63,64 Early observations by James et al. discriminated two types of 
cells in the SAN: (1) the “P-cells” mainly located in the center portion of the SAN, which 
were believed to be the pacemaking cells and (2) the “Transitional cells,” which can be found 
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throughout the complete SAN.99 In the more recent years sophisticated electrophysiological 
mapping techniques have become available, and in line with that increasing knowledge 
about specific ionic currents important for the understanding of action potential generation. 
The SAN as demonstrated in rabbit hearts seems to be a very heterogeneous structure.100 
Differences are seen in ion channel expression between the center and periphery of the SAN. 
In the center, the leading site to evoke action potentials, electrical coupling by gap junction 
proteins is weak (in human: Cx40 and Cx45 positive; and Cx43 negative)101 to protect this 
region from the inhibitory hyperpolarizing influences of the surrounding working (atrial) 
myocardium.102 Furthermore, a specific subset of ion currents is present to enable action 
potential generation.103,104 HCN4 (If or funny-current) a member of the Hyperpolarization-
activated cyclic nucleotide-gated channel family appeared to have a key role in action 
potential generation.105 For instance mutations in the human HCN4 gene have shown to 
result in SAN bradycardia.106 Furthermore, the funny current inhibitor Ivabradine is 
increasingly being applied in clinical practice for heart rate reduction, targeting the 
spontaneous diastolic depolarization of the SAN.107 The periphery of the SAN is characterized 
by a different subset of ionic currents and gap junction proteins.104 This region is still able 
to evoke action potentials, but also has the capability to drive the more hyperpolarized atrial 
myocardium.96
1.4.3-b The internodal pathways
Many researchers have performed detailed morpho-histological studies of the atria, in attempt 
to understand the propagation of the action potential between the two specialized nodes of the 
CCS i.e. the SAN and AVN. In the mature heart, three individual pathways were proposed, 
which after their anatomical location in the atria were called: anterior, posterior (Thorel´s 
bundle) and middle (Wenckebach´s bundle) internodal pathway. Based on the original 
description by James, the individual tracts can be identified by three important atrial myocardial 
structures, being the crista terminalis, the Eustachian valve and Bachmann’s bundle. The 
anterior pathway runs via the septum spurium into the Bachmann’s bundle, which retro-
aortically connects the right to the left atrium; the posterior pathway runs via the crista 
terminalis and the Eustachian valve; the middle pathway is a more poorly formed pathway 
and is anatomically more inconsistent (Figure 4).108-110  
In embryonic and fetal hearts marker gene expression studies also demonstrated the presence 
of internodal tracts in both human58 and animal models.59,111-113 In the developing embryo the 
3 internodal tracts correspond to: the right and left venous valves running in the dorsal wall 
of the right atrium in between the SAN and AVN, and the septum spurium the anterior fusion 
of the latter 2 valves. This suggests that the embryonic and fetal CCS is more extensive as 
compared to the mature CCS. These sinus venosus related structures may be involved in / or 




counterpart of the right venous valve can be recognized as the crista terminalis, a common 
site for atrial tachycardia.114 
The initial, assumed role of the internodal tracts in fast conduction mainly derives from 
histological observations like the arrangements of the cardiomyocytes110,115 and the suggested 
presence of Purkinje fibers.108 Nowadays the functional role of the internodal pathways is still 
open to discussion. Most agree that impulse propagation through the atria solely depends on 
cardiac tissue alignment,116 and not on specialized tracts. Furthermore, the absence of isolating 
tissue between the internodal tracts and the atrial working myocardium contradicts with the 
histological criteria, which can be used to define specialized conducting myocardial tracts in 
the heart, as were stated by Mönckeberg and Aschoff in 1910.108 However, a critical remark 
towards these criteria is that they do not apply to the atrial parts of the CCS i.e. the SAN and 
the AVN. On the other hand, in the late seventies two individual studies did show preferential 
conduction of the cardiac impulse via pathways resembling to the internodal tracts as described 
by James.108-110 In these studies, the administration of high doses of potassium in dog led to 
deprived electrical conduction in the atria except in sites corresponding with the internodal 
pathways and Bachman´s bundle.117,118 These observations are further substantiated by more 
recent studies in atrial preparations of canine hearts in which exposure to elevated potassium 
levels also resulted in preferential conduction via the internodal pathways.119  
1.4.3-c The atrioventricular node (AVN)
In 1906 Sunao Tawara (1873 – 1952) a Japanese pathologist who worked in the laboratory of 
Ludwig Aschoff (1866 – 1942; physician and pathologist) in Marburg Germany established 
the existence of an axis of histological specialized cells contained with fibrous sheaths as 
being responsible for rapid conduction from the atria to the ventricles. The AVN (also known 
as auriculoventricular node, Aschoff’s node and node of Aschoff and Tawara) made part of 
this specialize conduction system.120  During development the AVN can be identified as from 
approximately the fifth week in human (≈ 11 dpc in mouse).13,121 
Controversy still exists about the developmental origin of the AVN.122,123 The last decades 
different theories based on histological observations in multiple species have been put forward: 
(1) The AVN completely derives from the primary AV canal myocardium (first heart field);121 
124 (2) The existence of two AVN primordia located in the posterior wall in the common atrium, 
which then fuse to form the AVN primordium;58,125,126 (3) The AVN develops as left sided 
counterpart of the SAN. Subsequently, by remodeling of the sinus venous area the AVN 
becomes positioned at its mature location in the heart;127 (4) The AVN derives from a confluence 
of the sinu-atrial ring , AV ring and possibly the primary fold. By remodeling of this specialized 
ring tissue the AVN and other major parts of the CCS are formed.40,57 In contrast to this, some 
suggested that the AVN solely derives from a single ring of specialized myocytes i.e. the 
primary interventricular ring.128 
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The maturation of the AVN seems not to be completed at the time of birth, as a number of 
structural changes with regard to rearrangement of myocardium as well as fibrous tissue occurs 
in the first year of life.127,129 Persistence of a fetal phenotype of the AVN, so-called fetal 
dispersion,129 has been related to the appearance of sudden cardiac death in the young.130,131   
With regard to anatomy and electrophysiological properties the AVN is a highly complex and 
heterogeneous structure in which several myocardial regions can be discriminated: (1) The 
compact node connecting to the bundle of His; (2) The transitional zone located between the 
compact node and the atrial working myocardium, in which transitional cells are located;132-135 
(3) Nodal extension originating from the AVN running towards the vestibules of the tricuspid 
and mitral valves. In literature, these nodal extensions have been referred to as: posterior,136,137 
inferior,138,139 ostial,140 leftward and rightward141 nodal extensions. Some variances exist 
concerning the nodal extensions within and between species. In humans and rabbit hearts, the 
AVN (usually) has right sided nodal extensions, although left sided extensions can be observed 
in humans.136,141 137,142  
All separate myocardial regions within the AVN show a different expression of gap-junction 
proteins (Cx43, Cx40, Cx45 and Cx30.2/31.9)101,102,142 and ionic currents involved in action 
potential propagation and if mandatory initiation.137,138,143 Modern electrophysiological mapping 
studies144 as well as early electrode recordings46 generally agree that two different conducting 
pathways fast (α) and slow (β) into the compact node can be discriminated. These α and 
β-pathway are involved in certain type of cardiac arrhythmias i.e. AV nodal reentry tachycardia 
(AVNRT).145 There is still some debate on the exact anatomical structures, which encompass 
these α and β pathways. In immunohistochemical expression and optical mapping studies of 
the AV junction certain evidence was found that the β-pathway involves the isthmus between 
the coronary sinus and tricuspid valve. This region includes the right inferior nodal extension 
and the transitional cells located in that particular area.146,147 The α-pathway seemed to be 
located more to a superior position and encompasses the transitional cells abundantly expressing 
Cx43 like the atrial myocardium, enabling fast action potential propagation.148,149   
1.4.3-d The His-Purkinje system (HPs)
The HPS comprises the complete ventricular part of the conduction system, including the 
bundle of His, the LBB and RBB and the Purkinje system network. The bundle of His was 
first described in 1893 by Wilhelm His Jr (1863 – 1934), a Swiss born Cardiologist and 
Anatomist.150 During development the bundle of His becomes recognizable in human around 
5 to 6 weeks of development (mouse ≈ 10 dpc).121 The exact developmental process of this 
structure is still not clear just like the mechanism, which solely prevents this bundle from 
being interrupted by fibrous tissue during annulus fibrosus formation in the AV junction. 
However, several studies on CCS development describing the expression of HNK-1,151 G1N2,152 




ring) myocardium in the anlage of the bundle of His and primary bundle branches.55,59 
The ultimate part of the CCS is the Purkinje fiber network. Purkinje fibers were first described 
in a sheep heart ventricle in 1839 by Jan Evangelista Purkinje (1787 – 1869; a Czech 
physiologist and Anatomist).150 Purkinje fibers are mainly located (but not exclusively)153 in 
the ventricles where they create an extensive conduction network. Their morphology and 
location in the ventricles differs between species.154 During development Purkinje fibers 
become apparent around day 10 (HH 36) in chick in close association with coronary vessels 
and at a sub-endocardial position.155 Purkinje fiber differentiation has shown to be narrowly 
regulated by activation of endothelial localized factors (i.e. endothelin-1 and endothelin 
converting enzyme-1) through hemodynamic alterations in the developing heart.156  Furthermore, 
EPDCs have an essential role in proper differentiation of the Purkinje fibers in avian.30 With 
regard to electrophysiological properties Purkinje fibers contain a specific subset of ionic 
currents,157 which enables the capability of generating both automatic and triggered 
rhythms.158,159 
1.4.3-e The right atrioventricular ringbundle (RAVRB) and retro aortic root branch 
(RAoRB)
The RAVRB and RAoRB are not part of the mature CCS, however based on their postulated 
origin related to CCS development, expression patterns of specific CCS markers58,59,111 and 
possible involvement in certain types of arrhythmia160 they will be mentioned shortly in this 
section. In human fetuses both histological161 and marker gene expression studies58 demonstrated 
the presence of “specialized” myocardial tracts around the tricuspid orifice, the so-called 
RAVRB (see also Chapter 7). At embryonic stages these tracts were also noticed near the 
aorta i.e. the RAoRB.58 In animal hearts: avian,162 chick,163 mouse59 rat and rabbit,164 the 
complex of RAVRB and RAoRB is even more extensive and also encompasses a specialized 
tract around the mitral orifice, which will be referred to as the left AV ring bundle (i.e. LAVRB). 
With regard to the developmental origin of these structures, the RAVRB, RAoRB and the tract 
around the mitral orifice are believed to be remnants of the specialized ring tissue at the 
transitional zones in the developing heart.40,49,152 
Up till now there are no electrophysiological studies, which prove that the RAVRB, LAVRB 
and RAoRB do have a role in normal action potential conduction, although their involvement 
in certain types of arrhythmia i.e. Mahaim tachycardia is postulated.160,165 Interestingly, the 
immunohistochemical experiments in rat hearts demonstrated that the cardiomyocytes of the 
RAVRB and RAoRB show an expression pattern that is comparable to other parts of the CCS: 
Cx43 negative and HCN4 positive.138 Moreover, the HCN4 positive RAVRB and LAVRB 
seem to be continuous with the two inferior nodal extensions of the AVN as described in 
Chapter 1.4.3-c “The atrioventricular node”, which might indicate a role of these specialized 
tracts in AV conduction.138            
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Figure 7. The fibrous heart skeleton. The annulus fibrosus creates a continuum of isolating fibrous tissue between 
the atrial and ventricular myocardium (light blue in detail upper right corner) as is depicted in this frontally sectioned 
specimen of a mature human heart. Furthermore, it can be appreciated that the fibrous tissue of the annulus fibrosus 
is continuous with the atrioventricular valves (light blue in detail upper right corner), i.e. the tricuspid valves (TV) 
at the right and mitral valves (MV) at the left AV junction. AS indicates atrial septum; LA, left atrium; LV, left 




1.5 THE ANNULUS FIbROSUS AND ACCESSORY PATHWAYS (APs)
 
1.5.1 Annulus fibrosus: “The isolating system” 
In a mature heart the AV conduction axis comprises the only myocardial continuity between 
the atria and ventricles the remainder being separated by a layer of fibrous tissue at the AV 
junction i.e. the annulus fibrosus. Morphologically, this fibrous structure is in continuity with 
the fibrous tissue of the AV valves (mitral and tricuspid valves; Figure 7). Early in development, 
at the stage of the primary heart tube, the atrial and ventricular myocardium is continuous in 
the AV junction. During cardiogenesis separation of the atrial and ventricular myocardium 
occurs, which leads to electrical isolation of the atria from the ventricles. Several specific 
structures have been described to have a role in annulus fibrosus development: The atrial and 
ventricular myocardium, the AV canal myocardium, AV cushion tissue, tissue of the AV 
groove166 and recently an important role of EPDCs has been demonstrated.92,167 
Two different theories have been put forward underlying the process of annulus fibrosus 
formation. The first postulates that the annulus fibrosus completely derives from the 
invagination of AV sulcus tissue into the myocardium of the AV canal. Furthermore, this theory 
states that major parts of the AV cushions derive from this sulcus tissue.166 The second theory 
states that development of the AV junction involves the fusion of the AV sulcus tissue from 
the epicardial side with the endocardially located cushion tissue of the developing heart. In 
this theory the endocardial cushion tissue substantially contributes to formation of the AV 
valves.93,168-170 With regard to human annulus fibrosus development the study of Wessels et al. 
supports the latter theory, in which both AV sulcus and AV cushion tissue have an important 
role. This study demonstrated that formation of AV isolation starts around 7 weeks of human 
development near the antero-lateral portion of the future tricuspid valve orifice. By twelve 
weeks the complete AV junction has become isolated except for the AV conduction axis.93 
In Chapter 6 and 7 of this thesis the development of the annulus fibrosus in mouse and human 
are described, respectively. Furthermore, these chapters describe the role of periostin, which 
is able to regulate collagen-I fibrillogenesis,171 in the development of this isolating structure. 
1.5.2 Accessory pathways (APs): “substrate for arrhythmia”
The identification of the individual components of the CCS, particularly those involving the 
AV conduction axis, indirectly launched the discussion about APs. It was Stanly Kent (1863 
- 1958, British physiologist) who (wrongly) defined that the lateral myocardial connections 
through the AV groove, which he observed in a mammalian heart, were the pathways for 
normal AV conduction.172 However, this theory did not have much impact, since at the same 
time period the true AV conduction axis became well established by Tawara and His.150 
Nowadays, APs are defined as accessory bundles of cardiomyocytes, which interconnect the 
atrial and ventricular part of heart next to the AV conduction axis. These APs may either 
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conduct the action potential in an antegrade (atrium-to-ventricle) or a retrograde (ventricle-
to-atrium) manner. Furthermore, APs may form the substrate for certain types of supraventricular 
arrhythmias i.e. Wolff-Parkinson-White (WPW) syndrome and Mahaim tachycardia (Chapter 
1.6 “Cardiac arrhythmias in the young”).
Studies in both human and animal have shown that APs can be located anywhere at the AV 
junction and might be positioned endocardially or epicardially. Although it has been well 
established that abnormal development of the AV junction as observed in patients with Ebstein’s 
anomaly coincide with high numbers of APs,173,174 there is still debate on the exact origin of 
APs. Electrophysiological studies in human175,176 and animal177 demonstrated that not all APs 
share the same electrophysiological conducting properties, some APs even have decremental 
properties resembling to those of specialized CCS tissue,175 whereas others demonstrate a 
working myocardium phenotype. Moreover, morphological analysis of APs indicated that not 
all APs show the same cellular morphology.178-180  In clinical practice not all APs in patients 
suffering from AV reentry tachycardia (AVRT; Chapter 1.6 “Cardiac arrhythmias in the 
young”) react similar to anti-arrhythmic drugs.181 All these arguments may indicate that not 
all APs share a common developmental origin.    
In the late fifties it was already postulated that APs are remnants of the primary AV canal 
myocardium. Due to incomplete AV insulation i.e. annulus fibrosus development the atrial 
and ventricular myocardium are not completely separated, the myocardial substrate left in the 
AV canal composes the AP.182 Animal experiments performed in developing quail hearts 
contributed to this hypothesis. Electrophysiological recordings in embryonic and fetal quail 
heart showed presence of antegrade conducting APs in otherwise normal developing hearts.86,92 
These APs decreased in number and size at subsequent stage of development. From this was 
concluded that APs are part of the normal maturation process of the annulus fibrosus.86 
Moreover, in human two-thirds of newborns diagnosed with AVRT based on the presence of 
APs remain free of symptoms before the age of one year without invasive treatment 
strategies.183,184 This might suggest that annulus fibrosus formation and maturation is not 
finished by the time of birth and extends into the first year of life. The postnatal maturation 
of the heart also has been described for the AVN region,127 which is closely related to the 
annulus fibrosus. 
In the more recent years genetic mutations have been identified that coincide with  high 
percentage of APs. Mutations in the gene encoding the gamma2 regulatory subunit of AMP-
activated kinase (PRKAG-2) have been found in families with WPW-syndrome. Patients 
carrying this mutation suffer from ventricular pre-excitation, atrial fibrillation, conduction 
defects and cardiac hypertrophy.185,186 Mouse models with this specific mutation demonstrated 
postnatal development of APs responsible for ventricular pre-excitation.187 Another mutation 
recently related to AP etiology is in the Bone Morphogenetic Protein (BMP) receptor Alk3. 




the annulus fibrosus resulting in antegradely conducting APs.188   
APs may also be related to parts of the CCS. In rare cases APs interconnect the AVN and 
ventricular myocardium. More frequently APs are found between the fascicles and the 
ventricular myocardium, which were first reported by Mahaim (1897 – 1965; Belgian MD) 
and are therefore frequently referred to as Mahaim-fibers.189,190 Conduction via this specific 
type of APs show electrophysiological properties similar to the AVN, including automaticity.191 
Contemporary animal experiments studying CCS development by means of CCS-LacZ 
expression demonstrated a possible link between right ventricular inflow tract formation and 
atrio-fascicular tract via the trabecula septomarginalis i.e. moderator band.165
More uncommon causes of APs are intracardiac tumours i.e. rhabdomyomas (sarcomas), 
producing myocardial substrates in the AV junction that serve as AP for AVRT.192,193 Although 
this cause of an AP is rare sometimes AVRT is the initial presentation of intracardiac 
tumours.    
Up till now it is not known whether “physiological” APs, similar to those observed during 
normal avian heart development,86 can also be found in mammals including human. 
Furthermore, if APs are present during normal mammalian heart development, do they show 
a similar course at the developing annulus fibrosus? Are they electrophysiologically functional 
and do they have a relationship with the developing CCS? Answers to these questions can be 
studied in Chapter 6 and 7 of this thesis, where we for the first time describe the presence of 
APs during normal mammalian heart development. 
1.6 cARDiAc ARRHYTHMiAs iN THe YoUNG
1.6.1 Arrhythmia in the fetus
Fetal arrhythmias occur in 1-3% of all pregnancies.194-196 Prenatally detection and monitoring 
of fetal arrhythmias requires echocardiographic techniques like M-mode, pulse-wave and 
Doppler-flow measurements.197,198 Furthermore, other new techniques like fetal 
magnetocardiography (MCG) and transabdominal fetal ECG can be performed to evaluate 
fetal arrhythmias. 
In general three different types of fetal arrhythmia can be discriminated: irregular ectopic 
beats, tachycardia (heartrate >180 beats per minute (bpm)) and bradycardia (heartrate <100 
bpm).199 While arrhythmias may be well-tolerated in the fetus, at the severe end of the spectrum 
they may cause low cardiac output, fetal hydrops, and death. The presence of arrhythmia-
related hydrops is an important predictor of an adverse outcome, associated with a high risk 
of mortality.184,200  Furthermore, neurological complications can occur based on a dysfunction 
of the cerebrovascular autoregulation.201-203 
Supraventricular tachycardia (SVT) and atrial flutter (AF) are the most common causes of 
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fetal tachycardia.204 Fetal AF is characterized by a fast atrial heart rate, ranging between 300 
up to 550 bpm and is usually associated with 2:1 AV conduction, but AV conduction can range 
between 1:1 to 4:1. AF results from an intra-atrial electrical macro-reentrant circuit in the 
atrium around fixed or functional anatomical conduction barriers.196 Furthermore, fetuses with 
AF frequently appear to have APs and may also develop AVRT pre- and or post-natally.184,205 
AVRT is the most common type of SVT in the fetus and is characterized by the presence of 
electrophysiological functional APs crossing the isolating annulus fibrosus next to the AV 
conduction axis. Almost all causes of fetal and neonatal SVT are orthodromic AVRT, in which 
the action potential is conducted via the AV conduction axis and retrogradely (ventricle-to-
atrium) via the AP, creating a circus movement between the atria and ventricles. In the fetus 
and neonate antidromic AVRT are rare and characterized by antegrade (atrium-to-ventricle) 
conduction via the AP and retrograde conduction via the AV conduction axis. In fetal SVT 
cases ventricular pre-excitation (WPW-syndrome) is present in approximately 10% of postnatal 
ECG recordings, indicating that the majority of fetal SVT is caused by so-called concealed 
APs.195,206  Due to new techniques, WPW-syndrome has also been documented in the fetus. A 
number of case reports showed similar characteristics on fetal MCG recordings as observed 
in post-natal ECG recordings from WPW-syndrome patients i.e. (1) short PR-interval, (2) long 
QRS-complex duration, and (3) a delta-wave.207,208 It is postulated that (as is the case in adults) 
fetal ectopic atrial contractions (present in 1 to 2% of pregnancies) may trigger AVRT.209 Other 
rare forms of fetal tachycardia are, permanent junctional reciprocating tachycardia (PJRT), 
atrial ectopic tachycardia (AET), congenital junctional ectopic tachycardia and ventricular 
tachycardia.196 
Treatment of fetal SVT and AF includes anti-arrhythmic drug therapy, which can be 
administered either transplacentally or directly to the fetus through injections in the umbilical 
vein. Throughout the years several anti-arrhythmic drug agents have proven to be effective in 
treatment of fetal SVT and AF, including: Digoxin, Flecainide, Sotalol and Amiodarone. 
Success rates in suppression of SVT are highly variable between 32% and 100% of SVT and 
AF cases.196,210 Furthermore, there is not one single guideline for anti-arrhythmic drug therapy 
in fetal tachycardias and variances exists in treatment protocols between individual institutions. 
Later in pregnancy, after 34-35 weeks of gestation, a good alternative treatment option is 
delivery, by caesarean section, with postnatal SVT conversion i.e. anti-arrhythmic drug therapy 
or even radiofrequency ablation in exceptional cases in which drug therapy fails.      
In the fetus the majority of brady-arrhythmias are caused by an AV block (AVB).  In case of 
AVB the AV conduction axis is interrupted resulting in hampered impulse propagation to the 
ventricles. Congenital AVB can be associated with congenital structural heart malformations 
and frequently has a poor prognosis.211,212 Furthermore, AVB can be auto-immune mediated 
by maternal anti-Ro (SS-A), anti-La (SS-B),213 anti-U1 RNP214 and anti-cardiolipin215 antibodies, 




antibodies cause AVB remains unknown, although it has been suggested that an immune-
mediated necrotizing arteritis and collagen changes in the AVN region results in focal 
degeneration and fibrosus of that specific area.216,217 The auto-immune mediated AVB usually 
develops between the eighteenth and twenty-fourth week of development.218 Furthermore, 
progress of auto-immune AVB frequently occurs within days, and most of these fetuses (>95%) 
are diagnosed with established complete AVB.219 Another rare but important form of fetal 
bradycardia can occur in long QT-syndrome (LQTS) due to either functional 2:1 AVB or sinus 
bradycardia.220 Furthermore, a common and benign form of fetal bradycardia is caused by 
blocked atrial premature (ectopic) beats in bigeminy or trigeminy.196
Treatment of AVB mediated fetal brady-arrhythmia includes drug therapy or early delivery 
by cesarean section for postnatal interventions like pacemaker therapy. Prenatal steroid therapy 
focuses on improvement of fetal AVB, myocardial contractility, and fetal hydrops but its 
efficacy seems limited. Furthermore, beta sympathomimetic agents like Ritodrine and Fenoterol 
can be administered increasing fetal heart rate and myocardial contractility.196,219  
Despite treatment, the outcome of fetal AVB is poor in fetuses with hydrops, heart rates below 
55 bpm or structural heart malformations,211,212 which can be appreciated in Chapter 8 of this 
thesis that discusses the early and late outcome of severe fetal arrhythmia.
 
1.6.2 sVT in children
SVT is  the most common type of arrhythmias in children, with an estimated incidence of 1 
per 250-1000 of otherwise healthy children.221 AF and atrial fibrillation in children are attributed 
largely to structural heart disease. In the pediatric age group, ventricular tachycardia, including 
LQTS, and brady-arrhythmias i.e. sinus bradycardia and AVB are less frequently observed. A 
large retrospective review of emergency department visits showed that 55.1 per 100.000 of 
pediatric visitors (<18 years of age) presented with significant arrhythmias, of which the 
majority had SVT.222 
In children with structurally normal hearts AVRT is by far the most common mechanism of 
SVT in childhood occurring both in children with WPW-syndrome and in children with a 
concealed AP (concealed-WPW). The incidence of AVRT seems to vary within the young age 
group, which has been described in multiple studies. The first episode of SVT occurs, whether 
or not before birth, in approximately half of the cases before the age of one year.223,224 
Furthermore, incidence peaks have been observed in early childhood (6-9 years) and in 
adolescence.224,225 It seems that in infants SVT in the majority of cases resolves without invasive 
treatment before the age of one year (Chapter 8),183,184 nevertheless one third will have 
recurrences around the age of 8 years.224 In children diagnosed with SVT after the age of one 
year, spontaneous resolution only occurs in 15% of cases.223 
Another common category of SVT, AVNRT is rarely observed at fetal and neonatal stages, 
whereas postnatally the incidence gradually increases with age.  In AVNRT, tachycardia is 
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mediated by a reentry circuit, which is created by a fast (α) and a slow (β) conducting pathway 
within the AVN (Chapter 1.4.3-c “The atrioventricular node”).  
The spontaneous disappearance as well as occurrence of arrhythmias in the young might be 
related to postnatal cardiac maturation. After birth, morphological127,226 as well as 
electrophysiological227,228 changes within the heart have been described. These changes may 
create specific circumstances for cardiac arrhythmias to occur in one child or to resolve in 
another. This thesis focuses on cardiac development including that of the CCS, in relation to 
cardiac arrhythmias in fetuses and neonates.
 
1.7 AiM oF THis THesis
This thesis is separated in two parts, Part I and Part II in which normal and abnormal heart 
development are studied and related to congenital heart disease, in particular to the etiology 
of supraventricular arrhythmias. The aim of Part I is to describe the important role of the PHF 
in development of the venous pole, parts of the CCS and the epicardium of the heart. In Part 
II normal heart development, mainly with respect to anlage and maturation of the AV junction 
including the CCS and the isolating annulus fibrosus, is related to clinically observed AVRTs 
at perinatal stages of development.    
1.8 cHAPTeR oUTLiNe
Part i 
In Chapter 2 the important role of the homeobox gene Shox2 in development of the PHF 
derived sinus venosus myocardium is demonstrated, with special focus on the anlage and 
differentiation of the primary pacemaker (i.e. SAN) of the heart.  
In Chapter 3 the role of Shox2 in SAN development is further studied by means of 
electrophysiological recordings in wildtype and Shox2 mutant hearts. Furthermore, a role of 
the PHF in epicardial lineage development is substantiated by demonstrating an abrogated 
epicardial development in Shox2 mutants.    
Chapter 4 further delineates the formation of the PHF derived sinus venosus myocardium 
including major parts of the CCS by means of spatio-temporal expression of the transmembrane 
protein podoplanin.




mutants the abnormal formation of the venous pole of the heart could be linked to an abrogated 
EMT process in the coelomic epithelium from where the PHF cells presumably derive.       
  
Part ii
In Chapter 6 the development of the AV junction specifically with regard to the formation of 
the isolating annulus fibrosus is demonstrated during normal embryonic and fetal mouse heart 
development. Furthermore, the presence, location and course of functional APs crossing the 
annulus fibrosus is demonstrated at subsequent developmental stages.   
Chapter 7 shows the presence and course of APs in otherwise normal developing human 
embryonic, fetal and neonatal hearts. The presence of the APs were related to clinically 
observed perinatal AVRTs that in majority of cases are self-limiting before the age of one 
year. 
Chapter 8 retrospectively evaluates the perinatal management, outcome and long-term cardiac 
follow-up in severe case of fetal brady- and tachyarrhythmias.
In the general discussion, Chapter 9 the results of Part I and Part II of this thesis are 
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The identification of molecular pathways regulating the development of pacemaking and 
coordinated heartbeat is crucial for a comprehensive mechanistic understanding of arrhythmia 
related diseases. Elucidation of these pathways has mainly been complicated by an insufficient 
definition of the developmental structures involved in these processes and the unavailability 
of animal models specifically targeting the relevant tissues. We here report on a highly restricted 
expression pattern of the homeodomain transcription factor Shox2 in the sinus venosus 
myocardium, including the sinoatrial nodal region and the venous valves.
Methods and Results
To investigate its function in vivo, we have generated mouse lines carrying a targeted mutation 
of the Shox2 gene. While heterozygous animals did not exhibit obvious defects, homozygosity 
of the targeted allele led to embryonic lethality at 11.5 to 13.5 dpc. Shox2-/- embryos exhibited 
severe hypoplasia of the sinus venosus myocardium in the posterior heart field including the 
sinoatrial nodal region and venous valves. We furthermore demonstrate aberrant expression 
of Connexin40 and Connexin43 and the transcription factor Nkx2.5 in vivo specifically within 
the sinoatrial nodal region, and show that Shox2 deficiency interferes with pacemaking function 
in Zebrafish embryos. 
conclusion
From these results, we postulate a critical function of Shox2 in the recruitment of sinus venosus 
myocardium comprising the sinoatrial nodal region.    
 
iNTRoDUcTioN
Shox2 encodes a member of a small subfamily of paired-related homeodomain transcription 
factors1,2 that has been identified by virtue of its sequence similarity to the short stature 
homeobox gene SHOX3 causing various short stature syndromes. Human phenotypes caused 
by SHOX2 deficiency have not been identified so far. According to the complex embryonic 
expression pattern of Shox2, it has initially been implicated in craniofacial, limb, brain and 
heart development.1,2 This assumption has recently been confirmed by analyses of 
independently generated knockout mouse models that revealed crucial functions of Shox2 
in palate formation4 and chondrocyte maturation during bone development.5 In the current 
study we describe the expression of Shox2 and its crucial role in the developing venous pole 
of the embryonic mouse heart.
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The development of the vertebrate heart comprises multiple cell fate decisions that are 
necessary to create the diverse cell types required for an integrated function of the mature 
organ. Recently, new insights have shown that during cardiac development new myocardium 
is added at the arterial as well as the venous pole of the primary heart tube. The venous pole 
of the heart, also known as sinus venosus, is the location where blood drains into the heart. It 
is suggested that the sinus venosus myocardium in which the sinus venosus is incorporated 
predominantly derives from a second lineage of cardiomyocytes.6 We refer to this population, 
in contrast to the anterior heart field at the arterial pole, as the posterior heart field (PHF).7 
The sinus venosus myocardium compromises at the borderline of the right cardinal vein and 
the right atrium a sinoatrial nodal (SAN) region that can be both morphologically and 
immunohistochemically defined.8 
Nkx2.5 is an early precardiac marker and we have investigated its expression in the development 
of the PHF. Nkx2.5, the vertebrate homolog of the Drosophila tinman,9-11 encodes a 
homeodomain transcription factor, that amongst other functions is essential for normal 
development of the cardiac conduction system (CCS). Patients diagnosed with Nkx2.5 
haploinsufficiences exhibit several progressive heart defects including atrial and ventricular 
septal defects as well as atrioventricular conduction system abnormalities.12-16        
To substantiate our hypothesis that Shox2 has an essential role in heart development, we have 
established the detailed expression pattern within the developing heart, examined the effects 
of Shox2 depletion in Zebrafish embryos and generated mouse lines carrying a targeted 
mutation of Shox2. Furthermore, atrial myosin light chain (MLC-2a), Nkx2.5, Connexin40 
(Cx40) and Connexin43 (Cx43)17 were used to investigate the differentiation and possible 
aberrant formation of the PHF derived sinus venosus myocardium compromising the SAN 
region of Shox2-/- embryos. The results were evaluated with 3D reconstruction techniques. 
MATeRiAL AND MeTHoDs
All animal experiments were conducted according to German animal protection laws and 
approved by the regional board of Baden Württemberg (permission no. 35-9185.81/G-64/05). 
A short summary of the techniques is provided, which is supported by the expanded Material 
and Methods section for routine procedures.
We generated chimeras and mutant mice by a replacement of the targeting vector aiming at 
the Shox2 locus. Genomic DNA was prepared from tail biopsies and yolk sac as previously 
described.18 The details for construction of the targeting vector and the primer design of both 
DNA and RNA are provided in the expanded Material and Methods section.
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Whole mount and sectioned mouse embryos (9.5 dpc n=10; 10.5 dpc n=2; 11.5 dpc n=3; 12.5 
dpc n=2; 13.5 dpc n=1) were studied by in situ hybridization (ISH) using previously described 
protocols,19 and sections were subjected to immunohistochemistry using antibodies against 
MLC-2a and Nkx2.5 as well as markers for the developing CCS: Cx40 and Cx43. The standard 
procedures for immunohistochemistry are provided in the expanded Material and Methods 
section. For 3D visualisation we generated reconstructions of the developing sinus venosus 
area using AMIRA software.
To establish a possible hypoplastic development of the SAN region we performed volume 
measurements of this region in wildtype (n=3) and Shox2-/- (n=3) embryos of 11.5 dpc according 
to the Cavalieri method.20 Statistical analysis was performed with an independent samples 
t-test (P<0.05), using the SPSS 11.0 software program.
For Zebrafish studies we isolated the full-length Zebrafish Shox2 cDNA sequence, which was 
followed by whole-mount RNA ISH as previously described21 and are elaborated in the 
expanded Material and Methods section.
To compare the heart rate in age matched resting conscious animals, electrocardiograms were 
recorded using a custom made mouse jacket and silver electrode clips attached to the paws 
(Föhr Medical Instruments, Germany). Electrocardiograms were recorded on a Schwarzer 
Cardioscript (Schwarzer-Picker, Germany). 
The Authors had full access to and take responsibility for the integrity of the data. All authors 




Shox2 expression during heart development 
An initial insight into the possible functions of Shox2 during heart development was derived 
from expression analyses by antisense ISH on wildtype whole mount embryos, isolated 
embryonic hearts and serial sections. These analyses revealed Shox2 transcripts as early as 
8.5 dpc in the posterior region of the primitive heart tube. At 9.5 dpc, Shox2 expression was 
restricted to the inflow tract (Figure 1a), particularly to the mesenchyme of the transitional 
zone between the sinus venosus and the common atrium (Figure 1b), where the sinus venosus 
myocardium is formed. While the atrial and ventricular myocardium itself were negative 
for Shox2 expression at 10.5 dpc, both leaflets of the sinus venosus myocardium derived 
venous valves showed strong expression of Shox2 at this stage (Figure 1c). At 11.5 dpc 
Shox2 expression had expanded and now included the SAN region, as well as the venous 
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valves, two parallel bundles spanning the longitudinal axis of the atria (Figure 1d, e). These 
structures have previously been demonstrated to constitute an integral part of the developing 
conduction system by analyses of lacZ expression in the CCS-LacZ mouse.22,23 In addition, 
we observed a distinct staining in the upper ventricular region, which resembled the 
ventricular expression of CCS-LacZ and the primitive stages of left and right bundle branch 
formation (Figure 1d, e). This pattern of expression observed at 11.5 dpc was retained at 
later stages up to 13.5 dpc.       
Figure 1. Shox2 expression is highly restricted within the developing heart. Whole mount in situ hybridization 
on 9.5 dpc embryos shows that Shox2 expression in the developing heart is restricted to the posterior region (a). 
Expression is confined to the myocardium of the transitional zone where the sinus venosus (SV) connects to the 
common atrium at 9.5 dpc (white arrowhead in b) and the venous valves that originate from this myocardium at 
10.5 dpc (black arrowhead in c) as shown by in situ hybridization on serial sections. Whole mount analyses on 
hearts isolated at 11.5 dpc (d and e) reveal specific expression in the sinoatrial nodal region, including the venous 
valves, two bundles spanning the atria along their longitudinal axes (red arrowheads in d and e). At this stage, 
positive staining can also be detected in the primitive left and right bundle branches of the cardiac conduction system. 
A indicates atrium; V, ventricle; LA, left atrium; RA, right atrium; LV, left ventricle; RV, right ventricle. 
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The homozygous loss of Shox2 functions is lethal 
To investigate the functions of Shox2 in vivo, we have inactivated its mouse equivalent by 
gene targeting. Targeted mutation of Shox2 was performed in a classical homologous 
recombination approach using the replacement vector depicted in Figure 2a. In the targeted 
locus a PGK-neo cassette replaces 2282 bp of genomic DNA including the entire second exon 
of the Shox2 gene that encodes the majority of the homeodomain. This strategy allows 
concomitant disruption of both Shox2 isoforms, Shox2a and Shox2b, that have been described 
so far.1,2 While expression from the Shox2a promoter produces a compromised mRNA missing 
the major part of the homeodomain, utilization of the Shox2b promoter results in a non-coding 
mRNA missing the Shox2b ATG start codon. The resulting locus is therefore likely to represent 
a null allele. Targeted alleles were generated in two different ES cell lines (RI and E14), their 
presence confirmed by Southern-blot analyses and germ line transmission verified by PCR 
analysis of chimera offspring (Figure 2b, c). Furthermore, RT-PCR analysis using total RNA 
Figure 2. Targeted disruption of the Shox2 locus and morphological heart defects in Shox2-/- embryos. The 
structure of the Shox2 gene locus, the replacement vector and the targeted allele are depicted in (a). Black boxes 
represent the exons of the Shox2 gene. Positions of relevant restriction sites are given on top and the 5’ and 3’ homology 
regions for homologous recombination are denoted by dashed lines. Shox2a and Shox2b represent different isoforms 
generated by alternative transcriptional initiation and splicing. Shox2a comprises exons 1-6 while Shox2b is encoded 
by exons 2, 3, 4 and 6. Exon numbers are indicated. The predicted positions of the Shox2a and Shox2b promoters 
and the direction of neor transcription are indicated by arrows. Southern-blot analysis of EcoRI digested genomic 
DNA from parental and targeted embryonic stem (ES) cells (b). The 5’ probe (black bar in a) detects 15 kb and 9 kb 
fragments in wildtype and targeted DNA, respectively. ES, parental ES cell line; RI and E14 respective targeted ES 
cell clones. PCR analysis of yolk sac DNA isolated from 9.5 dpc embryos (c). The products correspond to wildtype 
and targeted alleles, respectively and genotyped embryos were phenotypically normal at this stage. RT-PCR results 
performed with primers flanking the alternatively spliced exon 5 and RNA from 10.5 dpc hearts reveals that both 
isoforms are affected in targeted embryos (d). Compared to wildtype embryos of 12.5 dpc (e), Shox2-/- embryos of 
similar age (f) show a severely hemorrhagic phenotype. Furthermore, pericardial oedema are frequently observed in 
homozygous Shox2-/- embryos of 11.5 dpc (h), compared to wildtype embryos (g). This suggests cardiovascular failure 
as the principle cause of death. R indicates EcoRI; B, BamHI; K, KpnI; AN, animals; EM, embryos; +/+, wildtype; 
+/-, heterozygous; -/-, homozygous. 
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from 10.5 dpc hearts revealed that both described isoforms, Shox2a and Shox2b, are affected 
in heterozygous embryos and could not be detected in homozygous embryos (Figure 2d).
Heterozygous mouse lines were bred into and maintained on both, C57BL/6 and CD1 
backgrounds. In both genetic backgrounds heterozygous animals were fertile, had 
comparable bodyweight and did not exhibit any obvious abnormalities. Furthermore, 
genotype analysis of 276 animals from three generations revealed frequencies of 51.8% 
and 48.2% for the Shox2+/+ and Shox2+/- alleles respectively (Table 1). We therefore 
concluded that Shox2+/- animals do not carry any gross abnormalities affecting overall 
integrity and body growth. Assessment of resting heart rates by ECG recordings 
furthermore revealed that there was no difference between wildtype and heterozygous 
animals. We observed some PR variability but no differences between the groups as for 
PQ-intervals, QRS duration or QT-intervals (Figure 3). 
While Shox2+/- animals did not exhibit any obvious phenotype, heterozygote inter-crosses 
yielded 38% Shox2+/+ and 62% Shox2+/- animals but no Shox2-/- offspring (n=87) although 
Shox2-/- embryos dissected at 9.5 dpc were viable and did not exhibit any obvious abnormalities. 
However, analyses of embryos at different developmental stages revealed that homozygous 
mutants died between 11.5 and 13.5 dpc. A normal Mendelian frequency for Shox2-/- embryos 
was observed up to 10.5 dpc (29%). At 12.5 dpc this frequency dropped to 13% with all Shox2-/- 
embryos exhibiting distinctive phenotypical features and at 14.5 dpc, only two homozygous 
embryos could be recovered (4.3%), both of which were dead at the time of dissection. 
This embryonic lethality, combined with the highly restricted Shox2 expression in the 
developing heart, suggested a heart defect as the most likely cause of death.
Table 1. Frequencies of heterozygous animals observed in mouse lines generated from two independently 
targeted embryonic stem cell clones.
E14 derived mouse line RI derived mouse line
Animals Shox2+/+ Shox2+/- Animals Shox2+/+ Shox2+/-
F2 (n=79) 48 (61%) 31 (39%) F2 (n=32) 14 (44%) 18 (56%)
F3 (n=34) 18 (53%) 16 (47%) F3 (n=52) 21 (41%) 31 (59%)
F4 (n=27) 11 (41%) 16 (59%) F4 (n=52) 31 (59%) 21 (41%)
total (n=140) 77 (55%) 65 (45%) total (n=136) 66 (49%) 70 (51%) 
Genotype frequencies were calculated for 276 animals from three generations. Both mouse lines are comparable and 
exhibit the expected Shox2-/+ frequencies.
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Shox2 deficient embryos exhibit heart defects
Consistent with the observed Shox2 expression in the developing heart, we observed several 
signs of cardiovascular failure in homozygous Shox2-/- embryos compared to wildtype 
embryos of similar age (Figure 2e-h). These included pericardial oedema (Figure 2g, h) and 
massive externally visible blood vessels throughout the embryo (Figure 2f). 
Immunohistochemical staining analyses with the MLC-2a, Nkx2.5, Cx40 and Cx43 specific 
antibodies were performed to reveal specific differences between wildtype and Shox2-/- 
embryonic hearts from 9.5 to 11.5 dpc. 
Figure 3. Except for some PR variability, the ECG recordings did not reveal any obvious differences between 
wildtype (a) and heterozygous animals (b) and resting heart rates of wildtype (c) and heterozygous knockout 
mice (d). Graphic representation of mean values calculated from six independent measurements of each genotype 
reveals identical heart rates between wildtype and heterozygous animals at a highly significant level (e). SEM indicates 
standard error of means; SD, standard deviation.
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At this stage, the shape of the primary heart tube was still clearly discernible and the looping 
process of the heart was not completed yet (data not shown).        
10.5 dpc
The embryonic heart clearly showed the common atrium and primitive left and right ventricle 
(Figure 4a,c). The atrial myocardium showed strong expression of MLC-2a, while the 
expression of MLC-2a in the ventricles was less strong (Figure 4c). Expression of Nkx2.5 
was observed both in the common atrium and primitive ventricles. The developing venous 
valves were positive for MLC-2a and Nkx2.5 (data not shown).  
The sinus venosus, was located caudo-dorsally to the common atrium and formed the inflow 
tract of the heart. At this stage two large vessels drain into the left and right horn of the sinus 
venosus, called the left and right common cardinal vein respectively. The pulmonary vein, 
which drains into the common atria, was clearly discernible but not enclosed by myocardium 
yet (Figure 4a). 
Figure 4. Three dimensional reconstructions of MLC-2a and Nkx2.5 expression patterns of a dorsal view of a 
wildtype (WT) and a Shox2-/- embryonic heart of 10.5 dpc. The MLC-2a and Nkx2.5 positive myocardium of the 
common atrium (CA) and primitive left and right ventricle (PLV and PRV) are indicated in brown and grey 
respectively (a, b). At this stage the pulmonary vein (pink) is not enclosed by myocardium yet (grey). The CA of the 
Shox2-/- embryo appeared to be slightly enlarged (compare a and b). The MLC-2a positive and Nkx2.5 negative sinus 
venosus myocardium in which the sinus venosus (blue transparent) is incorporated is indicated in lime green (a,b). 
The size of the sinoatrial node region (black arrow in a and b; asterisk in d and e, which are enlargements of boxes 
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A U-shaped band of myocardium, which formed the wall of the sinus venosus adjacent to 
the atrial myocardium was positive for MLC-2a and showed negative Nkx2.5 expression. 
This comprises the SAN region, which is located in the medial wall of the right cardinal 
vein (Figure 4a).
11.5 dpc
The embryonic heart showed further maturation, the septation of the atria and the ventricles 
was still not completed at this stage. The future left and right atria as well as the future left 
and right ventricle were clearly discernible. Both, the atrial and ventricular myocardium were 
positive for MLC-2a, and also showed expression of Nkx2.5 (Figure 5c, g). The more developed 
venous valves were positive for MLC-2a and also showed expression of Nkx2.5 (Figure 5c, 
i). Compared to earlier stages, the intensity of the expression of MLC-2a and Nkx2.5 appeared 
to be stronger at 11.5 dpc. The sinus venosus myocardium was positive for MLC-2a but 
negative for Nkx2.5 (Figure 5m, n) and Cx40 and Cx43 (Figure 6a, c, e).
A 3D reconstruction of the embryonic heart showed that the MLC-2a positive and Nkx2.5 
negative sinus venosus myocardium, formed a U-shaped structure, which is situated caudo-
dorsally to the atria (Figure 5a, m, n). In addition, the pulmonary vein showed further 
maturation nevertheless it was not enclosed by myocardium yet (Figure 5a). 
Figure 5. Shox2 deficient mice exhibit a different expression pattern of Nkx2.5 in the myocardium of the 
developing sinus venosus (SV) including the sinoatrial node (SAN) region. The three dimensional reconstructions 
show the dorsal view of a wildtype (WT) (a) and a Shox2-/- (b) embryonic heart of 11.5 dpc, in which the MLC-2a 
and Nkx2.5 positive myocardium of the atria and ventricles are indicated in brown and grey respectively (a, b). The 
MLC-2a positive myocardium of the SV is indicated in lime green where there is Nkx2.5 negativity (a, b) and black 
where Nkx2.5 is aberrantly positive (b). The blue arrow in (a) indicates the region of the SAN in a WT embryo and 
the red arrow in (b) indicates the same region in a Shox2-/- embryo. Immunohistochemical analysis demonstrates 
that the SAN region both in WT (d detail of box in c) and Shox2-/- hearts (e detail of box in f) is positive for MLC-2a. 
(g) Section of a WT heart in which the box indicates the region of the SAN, which is negative for Nkx2.5 (h 
enlargement of box in g). In WT hearts, the venous valves (arrow in i, enlargement of dotted box in g) are positive 
for Nkx2.5. Remarkably, in Shox2-/- embryos the hypoplastic SAN region (j enlargement of box in l) is positive for 
Nkx2.5. Furthermore, the Nkx2.5 positive venous valves in Shox2-/- embryos appeared to be severely hypoplastic 
(arrow heads in k, enlargement of dotted box in l). In WT embryonic hearts, the MLC-2a positive myocardium in 
which the SV is incorporated (m) is negative for Nkx2.5 (n). Conversely, in Shox2-/- embryos this specific myocardium 
is both positive for MLC-2a (o) and Nkx2.5 (p). LA indicates left atrium; RA, right atrium; LV, left ventricle; RV, 
right ventricle; in the 3D reconstruction: light grey indicates region negative for myocardium surrounding the 






Compared to wildtype hearts of similar age, the region of the common atrium seemed to be 
slightly enlarged. Besides this atrial enlargement, no major abnormalities were observed (data 
not shown). 
10.5 dpc
By comparing 3D reconstructions of wildtype and Shox2-/- embryonic hearts, the morphology 
appeared comparable with only the exception of a slightly dilated common atrium (compare 
Figure 4a and b). As in wildtype embryos, MLC-2a expression was found in the common 
atrium and primitive left and right ventricle, with strongest expression in atrial myocardium 
(Figure 4f). In addition, the atrial and ventricular myocardium showed expression of Nkx2.5. 
The sections showed that the venous valves in Shox2-/- embryos were hypoplastic, which were 
still MLC-2a positive and also showed expression of Nkx2.5. 
Figure 6. Compared to wildtype (WT), the sinoatrial node (SAN) region of Shox2-/- embryos showed an aberrant 
expression of Cx40 and Cx43 at 11.5 dpc. The SAN region (asterisk in a-f) including the artery for that region 
(black arrow in a and b) located in de medial wall of the right cardinal vein (RCV) is both in WT (a) and Shox2-/- (b) 
embryos positive for MLC-2a. (c, d) Sections stained with the Cx40 specific antibody, show that the SAN region in 
WT hearts is negative for Cx40 (c) and in Shox2-/- hearts positive (d). (e, f) Sections stained with the Cx43 specific 
antibody show that the SAN region in WT hearts is negative for Cx43 (e) and in Shox2-/- hearts moderately positive 
(f). RA indicates right atrium. Scale bars = 30μm. 
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The MLC-2a positive and Nkx2.5 negative myocardium lining the the sinus venosus and the 
cardinal veins did not differ essentially from that seen in the wildtype embryo. The SAN region 
was also MLC-2a positive but Nkx2.5 negative and did not show any malformations in 
development (Figure  4b, e, f). 
11.5 dpc
3D reconstructions of Shox2-/- embryonic hearts showed that the morphology of these hearts 
was altered dramatically. Compared to wildtype hearts, the left and right ventricles were 
markedly dislocated in Shox2-/- embryos (compare Figure 5a and b). The atria were severely 
dilated and the myocardial wall of the atria seemed to be much thinner. The atrial and 
ventricular myocardium was positive for MLC-2a (Figure 5f) and also showed expression of 
Nkx2.5 (Figure 5l). Here also, the atria showed the strongest expression of MLC-2a. The 
venous valves were severely hypoplastic and in some embryos even completely absent. 
Remnants of these valves were positive for MLC-2a and Nkx2.5 (Figure 5f, k). 
 
In Shox2-/- embryos the myocardium of the sinus venosus appeared less well developed. At a 
few locations where myocardium was lining the sinus venosus the myocardium was positive 
for MLC-2a and also showed expression of Nkx2.5 (Figure 5o, p). Interestingly, compared to 
wildtype embryos not only the size of the SAN region was markedly decreased (P=0.018, 
Power of 81.9%; compare Figure 5d and e) but this hypoplastic SAN region in contrast to 
wildtype embryos was positive for Nkx2.5 (Figure 5j). In addition, an aberrant expression of 
connexins was observed in the myocardium of the SAN region, which turned out to be positive 
for Cx40 (Figure 6d) and moderately positive for Cx43 (Figure 6f). 
Figure 7. Alignment of Danio rerio and Mus musculus Shox2a Amino acid. The overall identity and similarity of 
the longest Shox2 isoform (Shox2a) between the two species is 76% and 82% respectively. The differences in both 




3D reconstructions furthermore revealed that the U-shaped MLC-2a positive and Nkx2.5 
negative myocardial structure was almost absent (Figure 5b). 
Shox2 antisense morpholino injected Zebrafish embryos develop severe sinus 
bradycardia  
Since the loss of Shox2 functions directly affects the developing sinus venosus myocardium, 
which includes the SAN region, we addressed the possibility that a loss of Shox2 functions 
may lead to pacemaking and conduction deficiencies using an antisense morpholino based 
approach in Zebrafish embryos. The Zebrafish Shox2 gene encodes a protein that exhibits a 
similarity of 82% to the mouse protein (Figure 7) and expression of the Zebrafish Shox2 gene 
mirrors expression in human and mouse in the central and peripheral nervous system, the 
pectoral fin buds and the inflow tract of the heart (data not shown). Injection of morpholino-
modified antisense oligonucleotides specifically targeting the exon 3 splice site of Shox2 
(Figure 8) into early embryos led to severe cardiac dysfunction, with a pronounced sinus 
bradycardia (70±15 versus 165±25 beats per minute) and intermittent sinus exit block after 
72 hours of development, when the embryo is still able to survive on passive diffusion of 
oxygen and nutrients (see online movie 1 and 2*). Identical results were obtained with a 
morpholino-oligo targeting the ATG start codon. 
Figure 8. Specificity of injected anti-Shox2 morpholino. The injection of MO-zshox2, targeting the splice donor 
site of intron 3 results in an abnormal splice product (skipping of exon 3), leading to premature termination of 
translation.
*Online video material 1 and 2. Compared to the wildtype (movie 1), Shox2 deficient Zebrafish embryos exhibit 
severe sinus bradycardia and intermittent sinus exit blocks 72 hours post fertilization (movie 2). 
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DiscUssioN
In the present study we have investigated the expression pattern of Shox2 during cardiogenesis 
and its crucial function in sinus venosus myocardial development. Shox2 belongs to a small 
subfamily of homeodomain transcription factors and has previously been suggested to play a 
role in early heart development.1 Reevaluation of the embryonic expression pattern showed 
that the initial description of Shox2 expression in the outflow tract region of the developing 
heart could not be confirmed.1 The detailed analyses presented here, clearly demonstrates that 
Shox2 is expressed in the myocardium surrounding the developing sinus venosus as well as 
in a myocardial band on top of the ventricular septum. This sinus venosus myocardium is 
added to the venous pole of the heart and is recruited after formation of the primary heart 
tube.6 We will refer to the sinus venosus area as the PHF located at both, the right and left side 
of the developing atrium.7 For this study we concentrated on the right sided Shox2 expression 
that is prominent in the sinus venosus myocardium compromising the developing SAN region 
and the venous valves within the right atrium.
To elucidate the predicted functions of Shox2 in sinus venosus myocardium development, we 
have generated mice carrying a targeted mutation of the Shox2 gene and observed embryonic 
lethality in Shox2-/- embryos at 11.5 to 13.5 dpc due to cardiovascular failure. We have shown 
that there is a functional relationship between Shox2 and the formation of the myocardium of 
the PHF being evident from the observation that the PHF myocardial areas that normally 
express Shox2 are severely hypoplastic in Shox2-/- embryos. This leads to diminished 
myocardium surrounding the cardinal veins and a marked hypoplasia of the venous valves 
and the SAN region. As it is not known exactly where and to what degree the sinus venosus 
myocardium is incorporated in normal atrial development, it is possible that the observed thin 
dilated atrial wall is also a result of the insufficient recruitment of sinus venosus myocardium, 
or improper replication and differentiation of the existing or newly added myocardium. 
Alternatively, it can also be explained by ultimately failing heart functions. The latter could 
be attributed to a deficient function of the hypoplastic and abnormally differentiated SAN 
region.
Identification of regulatory pathways involved in CCS formation has been impeded mainly 
due to an insufficient definition of the developmental origin of structures involved in these 
processes and the unavailability of animal models specifically targeting these structures. The 
transition from descriptive to molecular analyses of CCS development has recently gained 
momentum with the generation of minK-lacZ and CCS-lacZ transgenic mice.22-24 Interestingly, 
the specific pattern of expression observed for Shox2 strongly correlates with the lacZ 
expression in the SAN region and venous valves in these transgenic animals. Shox2 therefore 
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represents an example of a homeodomain transcription factor with an expression pattern that 
overlaps with part of the developing CCS.
It is therefore appealing to not only show a role for Shox2 in the formation of the PHF 
myocardium but to also postulate a function in the differentiation of the SAN region, the future 
pacemaking area. We were able to verify this hypothesis by analysing the physiological effects 
of a specific downregulation of Shox2 expression by antisense morpholino injections into 
Zebrafish embryos. Indeed, anti-Shox2 injected embryos exhibited severe bradycardia and 
intermitted sinus exit blocks suggesting severe sinus arrhythmia and / or pacemaking system 
malfunction as the primary cause of death in Shox2 deficient animals.          
To gain more insight into the cellular and molecular mechanisms underlying the proposed 
Shox2 related SAN region malfunction, we have investigated the expression of Nkx2.5, Cx40 
and Cx43 in this area in wildtype and knockout embryos. In our model we confirm that Nkx2.5 
expression is absent in the cardiomyocytes of the normal developing SAN region7,25 that are 
destined to acquire pacemaking properties.  It can be postulated that the aberrant Nkx2.5 
positivity in the SAN region of the Shox2 knockout mouse interferes with its normal 
pacemaking function. This result is supported by recent data showing that transgenic mice 
ectopically expressing Nkx2.5 under the control of an α-MHC promoter present sinus 
bradycardia and prolonged PR-intervals.26 It seems tempting to postulate that the molecular 
pathway underlying the observed sinus bradycardia in our Zebrafish is identical in Shox2-/- and 
α-MHC-Nkx2.5 transgenic animals. It can furthermore be presumed that this mechanism acts 
in a stringent regional manner, since Nkx2.5 driven pathways have recently been shown 
indispensable for maturation and maintenance of other conduction system components 
including atrioventricular nodal cardiomyocyte lineage specification.27 The aberrant 
spatiotemporal Nkx2.5 regulation in Shox2-/- embryos was observed only within the hypoplastic 
SAN region but not within other regions exhibiting high levels of Shox2 expression, including 
the venous valves that in normal development do not show a lack of Nkx2.5 expression. Also, 
Nkx2.5 expression is present in the myocardium of the atrioventricular conduction system in 
both, normal and Shox2-/- embryos. Interestingly, this phenomenon also sheds light on the 
observation that patients diagnosed with Nkx2.5 haploinsufficiences exhibit atrioventricular 
but no SAN dysfunction.12-16 With our model, we can for the first time sufficiently explain 
both aspects of this phenotype. While the absent or abrogated Nkx2.5 expression explains 
atrioventricular conduction problems, these patients may not exhibit SAN disease because the 
developing SAN region is not primarily hampered as this area normally does not express 
Nkx2.5. 
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Cx40 and Cx43 have mainly been used for the characterisation of the adult SAN but also have 
value as markers for earlier differentiation stages.17 We have shown aberrant expression of 
these markers in the mutant SAN region. As Nkx2.5 has been reported to be involved in the 
regulation of connexins,9,28,29 the aberrant expression of Nkx2.5 might be linked to the abnormal 
expression patterns of Cx40 and Cx43 and thus explain a postulated disturbed pacemaking 
function in Shox2-/- embryos.
It is not clear at this stage if Nkx2.5 expression is directly regulated by Shox2 in the SAN 
region or if this is a downstream event within a more elaborate pathway. It is evident however 
that a complete understanding of the molecular mechanisms underlying the observed Nkx2.5 
regulation requires the identification of additional regulatory molecules specifically expressed 
within the SAN region and investigation of their potential to interact with and modulate the 
functional properties of Shox2. 
In summary, our data demonstrated the essential role of Shox2 in the developing embryonic 
heart. We have shown that Shox2 is necessary for the normal anlage of the PHF myocardium, 
which is uniquely Nkx2.5 negative. Furthermore, we have established a functional link between 
Shox2 and the expression of Nkx2.5 that itself was shown to play an important role in the 
development and maturation of the SAN region. This observation provides a working 
hypothesis to further investigate the recruitment of sinus venosus myocardium and the 
molecular pathways underlying critical cell fate decisions that are required for pacemaking 
differentiation.       
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We have shown that in early cardiac development the venous pole of the heart is subjected to 
extensive remodeling. Recruitment of second heart field sinus venosus myocardium is seen. 
This myocardium forms a U-shaped band lining the base of the left and right cardinal vein 
through the area of the dorsal mesocardium. This sinus venosus myocardium is unique in that 
it does not express the precardial marker Nkx2.5. Pacemaking activity is already functional in 
the sinus venosus myocardium during development and is restricted in adult life to the sinoatrial 
node. Shox2, a homeobox gene highly homologous to SHOX, which is involved in short stature 
syndrome in humans, is a novel marker for the sinus venosus myocardium. To unravel the 
role of Shox2 in heart development, Shox2 knockout mice were made. These mice showed 
embryonic lethality between 11.5 and 13.5 dpc, and the sinus venosus myocardium was 
markedly hypoplastic, including the sinoatrial nodal region. This latter region also showed 
abnormal differentiation in that genes that are normally negative in the developing node 
(Nkx2.5, Cx40 and Cx43) were now aberrantly positive. Shox2 downregulation in Zebrafish 
resulted in marked bradycardia because of diminished pacemaking function. Therefore, we 
assume that the embryonic lethality in the Shox2 mutant mice might result from a comparable 
process. The hypoplasia and abnormal differentiation of the sinoatrial nodal region could lead 
to a disturbed pacemaking function and resultant cardiac failure. 
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eXPANDeD MATeRiAL AND MeTHoDs
construction of the targeting vector, generation of chimeras and mutant mice
The replacement targeting vector aiming at the Shox2 locus was generated by inserting genomic 
DNA fragments into the plasmid pHR68. The 5’ homology region was amplified from the 
cosmid B212cos1 using primers Shox2 ATG-for: 5’-GGGAGAGCTTGAGCGCGAGGTTG-3’ 
and Shox2 int1-rev: 5’-GCAAGACAGTCTCATTACCAGAT-3’. The 3’ homology region 
represents a KpnI restriction fragment isolated from the cosmid B212cos. Correct insertion 
of the 5’ and 3’ homology fragments was verified by sequence analysis. The SalI digested 
targeting plasmid was electroporated into RI and E14 ES cells respectively. Homologous 
recombination was confirmed by Southern-blot analysis using a 578 bp BamHI fragment from 
the 5’ upstream region of the targeted locus (Figure 2a). ES cells from one correctly targeted 
RI and E14 clone were injected into C57BL/6 blastocysts that were implanted into 
pseudopregnant females as described.18 Heterozygous animals were sequentially bred into a 
C57BL/6 genetic background at least to F4. 
DNA and RNA analysis 
Genomic DNA was prepared from tail biopsies and yolk sacs as previously described. Animals 
were genotyped using the primer neo-for: 5’-TGAGCGGGACTCTGGGGTTCGA-3’ and 
Shox2-int1/2-for: 5’-CAGGGTTAGGAGTCTCTAGCCT’-3’ (Figure 2a). For embryo 
genotyping, these primers were used in combination with the primer Shox2-ex2-rev: 5’-TGCT 
TGATTTTGGTCTGGCCTTCGT-3’ residing within the replaced second Shox2 exon. 
RNA from whole embryos or isolated embryonic hearts was isolated using a QIAGEN 
RNAeasy Mini-Kit and RT-PCRs were carried out with the primers SO3- for:  5`GTGTTCT-
CATAGGGGCCGCCAGC 3` and Shox2-rev:  5`ACAGCGCTGTCCAGCTGCAGCTGCG 
3`. These primers flank the alternatively spliced exon 5 and allow discriminating between 
Shox2a and Shox2b.
immunohistochemistry and 3-D reconstructions 
Immunohistochemistry with the MLC-2a, Nkx2.5, Cx40 and Cx43 specific antibodies were 
performed by routine procedures. All embryos (wildtype 10.5 dpc n=1 and Shox2-/- 10.5 dpc 
n=1; wildtype 11.5 dpc n=4 and Shox2-/- 11.5 dpc n=4) were fixed in 4% paraformaldehyde 
(PFA), after dehydration they were embedded in paraffin. The embedded embryos were 5 μm 
sectioned and mounted 1 to 5 onto protein /glycerin coated slides so 5 different staining 
procedures could be performed on one embryo. After dehydration of the slides, inhibition of 
the endogenous peroxidase was performed for MLC-2a and Nkx2.5 with a solution of 0.3% 
H2O2 in PBS for 20 min. For Cx40 and Cx43 antigen retrieval was performed in 0.01M Citric 
buffer of pH 6.0 at 97˚C for 12 min. Overnight incubation of the slides was completed with 
70
chapter 2
the following primary antibodies: 1/2000 anti-atrial myosin light chain 2 (MLC-2a, gift from 
S.W. Kubalak) and 1/4000 anti-NK2 transcription factor related locus 5 (Nkx2.5, Santa Cruz 
Biotechnology, sc-8697), 1/100 anti-Connexin40 (Cx40, Santa Cruz Biotechnology, sc-20466) 
and 1/200 anti-Connexin43 (Cx43, Sigma, C6219). The primary antibodies were dissolved in 
PBS-Tween-20 with 1% Bovine Serum Albumin (BSA, Sigma Aldrich, USA). All slides were 
rinsed between subsequent incubation steps: PBS (2x) and PBS-Tween-20 (1x). Incubation 
with the secondary antibodies was performed for 40 min: for MLC-2a and Cx43 1/200 goat-
anti-rabbit-biotin (Vector Laboratories, USA, BA-1000) and 1/66 goat serum (Vector 
Laboratories,USA, S1000); for Nkx2.5 and Cx40 1/200 horse-anti-goat-biotin (Vector 
Laboratories, USA, BA-9500) and 1/66 horse serum (Brunschwig Chemie, Germany, S-2000) 
in PBS-Tween-20. Thereafter, a 40 min incubation with ABC-reagent (Vector-Laboratories, 
USA, PK 6100) was performed. For visualisation, all slides were incubated with 400 μg/ml 
3-3’di-aminobenzidin tetrahydrochloride (DAB, Sigma-Aldrich Chemie, USA, D5637) 
dissolved in Tris-maleate buffer pH7.6 to which 20 μl H2O2 was added: MLC-2a 5 min and 
Nkx2.5, Cx40 and Cx43 10 min. 0.1% Haematoxylin (Merck, Darmstadt, Germany) was used 
to counterstain the slides for 10 sec, followed by rinsing with tap water for 10 min. After 
dehydration, all slides were mounted with Entellan (Merck, Darmstadt, Germany). 
We made 3D reconstructions of the atrial and ventricular myocardium of MLC-2a stained 
sections of 10.5 and 11.5 dpc wildtype and Shox2-/- embryonic hearts, in which Nkx2.5 negative 
myocardium was manually added. The reconstructions were made as described earlier,23 using 
the AMIRA software package (Template Graphics Software, San Diego, USA).
Zebrafish in situ hybridization and Morpholino injection 
Whole-mount RNA in situ hybridization was essentially carried out as described.21 The full 
length Zebrafish Shox2 mRNA sequence was amplified and cloned into pCR II (Invitrogen) 
for in vitro transcription (Roche). Morpholino modified antisense oligonucleotides were 
designed against the splice donor site 5´-TGTATCCACGCACCTTTATGCAACT-3´ and the 
translational start site of Zebrafish Shox2 5´- ACGCTGTAAGTTCTTCC ATCACTGC-3´ and 
injected as described.21
71
Cardiac malformations in Shox2 knockout embryos
2
1 Department of Pediatric Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
2 Department of Anatomy & Embryology, Leiden University Medical Center, Leiden, The Netherlands.
3 Hubrecht  Institute, KNAW & University Medical Center Utrecht, Utrecht, The Netherlands.
4 Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.









Monique R.M. Jongbloed2, 4
Adriana C. Gittenberger-de Groot2
Submitted for publication







Shox2 has an important role in formation of the posterior heart field (PHF). The PHF contributes 
to major parts of the inflow tract of the heart including the cardiac conduction system and the 
epicardium. Here we hypothesize that mutation of the Shox2 gene leads to abnormal sinoatrial 
node (SAN) / pacemaking function as well as abnormal epicardial development in the heart.
Methods and Results
Electrophysiological recordings were performed in wildtype and Shox2-/- embryos of 12.5 
days post conception (dpc). Compared to wildtype the electrophysiological assessments in 
Shox2-/- embryos showed a significant (P=0.032) lower heart rate (105±36 bpm vs 74±15 
bpm), no differences were observed in atrioventricular conduction time (76±24 ms vs 80±14 
ms, respectively). Immunohistochemical analysis and 3D reconstructions with MLC-2a, 
Nkx2.5 and HCN4 specific antibodies, showed hypoplasia and aberrant differentiation of the 
PHF derived sinus venosus myocardium in Shox2-/- embryos of 12.5 dpc. In both wildtype 
and Shox2-/- HCN4 was widely expressed throughout the complete sinus venosus myocardium 
including the SAN, albeit decreased in Shox2-/- due to hypoplasia of this area. Expression of 
Wt1 and 3D reconstructions of the pro-epicardial organ (PEO) in Shox2-/- embryos showed a 
decreased PEO size at 9.5 dpc with normal epicardial spreading at 12.5 dpc. At latter stages 
the ventricles showed decreased numbers of epicardium derived cells and an abnormal 
ventricular wall morphology.
conclusions
Shox2 has a crucial role in development of the venous pole of the heart including the SAN 
and its pacemaking function. Furthermore, we, for the first time show that Shox2 is essential 
for proper epicardial lineage development.
 
iNTRoDUcTioN
The last decennium it has been well established that the heart generates from two large 
cardiogenic fields in the dorsal mesocardium: the first and second heart field.1 The first heart 
field gives rise to the primary heart tube and the second heart field contributes cardiomyocytes 
at the venous as well as the arterial pole of this tube. At the venous pole these cardiomyocytes 
are derived from a subgroup of the second heart field, the so-called posterior heart field (PHF). 
The PHF derived myocardium is characterized by specific expression patterns of several 
markers like the early cardiomyocyte marker NK2 transcription factor related locus 5 (Nkx2.5) 
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and gives rise to major parts of the developing cardiac conduction system (CCS).2,3
The homeobox gene Shox2 was shown to be indispensable in the formation of the PHF and 
mice lacking Shox2 die at early embryonic stages most probably due to severe cardiac failure.4 
Previously, we showed that mutations of Shox2 lead to a diminished anlage and aberrant 
differentiation of the PHF myocardium including the sinoatrial node (SAN), the posterior 
atrial wall and the venous valves. In the hypoplastic SAN an up-regulation of Nkx2.5, Connexin 
40 (Cx40), Connexin 43 (Cx43),4 Nppa and Tbx3 was observed.5 Although SAN / pacemaker 
dysfunction might be expected in Shox2-/- embryos, electrophysiological studies have not yet 
been performed in this specific mouse model. 
Contemporary studies identified specialized pacemaking channels in the developing SAN 
essential for action potential generation.6 The hyperpolarization-activated cyclic nucleotide-
gated channel (HCN) 4 is believed to be one of the most important currents involved in 
pacemaking. Human mutations in the HCN4 gene cause marked bradycardia.7,8 
Immunohistochemical analysis in mice showed that at early stages of cardiac development 
HCN4 is highly expressed in the PHF derived sinus venosus myocardium, including the region 
of the SAN. In addition, both Shox2 and Nkx2.5 seem to have an imperative role in the 
regulation of HCN4 expression during cardiogenesis.5,9 
Recently, we demonstrated that abnormal sinus venosus development might also coincide 
with an abnormal anlage of the epicardium of the heart.10 Aberrant epicardial development 
may also be expected in Shox2 mutants, since: (1) Shox2 expression is known to be highly 
restricted in the sinus venosus area including the pro-epicardial organ (PEO), a cauliflower-
like protrusion of mesothelial cells from which the epicardial cells derive11 and (2) both the 
cardiomyocytes of the inflow tract (derived from the PHF) and the PEO seem to originate 
from a common Tbx-18 expressing cardiac progenitor pool in the dorsal mesocardium.12,13 As 
from approximately 9.5 days post conception (dpc), epicardial cells start to migrate from the 
PEO over the developing heart thus forming a layer of epicardium. Subsequently, by epithelial-
to-mesenchymal-transformation (EMT) of epicardial cells, the so-called epicardium derived 
cells (EPDCs) are generated.11 EPDCs migrate into the myocardium fulfilling several important 
roles in development and maturation of the heart.14-16
In the current study we hypothesize that Shox2 has an important role in pacemaker function 
and epicardial development. To substantiate this hypothesis electrophysiological assessments 
and immunohistochemical analysis with the HCN4 specific antibody were performed in 
isolated wildtype and Shox2-/- hearts of 12.5 dpc. The role of Shox2 in epicardial development 
was studied by 3D reconstructions of the PEO of wildtype and Shox2-/- hearts. Furthermore, 
immunohistochemistry was performed with Wilm’s tumor 1 (Wt1), a specific marker for both 
epicardial cells and EPDCs.17  
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 MATeRiAL AND MeTHoDs
Animals and preparation of the hearts
All animal experiments were approved by the local medical ethical committee and conducted 
according to the Dutch animal protection law (Leiden, DEC No 6679). Mutant mice were bred 
by The Netherlands Institute of Developmental Biology (Hubrecht laboratory, Utrecht, The 
Netherlands) after replacing the targeted vector aiming at the Shox2 locus in a CD1 mouse 
strain as described previously.4 The presence of a vaginal plug one day after breeding was 
considered to be 0.5 dpc. For harvesting of the embryos, pregnant mice were sacrificed by 
cervical dislocation at 12.5 dpc. Thereafter an incision was made in the mid-abdominal region, 
followed by the extraction of the two laterally located uterus horns. The uterus was place in 
a Petri dish filled with heated Tyrode’s solution containing (in mmol/l) 130 NaCl, 4 KCl, 1,2 
KH2PO4, 0,6 MgSO47H2O, 20 NaHCO3, 1,5 CaCl22H2O and 10 glucose at 37˚Celsius (C). 
Subsequently in Tyrode´s solution of 0˚C the embryonic hearts were dissected one-by-one for 
electrophysiological recordings. The individual embryonic tails were harvested for standard 
genotyping of the embryos as described previously.4    











E8597A 12.5 WT 68 112.3
E8597B 12.5 WT 76 83
E8597C 12.5 Shox2-/- 67 84.3
E8598B 12.5 WT 80 61.1
E8598C 12.5 Shox2-/- 110 79.6
E8598D 12.5 Shox2-/- 80 102.9
E8599C 12.5 WT 85 79.5
E8599E 12.5 WT 151 84
E8601A 12.5 Shox2-/- 98 82
E8601C 12.5 WT 143 78.3
E8601D 12.5 Shox2-/- 60 64.7
E8601E 12.5 Shox2-/- 75 81
E8601F 12.5 Shox2-/- 87 73.8
E8601I 12.5 WT 145 48.1
E8418A 12.5 Shox2-/- 71 99.4
E8418C 12.5 Shox2-/- 59 62.9
E8418K 12.5 Shox2-/- 63 65.3
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electrophysiological recordings and genotyping
Electrophysiological recordings were conducted in isolated wildtype (n=7) and Shox2-/- (n=10) 
embryonic mouse hearts of 12.5 dpc (Table 1). Since genotyping of the embryos was performed 
after the electrophysiological experiments, all recordings are considered to be performed blind. 
For a detailed description of the recording equipment and the recording protocol we refer to 
the Expanded Material and Methods section. After recordings, all embryonic hearts were fixed 
in 4% paraformaldehyde (PFA) for further immunohistochemical processing.  
immunohistochemistry and in situ hybridization (isH)
Immunohistochemistry was performed with antibodies specifically against atrial myosin light 
chain 2 (MLC-2a, gift from S.W. Kubalak), Nkx2.5 (Santa Cruz Biotechnology, sc-8697), 
HCN4 (Alomon labs, APS-052) and Wt1 (Santa Cruz Biotechnology, SC-192). The preparation 
of sections and detailed descriptions of the immunohistochemical staining as well as ISH 
protocols can be found in previous publications.4,18
3D reconstructions
3D reconstructions were made of the PEO and developing venous pole of the heart as described 
before,19 using the AMIRA software package (Template Graphics Software, San Diego, USA).
statistical Analyses
Statistical analysis was performed using the SPSS 15.0 software package (SPSS Inc, Chicago, 
Ill). A students-t-test was executed if values were equally distributed (skew ness is |-1|), 
otherwise a Mann Whitney U-test was performed. Statistical significant results are defined 
as:  P < 0.05.
The authors had full access to and take responsibility for the integrity of the data. All authors 
have read and agree to the manuscript as written.
 
ResULTs
During the dissection of the embryos no visible differences were observed between wildtype, 
Shox2+/- and Shox2-/- embryos before the age of 12.5 dpc. After that age Shox2-/- embryos 
did not have a spontaneous heart beat anymore and showed a severely hemorrhagic 
phenotype. In addition, around 16.5 - 17.5 dpc only apoptotic remnants of Shox2-/- embryos 
were detected. Previous reports showed no differences between wildtype and Shox2+/- 
embryos.4,5 Therefore, the current study only described differences between wildtype and 




The expression of Shox2 was studied by antisense in situ hybridization in whole mount 
embryos, isolated hearts and serial sections of wildtype hearts as described previously.4 At 9.5 
dpc, expression of Shox2 was limited to the venous pole of the heart, including the region of 
the PEO, where formation of the sinus venosus occurs. From 10.5 to 12.5 dpc expression of 
Shox2 is clearly visible in the myocardium surrounding the left and right horn of the sinus 
venosus including the SAN, which is located at the medial border of the right sinus horn. 
Furthermore, Shox2 expression was clearly present in the developing venous valves, and at 
the top of the ventricular septum in the area of the putative left and right bundle branches.4    
Figure 1. Expression of HCN4 in wildtype (WT) and Shox2-/- heart of 12.5 dpc. (a) and (b) show reconstructions 
of the dorsal side of embryonic WT and Shox2-/- hearts of 12.5 dpc respectively, in which the HCN4 expression pattern 
in the sinus venosus area is indicated (light blue). Both in WT and Shox2-/- hearts the light blue HCN4 positive 
myocardium is continuous between the left and right horn of the sinus venosus. (c) HCN4 stained section through 
the WT heart indicated at the specific level in (a) showing that the SAN (asterisk in d boxed area in c) is positive for 
HCN4. At these stages HCN4 expression is also observed in the left sinus horn as indicated by the arrow head in 
(c). (e) Magnification of the boxed area in (f) which is a HCN4 stained section through the Shox2-/- heart at the level 
indicated in (b) clearly showing that the SAN (asterisk) expresses HCN4. LA indicates left atrium; LCV, left cardinal 
vein; LV, left ventricle; OFT, outflow tract; RCV, right cardinal vein; RV, right ventricle; VS, ventricular septum. 
In the reconstructions: pink indicates pulmonary vein; dark brown, atrial myocardium; light brown, ventricular 
myocardium. Scale bars: (c) and (f) = 300μm; (d) and (e) = 30μm.
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electrophysiological recordings and HcN4 expression at 12.5 dpc
All recordings were performed after a three minute calibration period of the hearts in the 
experimental setup. Table 1 summarizes the electrophysiological data of each individual heart. 
In total 7 wildtype and 10 Shox2-/- hearts of 12.5 dpc were assessed. In wildtype as well as in 
Shox2-/- embryos stable heart rates were recorded, and no sinus arrests or sinus exit blocks 
were observed in the mutant embryos. The mean recorded heart rate in wildtype and 
Shox2-/- embryonic hearts was 105±36 bpm and 74±15 bpm, respectively. Statistical analysis 
showed a significant decrease (P=0.032) of the heart rate in Shox2-/- embryos as compared to 
wildtype. No significant differences were recorded in mean AV conduction time between 
wildtype (76±24 ms) and Shox2-/- (80±14 ms) hearts.  
In wildtype hearts of 12.5 dpc the expression of the main cardiac pacemaker channel HCN4 
was present in the complete MLC-2a positive and Nkx2.5 negative U-shaped region of sinus 
venosus myocardium including the SAN (Figure 1a, c, d; Figure 2a, c-e). Furthermore, weak 
HCN4 expression was observed in the region surrounding the developing pulmonary vein and 
at the base of both the venous valves and the primary interatrial septum. In all embryonic 
hearts HCN4 expression in the left and right sinus venosus horns could be followed from 
section to section towards a direct connection to the developing atrioventricular node (AVN) 
region at the base of the AV groove (Figure 1a). 
In Shox2-/- embryos of similar age HCN4 expression was observed in the hypoplastic MLC-2a 
positive and Nkx2.5 negative sinus venosus myocardium. Expression of HCN4 was also present 
in the aberrantly Nkx2.5 positive areas of the U-shaped sinus venosus myocardium (Figure 1b; 
Figure 2b). The same accounts for the hypoplastic MLC-2a and Nkx2.5 positive SAN (Figure 
1b, e, f; Figure 2b, f-h) and for the base of the hypoplastic venous valves. The continuum of HCN4 
positive myocardium between the SAN and the developing AVN region was still present. 
Myocardial and epicardial development 9.5 dpc – 12.5 dpc
At 9.5 dpc both in wildtype and Shox2-/- hearts, the PEO located in close proximity to the sinus 
venosus, stained positive for Wt1. However, in Shox2-/- the size of this structure appeared to 
be decreased (Figure 3a-h).
At 10.5 dpc, in Shox2-/- embryos the common atrium was slightly dilated and the venous valves 
were hypoplastic. At these stages, the sinus venosus myocardium including the SAN was 
MLC-2a positive and Nkx2.5 negative in both wildtype and Shox2-/- embryos. In addition, in 
both wildtype and Shox2-/- embryos Wt1 stained sections showed normal epicardial spreading 
by formation of a single layer of Wt1 positive epicardium over the complete developing heart 
(data not shown).  
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At 11.5 dpc major differences were observed between wildtype and Shox2-/- hearts. In Shox2-/- 
the atria were dilated and the sinus venosus myocardium was hypoplastic including the SAN, 
the dorsal atrial wall and venous valves. In wildtypes the sinus venosus myocardium including 
the SAN stained positive for MLC-2a and negative for Nkx2.5. 
In Shox2-/- however, an aberrant differentiation of this area was observed staining positive for 
both MLC-2a and Nkx2.5. Both in wildtype and Shox2-/- AV cushions and outflow tract 
cushions could be discriminated in the AV canal and outflow tract region respectively. 
Compared to wildtype, the ventricles in Shox2-/- embryos seemed to be aberrantly positioned, 
with the right ventricle in a more superior position. At this stage no differences were observed 
in ventricular wall thickness and trabecular development between wildtype and Shox2-/- hearts 
(data not shown).     
Figure 2. Expression of MLC-2a and Nkx2.5 in the PHF in wildtype (WT) and Shox2-/- at 12.5 dpc. Three 
dimensional reconstructions of the dorsal side of WT and Shox2-/- embryonic hearts of 12.5 dpc are shown in (a) and 
(b) respectively. Compared to WT (a) the PHF derived MLC-2a positive and Nkx2.5 negative sinus venosus 
myocardium (green) is severely hypoplastic in Shox2-/- embryos (b). The aberrant differentiated, Nkx2.5 expressing 
sinus venosus myocardium in Shox2-/- is indicated in black (b). (c) Shows a transverse MLC-2a stained section through 
the embryonic heart as indicated in (a). In WT the sinoatrial node (SAN, asterisk in d-e) is positive for MLC-2a (d, 
magnification of boxed area in c) and negative for Nkx2.5 (e, consecutive section of d). In Shox2-/- the hypoplastic 
SAN is positive for MLC-2a (f, magnification of boxed area in h, which is transverse MLC-2a stained section through 
the Shox2-/- heart as indicated in b) and positive for Nkx2.5 (g, consecutive section of f). LCV indicates left cardinal 
vein;  LV, left ventricle; OFT, outflow tract; PV, pulmonary vein; RA, right atrium; RCV, right cardinal vein; RV, 
right ventricle; In the reconstruction: light brown, ventricular myocardium; dark brown, atrial myocardium; blue 
transparent, sinus venosus. Scale bars: (c) and (h) = 300μm; (d-g) = 30μm.  
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At 12.5 dpc the structural abnormalities between wildtype and Shox2-/- became more 
pronounced. In wildtype hearts the volume of the sinus venosus myocardium including the 
SAN increased and retained its MLC-2a positive and negative Nkx2.5 expression pattern 
(Figure 2a, c-e). In Shox2-/- hearts the same area was severely hypoplastic and at many locations 
abnormally positive for Nkx2.5 (Figure 2b, f-h). At these stages in wildtype the pulmonary 
vein was almost completely surrounded by myocardium, which was MLC-2a positive and 
showed a mosaic expression pattern for Nkx2.5.  In Shox2-/- the myocardium in this area was 
hypoplastic, stained positive for MLC-2a and also showed Nkx2.5 mosaic expression (data 
not shown). At this stage the aberrant positioning of the ventricles in Shox2-/- hearts became 
even more apparent. The 3D reconstructions of Shox2 mutants clearly show that the right 
ventricle is dilated and aberrantly positioned to a more superior region. Similar to previous 
stages AV and outflow tract cushions could be discriminated both in wildtype and Shox2-/- 
hearts (Figure 4a-d). 
Figure 3. PEO formation in wildtype (WT) and Shox2-/-embryos. Caudo-dorsal views of 3D reconstructions of 
WT (a) and Shox2-/- (b) embryonic hearts of 9.5 dpc. (c) Wt1 stained section of the WT heart reconstructed in (a). (d) 
Magnification of the boxed area in (c) of the PEO (asterisk) staining positive for Wt1. (e) Isolated reconstruction of 
the PEO of the WT heart indicated in (a). (f) Wt1 stained section of the Shox2-/- heart reconstructed in (b). (g) 
Magnification of boxed area in (f) shows the PEO (asterisk) positive for Wt1. (h) Isolated reconstruction of the PEO 
of the Shox2-/- heart in (b), clearly showing that the size of the PEO is decreased (compare e and h). A indicates 
common atrium; LCV, left cardinal vein; RCV, right cardinal vein; V, ventricular part of the heart; In the 
reconstructions: light brown indicates ventricular myocardium; dark brown, atrial myocardium; blue, sinus venosus 
lumen. Scale bars: (c) and (f) = 200μm; (d) and (g) = 30μm.
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At 12.5 dpc, for the first time differences in the thickness of the ventricular wall and the 
anlage of ventricular trabeculation were observed between wildtype and Shox2-/- embryos. 
Compared to wildtype embryos Shox2-/- embryos appeared to have a thinner ventricular wall 
at many locations. In addition, the ventricles showed less trabeculation (Figure 5a, b). At 
these stages in wildtype as well as in Shox2-/- hearts the Wt1 stained sections showed that the 
complete atrial and ventricular walls were covered with a layer of Wt1 positive epicardial 
cells (Figure 5a, c, b, e). In wildtype hearts many EPDCs were already discriminated, however 
in Shox2-/- hearts the number of EPDCs seemed to be decreased. Especially at locations 
adjacent to a thin ventricular myocardial wall less EPDCs in the subepicardial space were 
observed (Figure 5a-f). 
   
Figure 4. Cardiac morphology of wildtype (WT) and Shox2-/- hearts at 12.5 dpc. Reconstructions of frontal views 
of WT (a) and Shox2-/- (b) hearts of 12.5 dpc are demonstrated in which the lumen of the right ventricle (RV; green), 
left ventricle (LV; red) and left atrium (LA; dark grey) are indicated, in Shox2-/- the right atrial lumen (RA; dark 
grey) can also be observed. Furthermore, the atrioventricular cushions (AVc; light yellow) and Outflow cushions 
(OFc; dark yellow) are designated. In Shox2-/- hearts the RV is severely dilated and positioned in a more superior 
position (b) as compared to WT (a). (c) and (d) show left-lateral views of hearts in (a) and (b) respectively, clearly 
indicating that the dilated RV in Shox2-/- is located superiorly to the LV; light grey indicates contours of atrial as well 
as ventricular myocardium.    
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DiscUssioN
The development and maturation of the venous pole of the heart has been a matter of debate 
for years. However, contemporary studies gained more insight in the formation of this rather 
complex cardiac region. It was shown that the PHF adds newly formed cardiomyocytes to the 
venous pole of the primary heart tube, and that major parts of the CCS, including the SAN 
are derived from this group of secondarily added myocytes.2,4,9 It has been even postulated 
that the PHF plays a role in the development of the AVN.2,20
Mutations in several genes like podoplanin,18 Tbx1821,22, Tbx322,23 and Shox24,5 can result in a 
disturbed anlage and / or differentiation of the venous pole (i.e. sinus venosus) of the heart. 
Furthermore, we recently demonstrated in podoplanin10 and Pdgfrα24 mutant mice that abnormal 
epicardial development may also coincide with hampered PHF anlage. 
In the present study we examined the pacemaking function of the SAN as well as epicardial 
development in Shox2 mutants. We confirmed hypoplasia and aberrant differentiation of the 
venous pole of the heart including the SAN in Shox2 mutant mice of 12.5 dpc. At these stages 
electrophysiological recordings demonstrated a regular but significantly slower sinus rhythm 
Figure 5. Expression of Wt1 in wildtype (WT) and Shox2-/- hearts of 12.5 dpc. Compared to the ventricular 
morphology of WT hearts as indicated by the MLC-2a stained section in (a), the ventricular morphology is abnormal 
in Shox2-/- hearts of similar age showing a thin ventricular wall and less trabeculae (b). (c) Consecutive Wt1 stained 
section of the boxed area in (a) clearly shows that the epicardium is Wt1 positive. Wt1 positive EPDCs can be 
discriminated and are indicated by the arrowheads in (d), which is a magnification of the boxed area in (c). (e) 
Consecutive Wt1 stained section of the boxed area in (b) showing a single layer of Wt1 positive epicardium in the 
Shox2-/- heart. In Shox2-/- hearts almost no EPDCs were observed in the subepicardial layer as indicated in (f), which 
is a magnification of the boxed area in (e); Scale bars: (a) and  (b) = 300μm; (c-f) = 30μm. 
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in Shox2-/- embryos as compared to controls. The AVN function remained intact in the mutant 
mice as indicated by normal AV conduction times. Remarkably, the expression of pacemaker 
channel HCN4 could clearly be observed in the hypoplastic SAN. The epicardial lineage 
development indeed appeared to be abnormal in Shox2 mutants, including a diminished size 
of the PEO and a decreased numbers of EPDCs in the subepicardial space.
Shox2, HcN4 and decreased pacemaking.
HCN4 is considered to be the most important channel for cardiac pacemaking,6 especially in 
the maintenance of a stable heart rate. Recent studies in humans demonstrated that mutation 
in the HCN4 gene causes marked sinus bradycardia.7,8 In mouse heart development, HCN4 
can already be detected at the complete venous pole of the heart at very early embryonic 
stages.9 During development the expression pattern of HCN4 becomes more restricted and is 
predominantly observed in the SAN. However, in the hearts of two months old mice HCN4 
is also observed in the AVN region and the right atrioventricular ring bundle, which has been 
suggested to enable action potential generation at other regions outside the SAN.25     
The regulation of HCN4 expression during embryonic development has not yet been elucidated. 
Mommersteeg et al. recently postulated that in early embryonic development (<14.5 dpc) 
Nkx2.5 represses expression of HCN4.9 The current study confirms this relation, with respect 
to the sinus venosus myocardium in wildtype embryos of 12.5 dpc. At later stages (>14.5 dpc), 
except for the SAN the complete sinus venosus myocardium gains an atrial differentiation 
program, becoming positive for Nkx2.5, Cx43, Cx40 and losing expression of HCN4.9,18
The regulation of HCN4 in the SAN region seems to be more controversial. Espinoza-Lewis 
et al. showed absence of HCN4 expression in Shox2-/- embryos of 11.5 dpc.5 They suggested 
that an Shox2 mediated aberrant up-regulation of Nkx2.5 in the SAN, down regulates HCN4, 
which bears resemblance to the atrial differentiation program of the remainder of sinus venosus 
myocardium in wildtype hearts (>14.5 dpc). This is in contrast to the findings in our study 
that clearly showed that HCN4 is still expressed in the hypoplastic Nkx2.5 positive sinus 
venosus myocardium including the SAN in Shox2-/- embryos of 12.5 dpc. Recent findings on 
the role of Tbx3 in SAN development also demonstrated that Nkx2.5 positive and HCN4 
positive areas do have overlap in some parts of the SAN, i.e. the SAN-tail.22 Therefore, we 
postulate that HCN4 is not solely regulated by Nkx2.5 and that the transcriptional regulation 
of the main cardiac pacemaking channel involves a more elaborate pathway. 
Initial morphological26 and modern immunohistochemical marker studies22,27 both demonstrated 
that different areas within the developing SAN can be discriminated, i.e. a solid node and a 
tail extending on the endocardial surface of the terminal crest. From developmental origin 
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point-of-view it has recently been shown that the solid node derives from Tbx18 and Isl1 
expressing precursor cells of the SHF.13 Moreover, Tbx18 mutants fail to develop a solid node. 
Less however is known about the development of the SAN-tail, which is a Tbx18 negative 
and Nkx2.5 and HCN4 positive structure.22 Examination of the structure-function relationship 
within the SAN of human and animal models28 showed that the solid node as wells as the tail 
of the SAN is able to generate action potentials.27 The solid node is the main pacemaker 
location within the SAN, however if heart rate decreases the dominant pacemaking area tends 
to shift towards the SAN-tail.28 Moreover, the different areas within this “pacemaking complex” 
react differently to neuronal and adrenal signaling.29 For instance stimulation of the sympathic 
nervous system leads to a superior shift of the main pacemaker site resulting in an increase of 
heart rate.30  
The significant lower heart rate in Shox2-/- hearts observed in the current study might be related 
to abnormal anlage of the pacemaking complex and not solely to absence of HCN4 as stated 
by others.5 We postulate that in Shox2-/- hearts, due to aberrant anlage of the PHF, the majority 
of the solid node is absent. Therefore, pacemaking in Shox2-/- hearts might occur in a lower 
SAN region (i.e. tail), which may explain the slower heart rate since under physiological 
circumstances this area renders slower pacemaking properties as compared to the solid nodal 
area of the SAN.28 A second explanation might of course be the aberrant differentiation of the 
SAN in Shox2-/- showing up-regulation of Nkx2.5, Cx40, Cx43,4 Nppa and down-regulation 
of Tbx3.5 The latter one has shown to be important for maintaining a SAN gene differentiation 
program during development.22,23 Normally, markers like Cx40 and Cx43 are weakly expressed 
or absent in the SAN31 to prevent the SAN from the inhibitory hyperpolarizing influences of 
the surrounding atrial myocardium.32 Although arrhythmias related to abnormal expression of 
these markers has been described in patients,33,34 isolated up-regulation in the SAN and aberrant 
pacemaking has not yet been documented. 
Shox2 and epicardial development
The epicardium covers the outer layer of the heart and derives from the PEO, which is located 
in the area of the developing sinus venosus.11 Studies in mouse embryos have shown that the 
formation of the PEO occurs around 9.5 dpc. As from that moment Wt1 positive epicardial 
cells start to migrate over the complete surface of the embryonic heart. Subsequently, EMT 
of the epicardium gives rise to the so-called EPDCs which temporarily express Wt1.17 EPDCs 
then invade the myocardium contributing to several essential processes of heart 
development.10,11,24
Mechanical manipulation of the PEO in chick / quail embryos results in several cardiac 
malformations related to an abrogated epicardial spreading and EPDC formation, such as 
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myocardial non-compaction and abnormal development of the coronary arteries, the Purkinje 
system and AV valves.14,15,35 Furthermore, a disturbed AV isolation is observed resulting in 
high numbers of accessory AV myocardial connections causing pre-mature electrical activation 
of the ventricles.15,16 Moreover, the epicardium has an important role in stimulation of 
myocardial proliferation in the developing ventricles by secretion of several myotrophic 
factors.36 Therefore, we postulate that the ventricular abnormalities observed in Shox2-/- i.e. 
thin myocardium, abnormal ventricular trabecularization and right ventricular dilatation and 
dislocation are related to abnormal epicardial development. Due to a decreased PEO size less 
epicardial cells spread over the surface of the developing Shox2-/- heart. Subsequently, a 
hampered EMT process will lead to a reduced amount of EPDCs in these hearts causing the 
ventricular abnormalities that were observed. 
Recently we demonstrated in podoplanin10 and Pdgfrα24 mutants a disturbed epicardial lineage 
development. Interestingly, more or less identical to the Shox2 gene, podoplanin and Pdgfrα 
also have an essential role in development of the PHF derived sinus venosus myocardium. 
Therefore, we postulated that the PHF contributes to formation of both the sinus venosus 
myocardium and the PEO,10 since the coelomic epithelium contributes mesenchyme to the 
PEO12,13,37 as well as the PHF-derived structures at the venous pole of the heart.1,2 
The disturbed epicardial development observed in Pdgfrα as well as podoplanin knockouts 
highly correspond to that observed in Shox2 mutants. However, the Pdgfrα and podoplanin 
mutants not only showed decreased numbers of EPDCs and a decreased PEO size, but also 
hampered epicardial adhesion and spreading.10,24 The epicardial abnormalities may be related 
to the specific role that these genes have in the EMT process. Unlike the expression pattern 
of Shox2, both podoplanin and Pdgfrα are also present in the complete epicardial layer covering 
the heart suggesting a local involvement in EMT. Interestingly, for Pdgfrα a functional link 
in regulation of Wt1 expression has recently been demonstrated.24 Wt1, expressed in the 
epicardium and EPDCs,17 is known to regulate expression of several important factors in EMT 
like Snail and the cell-to-cell adhesion protein E-cadherin.38 Moreover, podoplanin mutants 
showed an aberrant up-regulation of E-cadherin, which was postulated to be the underlying 
mechanism of the epicardial abnormalities in that particular mouse model.10 Thus far, similar 
mechanisms have not been identified in Shox2 mutants. 
coNcLUsioN
The current study confirms the hypoplasia and aberrant differentiation of the PHF derived 
sinus venosus myocardium in Shox2-/- embryos of 12.5 dpc. We show that knocking out the 
Shox2 gene causes sinus bradycardia despite the persistence of the pacemaker channel HCN4 
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in the hypoplastic SAN. Furthermore, we for the first time showed that Shox2 has an important 
role in epicardial lineage development. Our results support the hypothesis that the sinus venous 
myocardium and the PEO derive from a common pool of progenitor cells (i.e. the PHF), since 
Shox2 mutants show defects of the venous pole as well as the epicardium. Finally, the current 
study also sheds new light on the etiology of the early embryonic death observed in Shox2 
mutants. We suggest that two mechanisms are involved: (1) disturbed cardiac pacemaking due 
to abnormal anlage and differentiation of the SAN and (2) abnormal ventricular maturation 
caused by abnormal epicardial lineage development, which results in ventricular 
dysfunction.
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eXPANDeD MATeRiAL AND MeTHoDs
electrophysiology recording protocol
The embryonic hearts were attached with fine wires through extra-cardiac tissue in a fluid 
heated, temperature controlled (Physitemp instruments Inc, Clifton NJ, USA) petridish of 
35.5-37˚Celsius onto a layer of agarose gel (Roche Diagnostics GmbH, Mannheim, Germany). 
During the equilibration period of 3 minutes and the subsequent electrophysiological recordings 
the hearts were constantly super-perfused with Carbogenated (95% O2 and 5% CO2) Tyrode’s 
solution containing (in mmol/l) 130 NaCl, 4 KCl, 1,2 KH2PO4, 0,6 MgSO47H2O, 20 NaHCO3, 
1,5 CaCl22H2O and 10 glucose of 37˚Celsius. 
For electrophysiological extracellular recordings 4 unipolar tungsten electrodes (tip: 1-2μm; 
impedance 0.9-1.0MΩ; WPI Inc, Sarasota FL, USA) were placed on the right atrium (RA), 
right ventricular base (RVB), left ventricular base (LVB) and left ventricular apex (LVA) using 
microscopic guided micromanipulators (Wild Heerbrugg, M7A, Switzerland). Furthermore, 
an Ag/AgCl electrode in the Petri dish served as reference electrode. The complete experimental 
setting was located in a Faraday cage to prevent the recordings from exterior electrophysiological 
disturbances.
All electrograms were recorded with a high-gain, low-noise, direct-current bioamplifier system 
(Iso-DAM8A; WPI Inc) with 4 isolated preamplifier modules with an output impedance of 
>1012Ω. The signals were band-pass (300Hz-1kHz) and notch filtered (50Hz) before being 
digitized at a sample rate of 1≥kHz with a computerized recording system (Prucka Engineering 
Inc, Houston, Tex) and stored on optical disks for offline analysis. 
All electrophysiological recordings were performed under stable sinus rhythm after a 3 minute 
calibration period. The basal cycle length/HR of each heart was calculated by the average of 
10 consecutive beats. The AV conduction time is defined as the time interval between atrial 
activation and the first ventricular activation either at the LVA or at the LVB / RVB. 
After EP recording all hearts were fixed in 4% paraformaldehyde for immunohistochemical 
processing.
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Nkx2.5 negative myocardium of the posterior heart 
field and its correlation with podoplanin expression 






Recent advances in the study of cardiac development have shown the relevance of addition 
of myocardium to the primary myocardial heart tube. In wildtype mouse embryos (9.5-15.5 
days post conception) we have studied the myocardium at the venous pole of the heart using 
immunohistochemistry and 3D reconstructions of expression patterns of MLC-2a, Nkx2.5 
and podoplanin, a novel coelomic and myocardial marker. Podoplanin positive coelomic 
epithelium was continuous with adjacent podoplanin and MLC-2a positive myocardium that 
formed a conspicuous band along the left cardinal vein extending through the base of the atrial 
septum to the posterior myocardium of the atrioventricular canal, the atrioventricular nodal 
region and the His-Purkinje system. Later on podoplanin expression was also found in the 
myocardium surrounding the pulmonary vein. On the right side podoplanin positive cells were 
seen along the right cardinal vein, which during development persisted in the sinoatrial node 
and part of the venous valves. In the MLC-2a and podoplanin positive myocardium Nkx2.5 
expression was absent in the sinoatrial node and the wall of the cardinal veins. There was a 
mosaic positivity in the wall of the common pulmonary vein and the atrioventricular conduction 
system as opposed to the overall Nkx2.5 expression seen in the chamber myocardium. We 
conclude that we have found podoplanin as a marker that links a novel Nkx2.5 negative sinus 
venosus myocardial area, which we refer to as the posterior heart field, with the cardiac 
conduction system.  
 
iNTRoDUcTioN
In early cardiac development the myocardium of the heart tube develops from two bilateral 
cardiogenic plates (primary heart field) that fuse to a common primary heart tube.1,2  The earlier 
observations by cell marker research in chicken embryos of De La Cruz3 that myocardium is 
added to this primary heart field, is now supported by several studies that in most cases refer 
to addition of myocardium at the outflow tract of the heart, being from the anterior4 or 
secondary5 heart field. Newly recruited myocardium is not only added at the outflow tract but 
also at the inflow tract. This myocardium is derived from the splanchnic mesoderm running 
from the arterial pole (outflow tract) to the venous pole (inflow tract) which is also referred 
to as second heart field,6 or second lineage.6,7 Recently a number of genes / proteins, considered 
as early markers of the second lineage, have been reported, such as fibroblast growth factor 
8 and 10,8 Isl1,6 inhibitor of differentiation Id2,9 GATA factors targeting Mef2c10,11 and Tbx1 
and Tbx18.12,13
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Terminology in this rapidly evolving area of recruitment of new myocardium is still somewhat 
confusing as most cell differentiation markers and sometimes there lineage tracing have 
different spatio-temporal boundaries. 
From 9.5 days post conception (dpc) onwards we have become particularly interested in 
recruitment of myocardium at the venous pole, which we refer to by the new positional term: 
posterior heart field (PHF), as an addition to the anterior heart field at the outflow tract. We 
have discovered that a novel gene in heart development, called podoplanin, not only demarcates 
a specific area of myocardium at the sinus venosus of the heart, but is also expressed in major 
parts of the cardiac conduction system (CCS). In the differentiation of the CCS a number of 
markers have already been reported that are expressed in the sinoatrial and atrioventricular 
conduction system such as HNK1 and Leu7,14-16 PSA-NCAM,17 Msx218 and the reporter genes 
CCS-LacZ,19-21 MinK,22 Tbx323 and cardiomyocytes – antigens.24 Very recently a Mesp-1 non-
expressing myocardial population was reported in the ventricular conduction system.25 All 
these studies, however, concentrate on the differentiation of the CCS myocardium as opposed 
to the chamber myocardium and do not, as is suggested by our present findings, provide a link 
with the recruitment of second lineage myocardium.
Podoplanin is a 43-kd mucin type transmembrane glycoprotein,26 which has not been described 
during heart development. It was first called E11 antigen by Wetterwald  as a new marker for 
an osteoblastic cell line. The protein is also found in other cell types including the nervous 
system, the epithelia of the lung, eye, oesophagus and intestine,27 the mesothelium of the 
visceral peritoneum26  and podocytes in the kidney.28 Furthermore, it has recently been 
investigated as a marker for lymphatic endothelium.29
Our study of podoplanin expression in the developing myocardium of the PHF is combined 
with a novel finding regarding Nkx2.5, which is an early marker of cardiac progenitor cells30  
and demarcates the cardiac field31 in concert with GATA-4/5/6.32 Nkx2.5 is also shown to be 
essential for normal differentiation and function of the CCS in both human33 and mouse 
studies.34
In this study we will describe development of novel sinus venosus myocardium, in close 
correlation with the mesothelial lining of the pericardio-peritoneal coelomic cavity that is 
demarcated by positive podoplanin expression and Nkx2.5 non-expression. The podoplanin 
expression in the CCS provides a possible link between this novel myocardium from the PHF 
with the development of the sinoatrial node and other parts of the CCS.  
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MATeRiAL AND MeTHoDs 
We studied the lining of the thoracic cavity and heart in wildtype mouse embryos of 9.5 dpc 
(n=8), 10.5 dpc (n=8), 11.5 dpc (n=7), 12.5 dpc (n=8), 13.5 dpc (n=8), 14.5 dpc (n=9) and 
15.5 dpc (n=2). The embryos were fixed in 4% paraformaldehyde (PFA) and routinely 
processed for paraffin immunohistochemical investigation. The 5 μm transverse sections were 
mounted onto egg-white / glycerin coated glass slides in a 1 to 5 order, so that 5 different 
stainings from subsequent sections could be compared. 
immunohistochemistry
After rehydration of the slides, inhibition of endogenous peroxidase was performed with a 
solution of 0.3% H2O2 in PBS for 20 min. The slides were incubated overnight with the 
following primary antibodies: 1/2000 anti-atrial myosin light chain 2 (MLC-2a, which was 
kindly provided by S.W. Kubalak, Charleston, SC, USA), 1/4000 anti-human Nkx2.5 (Santa 
Cruz Biotechnology, Inc.,CA, USA) and 1/1000 anti-podoplanin (clone 8.1.1. Hybridomabank, 
Iowa, USA). All primary antibodies were dissolved in PBS-Tween-20 with 1% Bovine Serum 
Albumin (BSA, Sigma Aldrich, USA). Between subsequent incubation steps all slides were 
rinsed as follows: PBS (2x) and PBS-Tween-20 (1x). The slides were incubated with secondary 
antibodies for 40 min: for MLC-2a 1/200 goat-anti-rabbit-biotin (Vector Laboratories, USA, 
BA-1000) and 1/66 goat serum (Vector Laboratories, USA, S1000) in PBS-Tween-20; for 
Nkx2.5 1/200 horse-anti-goat-biotin (Vector Laboratories, USA, BA-9500) and 1/66 horse 
serum (Brunschwig Chemie, Switserland, S-2000) in PBS-Tween-20; for podoplanin 1/200 
goat-anti-Syrian hamster-biotin (Jackson Imunno research, USA, 107-065-142) with 1/66 goat 
serum (Vector Laboratories, USA, S1000) in PBS-Tween-20. Subsequently, all slides were 
incubated with ABC-reagent (Vector Laboratories,USA, PK 6100) for 40 min. For visualisation, 
the slides were incubated with 400 μg/ml 3-3’di-aminobenzidin tetrahydrochloride (DAB, 
Sigma-Aldrich Chemie, USA, D5637) dissolved in Tris-maleate buffer pH7.6 to which 20 μl 
H2O2 was added: MLC-2a 5 min; Nkx2.5 and podoplanin 10 min. Counterstaining was 
performed with 0.1% haematoxylin (Merck, Darmstadt, Germany) for 10 sec, followed by 
rinsing with tap water for 10 min. Finally, all slides were dehydrated and mounted with 
Entellan (Merck, Darmstadt, Germany). 
3D reconstructions
We made 3D reconstructions of the atrial and ventricular myocardium of MLC-2a stained 
sections of 11.5 dpc and 13.5 dpc embryos in which podoplanin positive and Nkx2.5 negative 
myocardium from adjacent sections were manually superimposed to show overlapping areas. 
The reconstructions were made as described earlier20 using the AMIRA software package 
(Template Graphics Software, San Diego, USA). 
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ResULTs
Below we will describe the expression patterns of MLC-2a, podoplanin and Nkx2.5 in the 
PHF in several subsequent stages of heart development (9.5-15.5 dpc), while in Figures 1-3 
typical examples and 3D reconstructions of the expression patterns of these proteins are 
provided.
stage 9.5 dpc 
At this stage the heart is still in the looping phase and the boundaries of the primary heart tube 
can easily be demarcated by immunohistochemistry. The MLC-2a and Nkx2.5 staining of the 
myocardium stops at the transition with the negatively stained coelomic epithelium at the 
dorsal mesocardium. This squamous coelomic epithelium is part of the lining of the pericardio-
peritoneal cavities, which are laterally flanked by the cardinal veins. Podoplanin is slightly 
positive at the left side and negative at the right side on the medial border of the cardinal veins 
wall. There is no podoplanin staining discernable at other sides at this stage yet.
stages 10.5 dpc and 11.5 dpc
Serial MLC-2a stained sections have been reconstructed to form a 3D image. Figures 1a and 
1b show the dorsal face of the heart in which the various staining patterns are depicted. The 
line in Figure 1a shows the level of the sections depicted in c-k. Septation of the ventricular 
inlet and atrium has started. On the right side the venous valves are already recognizable 
(Figure 1c). Podoplanin expression is observed in the coelomic lining and in the mesenchyme 
adjoining the medial wall of the left superior cardinal vein (Figure 1b and k) with light staining 
alongside the right superior cardinal vein at the position of the developing right sinoatrial node 
(Figure 1b, i and j). The left sided expression envelops the sinus venosus confluence of the 
cardinal veins (Figure 1b) and extends in the myocardium to the posterior region of the 
atrioventricular canal (Figure 1i and k), which is the site of the future atrioventricular node. 
The podoplanin positive mesenchyme is differentiating into myocardium as indicated by the 
overlapping expression with MLC-2a (compare Figure 1a and c-e with 1b and i-k). These 
overlapping areas are Nkx2.5 negative in contrast to the marked Nkx2.5 staining in the MLC-
2a positive myocardium of the atria and the ventricles (Figure 1a and f-h).
stages 12.5 dpc and 13.5 dpc
The 3D reconstruction of MLC-2a stained sections from an 13.5 dpc embryonic heart (dorsal 
face shown) are depicted in Figures 2a and 2b. The cardiac chambers are now clearly 
discernable. As expected the MLC-2a is more markedly expressed in the atrial and sinus 
venosus myocardium than in the ventricular myocardium (Figure 2c and e). The coelomic 
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At the venous pole we now discern marked podoplanin expression in the myocardium of the 
developing right sided sinoatrial node and the patchy staining in the venous valves, while the 
adjoining atrial myocardium is podoplanin negative (Figure 2k and l). The sinoatrial nodal 
myocardium is still in close contact with the adjacent markedly podoplanin positive coelomic 
lining (Figure 2k and l). Bordering the left cardinal vein a similar podoplanin positive cell 
cluster is seen, as well as podoplanin positive myocardial strands running along the posterior 
left atrial wall that merge with the myocardial cells of the common pulmonary vein (Figure 
2m and n). The continuity of these strands is obvious with patches of cuboidal podoplanin 
positive cells, as opposed to squamous podoplanin positive epithelial cells, lining both the 
pleural (Figure 2k-n) and pericardial cavity (Figure 2k-n). Both left and right sided podoplanin 
positive cell clusters as well as the myocardium of the wall of both cardinal veins are positive 
for MLC-2a although the staining is somewhat less intense compared to the main body of the 
atrial wall (Figure 2c-f).
The expression of Nkx2.5 (Figure 2a and g-j) does not overlap completely with the MLC-2a 
or the podoplanin staining. Nkx2.5 is negative in the right sinoatrial node, the posterior cell 
cluster between the left cardinal vein and the pulmonary vein and in the wall of the right and 
left cardinal veins (Figure 2g-j). A podoplanin and MLC-2a positive myocardial cell strand 
extends from the left side of the sinus venosus and stretches by way of the dorsal mesocardium 
and the spina vestibulum deep into the crux of the heart (Figure 2e, i and m). The staining 
encircles the orifice of the left cardinal vein, which opens into the right atrial cavity (not 
shown). This myocardial strand extends through the basis of the atrial septum to the position 
of the atrioventricular node and can be followed to the common bundle (Figure 2e, i and m), 
bundle branches (Figure 3a-d), the moderator band and the Purkinje system (not shown). Up 
to the level of the bundle branches this strand shows a mosaic Nkx2.5 staining which is 
Figure 1. Dorsal view of a reconstruction (a, b) of an 11.5 dpc wildtype mouse heart of the myocardium stained 
with MLC-2a (atria brown and ventricles grey). In (a) the Nkx2.5 negative pattern is added (lime green) and (b) 
shows the podoplanin positive pattern (turquoise). The left (LCV) and right (RCV) cardinal veins and their sinus 
venosus (SV) confluence are transparent blue. (c-e): Sections stained with MLC-2a (c: overview and details d: line 
box and e: dotted box) show marked expression in the myocardium of the wall of the atria (RA and LA). Also the 
anlage of the sinoatrial node (SAN) and a left sided mesenchymal population (asterisk in e) as well as the wall of 
the LCV show MLC-2a expression. (f-h): Staining in consecutive sections with Nkx2.5 (lime green in reconstruction 
(a) and overview in (f), with higher magnification in (g) and (h), show a marked  expression in the atrial wall (g) and 
negativity in the mesenchyme (asterisk in h) and the SAN (g). There is no staining in the wall of the LCV. Podoplanin 
staining is positive in some parts of the coelomic cavities (arrows in h and k). This is not shown in the reconstruction 
(b) where only the overlap of MLC-2a and podoplanin (turquoise) is shown. Podoplanin is more intense at the left 
side at this stage of development (k) specifically in the pre-myocardial mesenchyme running from the left pericardio-
peritoneal canal, caudal of the anlage of the common pulmonary vein (PV; pink in a and b) through the base of the 
atrial septum to the posterior part of the atrioventricular canal dorsal of the inferior atrioventricular cushion (AVC) 
(i and k). Scale bars: (c-k) = 100μm. 
100
chapter 4
therefore less marked than the surrounding myocardium (Figure 2i). A mosaic Nkx2.5 staining 
is also observed in the venous valves (not shown).
At stage 13.5 dpc the common pulmonary vein for the first time is clearly discernable with a 
myocardial sheath in which podoplanin positive cells are extending (Figure 2m and n). 
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MLC-2a and Nkx2.5 are positive in the pulmonary wall although both are less marked as 
compared to the adjacent atrial wall (Figure 2f and j). Between the left cardinal vein and the 
myocardial pulmonary venous wall a small cluster of podoplanin and MLC-2a positive and 
Nkx2.5 negative myocardial cells is still present (Figure 2f, j and n).
stages 14.5 dpc and 15.5 dpc
The left sided podoplanin expression in the myocardium is disappearing. The staining is only 
retained in the right sinoatrial node and it has become more marked in the common and right 
and left bundle branches (Figure 3e and f).
Figure 2. Dorsal view of a reconstruction (a, b) of an 13.5 dpc wildtype mouse heart of the myocardium stained 
with MLC-2a (atria brown and ventricles grey). The Nkx2.5 negative region is superimposed in (a), whereas the 
podoplanin positive region is presented in (b). The left (LCV) and right (RCV) cardinal veins which have an 
independent entrance into the right atrium are transparent blue. The transsection (1) for the sinoatrial node (SAN) 
and the left sided podoplanin expression and pulmonary vein (PV in pink) (2) are indicated. (c-f): Sections stained 
with MLC-2a antibody (c and e: overviews at transsections 1 and 2 and magnifications d and f: boxed areas) show 
marked expression in the myocardium of the wall the atria (RA and LA) and somewhat lesser in the right (RV) and 
left (LV) ventricle. The LCV in (f), RCV in (d) and the SAN in (d) are positive. A cluster of moderately MLC-2a 
positive cells (arrow in f) is positioned in the mesenchyme between the LCV and PV. Nkx2.5 staining is markedly 
positive in all major components of the heart. Absence of staining (lime green in a) is seen in the wall of the RCV 
(h), the SAN (g and h), the LCV and the mesenchymal cell cluster (arrow in j). The PV has a less marked Nkx2.5 
(mosaic) staining (j). The same accounts for a circular structure situated at the site of the common bundle at the top 
of the ventricular septum (VS) (dotted circle in e, i and m). Podoplanin staining is observed on both right and left 
sided MLC-2a areas (turquoise in b). This encomprises the SAN (k and l) and the left sided cluster between LCV, 
partly merging with the PV wall (arrow in n) and extending into the base of the atrial septum (AS). It is also positive 
in the common bundle (dotted circle in m) extending over the top of the VS (k). Podoplanin is also positive in the 
lining of the coelomic cavity. In areas with underlying podoplanin positive myocardial cells the coelomic cells are 
cuboid (open arrow in k-n). In the remaining coelomic lining, like the epicardium (arrowhead in n and o) the 




The contribution of myocardium to the primary heart tube has been acknowledged for many 
years by tracing cells with marker constructs3,35 as well as molecularly based tracing techniques 
using reporter mice.7,10-12,36 From these studies the addition of myocardium to, in particular the 
outflow tract, is obvious. Moreover, Kelly7 described the recruitment of cardiomyocytes from 
the splanchnic mesoderm to the outflow and inflow tract of the heart as a second myocardial 
lineage adding to the first lineage. The regulation of continued cardiogenesis at the inflow 
tract of the heart, which already starts at 8.5 dpc, is far from unravelled and has to fit in the 
multiple transcriptional domains of i.e. atrial chambers.37 This process will be complicated if 
Figure 3. Reconstruction of the podoplanin expression (turquois) depicting the various parts of the myocardium 
of the conduction system in the same 13.5 dpc embryo depicted in Figure 2a. Left frontal view shows the position 
of the sinoatrial node (SAN) next to the right cardinal vein (RCV), the presence in the right (RVV) and left (LVV) 
venous valves (b) merges in the region of the atrioventricular node (AVN) visible in the left lateral view. The expression 
is also found in a left atrioventricular ring of myocardium (LAVR). The AVN myocardium continues as a common 
bundle (CB) in the right (RBB) and left (LBB) bundle branches. (c-f): Sections of the thorax and heart of wildtype 
mouse embryos of 13.5 dpc (c with box magnified in d) and 15.5 dpc (e with box magnified in f) stained for podoplanin 
which is clearly visible in the common bundle (CB) in (c, d, e and dotted circle in f), as well as in the RBB and LBB 
(e and f) on top of the ventricular septum (VS). PV indicates Pulmonary vein; SS, Septum spurium. Scale bars: (c-f) 
= 100μm.
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it is comparable with the situation at the outflow tract in which many genes are involved such 
as Isl1,6 GATA factors targeting Mef2c,10,11 Tbx1,12 Tbx4,38 Id2,9 and many others including 
members of the fibroblast growth factor and TGF beta family.39 Our study adds podoplanin 
to this list for the PHF, which is most probably a subpopulation of the second lineage.6,7 
Podoplanin and MLc-2a in the posterior heart field
Podoplanin is expressed in several tissues in the developing embryo but for this study the 
reported expression in the coelomic lining,26 the underlying mesenchyme and the myocardium 
of the CCS is important. Expression in other tissues did not pose problems in interpretation 
as patterns are well separated in time and space. The coelomic epithelium was clearly activated 
at specific sites, being irregular and cuboidal which might indicate an ongoing process of 
epithelial-mesenchymal transformation (EMT). Similar EMT events have been described for 
the endocardium of the atrioventricular cushions40,41 as well as epicardium derived cells 
(EPDCs)42,43 expressing Wt1;44-46 and cytokeratin.47 As a podoplanin reporter mouse has not 
been developed we cannot unequivocally prove EMT. It is remarkable that the podoplanin 
expression is retained in the mesenchyme underlying the coelomic epithelium and that we 
have shown that we are dealing with a myocardial progenitor cell by the overlapping expression 
with MLC-2a. Although MLC-2a is described to be specific for atrial myocardium,48 it also 
stains the myocardium of the sinus venosus and somewhat weaker the ventricular 
cardiomyocytes. The contribution of novel myocardium to the PHF at the sinus venosus seems 
to stop after 15.5 dpc as the podoplanin expression diminishes and the coelomic epithelium 
becomes quiescent resuming a squamous phenotype.
A functional role for podoplanin is still to be found. Data are emerging describing an EMT 
process of podoplanin dependent downregulation of E-cadherin in invasive and migratory 
cells of oral mucosal cancer cells.49 Also an EMT independent process in adult tissues has 
been described, where podoplanin induces the reorganisation of ezrin-radixin-moesin (ERM) 
proteins and the actin cytoskeleton via downregulation of RhoA signal, resulting in collective 
tumor cell migration and conelike invasion.50 For our study it would support a possible role 
for podoplanin in migration and invasion of the PHF myocardium into parts of the CCS.
Nkx2.5 expression and the posterior heart field
As a marker for pre-cardiac mesoderm and myocardial cells we also used an antibody against 
human Nkx2.5.51,52 We found that the U-shaped PHF myocardium was negative for Nkx2.5. 
During development this resulted in a Nkx2.5 negative right sided sinoatrial node. In the 
podoplanin positive venous valves, the base of the atrial septum and the atrioventricular 
conduction system, there seemed to be a mosaic Nkx2.5 expression as opposed to the overall 
expression in the atrial and ventricular wall comparable to the heterogeneous pattern of Nkx2.5 
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expression pattern described previously.53 The myocardial contribution to the sinus venosus 
from precursors that are Nkx2.5 negative was also recently described.13 
The function of Nkx2.5 in cardiogenesis seems very important but is still far from clear. 
Different noggin-sensitive Nkx2.5 enhancers are found in various segments of the heart during 
development, indicative for chamber-specific functions,54 whereas cofactors such as GATA-4 
are equally important. Furthermore, the differentiation of cardiac Purkinje fibers requires 
precise spatiotemporal regulation of Nkx2.5 expression,52 probably in a dose-dependent way.54 
The mechanism of Nkx2.5 regulation is probably dependent on repressor systems for which 
strong candidates include Tbox family members, such as Tbx2 and Tbx5.55 Most studies have 
concentrated on Nkx2.5 in intracardiac patterning and differentiation. The implications of a 
population of Nkx2.5 negative myocardial cells in the PHF have to be evaluated further, while 
at least Tbx18 plays a role.13
The posterior heart field and development of the cardiac conduction system
Several marker studies have linked sinus venosus myocardium to the development of the 
cardiac conduction system. These include HNK1 and Leu7,14-16 PSA-NCAM17 and more 
recently the transgenic reporter mice for CCS-LacZ19-21 and MinK.22 Our own studies on HNK1 
and Leu714-16 provide in general the same pattern for the CCS as now found in our study for 
podoplanin. The CCS-LacZ mouse shows that the complete cardiac conduction system 
myocardium is positive. CCS-LacZ does not differentiate between Nkx2.5 expressing and 
non-expressing myocardial cells as the right sinoatrial node is CCS-LacZ positive. Also other 
reported markers as Tbx323 do not reflect the described podoplanin positive PHF myocardium. 
In this respect the recent elegant reporter gene study of Mesp-1 expressing and non-expressing 
myocardial cells in the heart is of great interest.25 These authors show that there is a myocardial 
heterogeneity in the atrioventricular conduction system. They also show that this does not 
refer to a neural crest derived population. The latter origin was shown by our group to align 
with the CCS,56 although we never found the neural crest cells to attain a myocardial phenotype. 
The Mesp-1 study does speculate on the origin of the non-expressing Mesp-1 cells but has 
not traced them to the PHF. There are no data on their contribution to the sinoatrial and 
atrioventricular node. 
In literature there are two main concepts for development of the CCS. The first one provides 
evidence for an autonomous origin of the central conduction system from cardiomyocytes 
residing in the primary heart tube.57 This myocardium retains a primitive phenotype after 
ballooning of the atrial and ventricular cavities has started. Tbx2 and Tbx3, and ANF are 
important genes guiding this process.58 In this concept the atrioventricular node derives from 
the primitive myocardium of the atrioventricular canal. The origin of the cells of the conduction 
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system and specifically the atrioventricular node is still under debate. It seems evident that 
part of the posterior atrioventricular node originates from the myocardium59 of the primary 
heart tube. Our current findings, supported by the Mesp-1 study do not exclude a contribution 
of myocardium from the PHF to the CCS, which is further strengthened by the extensive clonal 
cell tracing study of the Buckingham group.60
The second concept on conduction system differentiation works along local differentiation 
pathways of the myocardium of the heart tube61 by induction and signaling. This concept is 
more in line with our data on secondary differentiation of the conduction system in which 
both EPDCs62 and neural crest cells63 might play the inductive role. It does not exclude 
secondary sources of myocardium, which in part correlate with migration pathways of EPDCs 
and neural crest cells. 
The posterior heart field and functional clinical implications
Our data show an early and transient left sided counterpart of the sinoatrial node. In the early 
embryonic heart using voltage-sensitive dye, the pacemaking activity has initially been located 
to originate at the left side,64  which would fit with our observations. It also supports the reports 
on the anlage of a left sinoatrial node, which is found as an anomaly in left atrial isomerism.65 
A possible role for podoplanin in the electrophysiology of CCS still has to be investigated. It 
has been reported, however, to be essential for water transport,27 Ca dependent cell 
adhesiveness49 and cationic, anionic and amino acid transport.66 These aspects might be linked 
to cellular communications important for cardiac conduction. 
Mutations of the Nkx2.5 gene in human patients lead to conduction system disturbances and 
atrial septal defects.33,67 Comparable to these mutations in human patients is the Nkx2.5 
haploinsufficiency in mice embryos. The effects of Nkx2.5 haploinsufficiency, described above, 
are weaker in mice but convergent with those in human.68 Our study provides a new insight 
in that Nkx2.5 negative PHF myocardium is continuously added to the already Nkx2.5 positive 
myocardium of the primary heart tube. We show that PHF myocardium forms the sinoatrial 
node, which is Nkx2.5 negative. PHF myocardium might also add cells through the base of 
the atrial septum to the region of the atrioventricular conduction system and to the venous 
valves, which play a role in development of the conduction system20 as well as in the formation 
of the atrial septum.69 In this way atrial septal defects33 found in Nkx2.5 human mutation 
patients may relate to a deficient contribution from the PHF myocardium to the venous valves. 
Most studies are dealing with Nkx2.5 mutations with ensuing underexpression. In an 
overexpression study, which would influence the Nkx2.5 negative sinoatrial node, defects in 
pacemaker activity with bradycardia have been described.34 In conclusion the temporo-spatial 
information in this study on the late contribution of Nkx2.5 negative as well as positive 
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Podoplanin deficient mice show a Rhoa related 






We investigated the role of podoplanin in development of the sinus venosus myocardium 
comprising the sinoatrial node, the dorsal atrial wall and the primary atrial septum as well as 
the myocardium of the cardinal and pulmonary veins. We analyzed podoplanin wildtype and 
knockout mouse embryos between 9.5-15.5 days post conception (dpc) using 
immunohistochemical marker podoplanin, sinoatrial node marker HCN4, myocardial markers 
MLC-2a, Nkx2.5 as well as Cx43, coelomic marker WT-1 and epithelial-to-mesenchymal 
transformation markers E-cadherin and RhoA. 3D reconstructions were made and myocardial 
morphometry were performed. Podoplanin mutants showed hypoplasia of the sinoatrial node, 
the primary atrial septum and dorsal atrial wall. Myocardium lining the wall of the cardinal 
and pulmonary veins was thin and perforated. Impaired myocardial formation is correlated 
with abnormal epithelial-to-mesenchymal transformation of the coelomic epithelium due to 
upregulated E-cadherin and downregulated RhoA, which are controlled by podoplanin. Our 




During early embryogenesis the lateral plate mesoderm splits into two layers: the somatic and 
the splanchnic mesoderm forming the outer and the inner layer of the coelomic cavity.1,2 The 
somatic mesoderm is involved in development of the body wall and extremities while 
myocardial precursors are restricted to the splanchnic mesoderm.3,4 Subsequently, the left and 
right primary heart fields (cardiogenic plates) fuse at the ventral midline resulting in the 
primary linear heart tube, which starts looping at 8.5 days post conception (dpc).1,2,5
Previous studies of heart development5-7 have shown that further development of the heart 
tube is related to the addition of cells at both the arterial and venous pole of the heart, forming 
the outflow and the inflow tract myocardium, respectively. These early observations on the 
addition of the secondary myocardium have recently been supported by several studies 
describing the addition of myocardium at the arterial pole, being secondary8 and anterior heart 
fields9-12 and the posterior heart field (PHF) at the venous pole12-15 of the developing heart. The 
complete length of the splanchnic mesoderm contributing to the addition of myocardium at 
both poles of the heart was called second heart field14 or second lineage.10,12,14 
A number of genes and proteins, considered as early markers of the second heart field at the 
outflow and inflow tract, have been reported, such as MesP1,16 Fibroblast growth factor (Fgf) 
113
Podoplanin and venous pole development 
5
8 and 10,9 BMP-2 and Nkx2.5,8,13,15 Isl1,14 inhibitor of differentiation Id2,17 GATA factors 
targeting Mef2c,18,19 Tbx1, Tbx3 and Tbx1815,20 and Shox2.21 Recently we have added podoplanin 
to this list as a novel gene in cardiac development. 
As a coelomic and myocardial marker, podoplanin is specifically expressed in the mesenchyme 
and in the myocardium at the venous pole.13,22 Studying the mesenchymal population, 
podoplanin expression was observed in the proepicardial organ and epicardium.13,22,23 In the 
cardiomyocyte population podoplanin staining was seen in major parts of the developing 
atrioventricular cardiac conduction system, in sinus venosus myocardium including the 
sinoatrial node, the venous valves, the dorsal mesocardium, the dorsal atrial wall and primary 
atrial septum. Also the myocardium surrounding the cardinal veins and the common pulmonary 
vein belongs to this population.13,22 In earlier publications, podoplanin, a 43-kd mucin type 
transmembrane glycoprotein, first named E11 antigen as a new marker for an osteoblastic cell 
line,24 was also reported in the nervous system, the epithelia of lung, eye, oesophagus and 
intestine,25 the mesothelium of the visceral peritoneum,24 the coelomic wall (pericardium) 
lining the pericardial cavity13 and the epicardium,22 the podocytes of the kidney26 and the 
lymphatic endothelium.27 
To elucidate a possible functional role of podoplanin in cardiac development and more 
specifically in the development of the sinus venosus myocardium, we studied podoplanin 
knockout mouse embryos and used several immunohistochemical markers. To investigate 
the sinus venosus myocardium including the sinoatrial node we have used hyperpolarization-
activated, cyclic nucleotide-gated cation 4 (HCN4).28-30 In addition, atrial myosin light chain 
2 (MLC-2a), NK2 transcription factor related locus 5 (Nkx2.5) and connexin 43 (Cx43) 
were used. Furthermore, we studied E-cadherin, a cell to cell adhesion protein, and RhoA 
important for epithelial-to-mesenchymal transformation (EMT) of the coelomic epithelium, 
a process that allows epithelial cells to become mobile mesenchymal cells.31 To visualize 
the epithelium and mesothelium of the coelomic cavity, the epicardium and sites of active 
EMT we have used Wilm’s tumor suppressor protein (WT-1).32-34 It has been described that 
the PHF and resulting myocardium are derived from the epithelial lining of the coelomic 
cavity (splanchnic mesothelium) by EMT.13 During normal development, loss of E-cadherin 
is needed for proper EMT resulting in loss of epithelial features35 and consecutive 
development into migratory mesenchymal cells. During abnormal development, an 
upregulated state of E-cadherin, by e.g. lack of podoplanin, causes an altered EMT.22,36 
Podoplanin can, therefore, be considered as an inhibitor of E-cadherin stimulating EMT. In 
addition, RhoA activation by podoplanin and ezrin interaction have been described to lead 
into podoplanin-induced EMT.37 Similar to E-cadherin, lack of podoplanin might lead to 
downregulated RhoA and altered EMT.  
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In the current paper we studied the role of podoplanin in the development of the sinus venosus 
myocardium derived from the PHF, which is a part of the more extensive second heart field. 
We demonstrate that knocking out the podoplanin gene leads to myocardial abnormalities in 
sinus venosus myocardium at the venous pole of the developing mouse heart.      
 
MATeRiAL AND MeTHoDs
Generation of podoplanin-/- mice and harvesting of embryos
The podoplanin knockout mice were generated by homologous recombination in embryonic 
stem cells from the 129S/v mouse line by inserting a neomycin phosphotransferase cassette 
in a 7.7kb genomic fragment encompassing exons II to V. The complete description of this 
model was reported previously.22 Briefly, the heterozygous ES cell clones were test-bred for 
germline transmission with Swiss mice to generate podoplanin+/- offspring (50% 129S/v: 50% 
Swiss genetic background) using standard procedures. These mice were crossed to obtain 
podoplanin-/- embryos and podoplanin+/+ (wildtype) littermates. The morning of the vaginal 
plug was stated 0.5 dpc. Pregnant females were sacrificed and embryos were harvested. 
General description 
We investigated the lining of the coelomic cavity and the morphology of the sinus venosus 
myocardium of the heart in 27 wildtype mouse embryos of 9.5 dpc (n=4), 10.5 dpc (n=4), 
11.5 dpc (n=3), 12.5 dpc (n=4), 13.5 dpc (n=5), 14.5 dpc (n=4) and 15.5 dpc (n=3) and 
compared these with 37 podoplanin knockout mouse embryos of 9.5 dpc (n=4), 10.5 dpc 
(n=4), 11.5 dpc (n=6), 12.5 dpc (n=8), 13.5 dpc (n=6), 14.5 dpc (n=5) and 15.5 dpc (n=4). All 
embryos were fixed in 4% paraformaldehyde (PFA) and routinely processed for paraffin 
immunohistochemical investigation. 
immunohistochemistry
Immunohistochemistry was performed with antibodies against MLC-2a (1/6000, kindly 
provided by S.W. Kubalak, Charleston, SC, USA), Nkx2.5 (1/4000, Santa Cruz Biotechnology, 
Inc., CA, USA, SC-8697), podoplanin (clone 8.1.1., 1/500, Hybridomabank, Iowa, USA), 
WT-1 (1/1000, Santa Cruz Biotechnology, Inc., CA, USA, sc-192), E-cadherin (1/150, Santa 
Cruz Biotechnology, Inc., CA, USA, SC-7870), HCN4 (1/1000, Alomone labs, The Netherlands, 
APC-052), RhoA (1/2000, Santa Cruz Biotechnology, Inc., CA, USA, SC-418) and Cx43 
(1/200, Sigma-Aldrich Chemie, USA, C6219). The primary antibodies were dissolved in 
phosphate buffered saline (PBS)-Tween-20 with 1% Bovine Serum Albumin (BSA, Sigma 
Aldrich, USA). Between subsequent incubation steps all slides were rinsed in PBS (2x) and 
PBS-Tween-20 (1x). The slides were incubated with the secondary antibody for 45 min: for 
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MLC-2a, WT-1, E-cadherin, HCN4 and Cx43 with 1/200 goat-anti-rabbit-biotin (Vector 
Laboratories, USA, BA-1000) and 1/66 goat serum (Vector Laboratories, USA, S1000) in 
PBS-Tween-20; for Nkx2.5 with 1/200 horse-anti-goat-biotin (Vector Laboratories, USA, 
BA-9500) and 1/66 horse serum (Brunschwig Chemie, Switserland, S-2000) in PBS-Tween-20; 
for podoplanin with 1/200 goat-anti-Syrian hamster-biotin (Jackson Imunno research, USA, 
107-065-142) and 1/66 goat serum (Vector Laboratories, USA, S1000) in PBS-Tween-20 and 
for RhoA with 1/200 horse-anti-mouse-biotin (Santa Cruz Biotechnology, Inc., CA, USA, 
SC-9996-FITC) and 1/66 horse serum (Brunschwig Chemie, Switserland, S-2000) in PBS-
Tween-20. The slides were incubated with ABC-reagent (Vector Laboratories,USA, PK 6100) 
for 45 min. For visualization the slides were incubated with 400 μg/ml 3-3’di-aminobenzidin 
tetrahydrochloride (DAB, Sigma-Aldrich Chemie, USA, D5637) dissolved in Tris-maleate 
buffer pH 7.6 to which 20 μl H2O2 was added: MLC-2a, and E-cadherin 5 min; Nkx2.5, HCN4, 
Cx43, WT-1 and podoplanin 10 min. Counterstaining was performed with 0.1% haematoxylin 
(Merck, Darmstadt, Germany) for 5 sec, followed by rinsing with tap water for 10 min. All 
slides were dehydrated and mounted with Entellan (Merck, Darmstadt, Germany). 
3D reconstructions
We made 3D reconstructions of the sinus venousus myocardium based on MLC-2a, Nkx2.5 
and HCN4 stained sections of wildtype as well as podoplanin knockout embryos of 12.5 dpc 
in which the morphological differences were shown. The reconstructions were made as 
previously described38  using the AMIRA software package (Template Graphics Software, San 
Diego, USA).
Morphometry of the myocardium  
Based on HCN4, MLC-2a and Nkx2.5 stained sections, sinus venosus and separately sinoatrial 
node myocardial volume estimation was performed of 12 wildtype mouse hearts of 11.5 dpc 
(n=3), 12.5 dpc (n=3), 13.5 dpc (n=3), 14.5 dpc (n=3) and 12 podoplanin knockout mouse 
hearts of 11.5 dpc (n=3), 12.5 dpc (n=3), 13.5 dpc (n=3), 14.5 dpc (n=3) based on Cavalieri’s 
principle as described previously.39 Statistical analysis was performed with an independent 
sample-t-test (P<0.05) using the SPSS 11.0 software program (SPSS Inc, Chicago, III). In 
summary, regularly spaced points (100 mm2 for sinus venosus myocardium and 49 mm2 for 
sinoatrial node myocardium) were randomly positioned on the HCN4 stained myocardium. 
The distance between the subsequent sections of the slides was 0.075 mm for sinus venosus 
myocardium and 0.025 mm for the sinoatrial node. The volume measurement was done using 
the HB2 Olympus microscope with a 100x magnification objective for the sinus venosus 
myocardium and 200x for the sinoatrial node.






We studied the embryonic phenotype of the podoplanin knockout mice, which show an 
increased embryonic death of approximately 40% of the homozygote embryos between 10-16 
dpc. Additionally, 50% of the neonatal homozygote knockout mice die within the first weeks 
of life, while heterozygous mutants reach sexual maturity. The cause of embryonic death has 
been correlated to the cardiac defects22 while the cause of neonatal death is still unknown.
Figure 1. Transverse sections showing EMT sites of the coelomic cavity epithelium in the hearts of 10.5 dpc 
wildtype (WT) and podoplanin knockout (podoplanin-/-) mouse embryos. To demarcate the coelomic mesothelium 
and sites of active EMT, we studied WT-1 staining (a, b, e and f) and E-cadherin staining (c and g). WT-1 positivity 
was found in the mesothelium (asterisk in b and f) and epithelium (CE) of the coelomic cavity and epicardium (EP) 
of the WT embryos (a and b). WT-1 staining was more extensive at the corners of the coelomic cavity (asterisk) below 
the left cardinal vein (LCV), where the CE appeared to be cuboidal and well organized (b). In the podoplanin-/- 
embryos WT-1 was also present in these regions (e and f), however, the CE was disorganized and the cells were 
irregular in shape and size (compare a and b with e and f). E-cadherin staining appeared stronger in both the EP and 
CE of the podoplanin-/- embryos (g) as compared to the WT mouse embryos (c). Remarkably, in the podoplanin-/- 
E-cadherin staining was not only upregulated in the CE but also in the underlying mesothelial cells (c and g). In WT 
embryos RhoA expression was seen in the coelomic mesenchyme, CE and epicardium (d). In the mutants overall 
expression of RhoA was downregulated (h).  LA indicates left atrium. Scale bars: (a), (e) = 60μm; (b-d), (f-h) = 30μm; 
magnification box in (c), (d), (g) and (h) = 20μm.    
117
Podoplanin and venous pole development 
5
Several marked morphological cardiac abnormalities were observed in the knockout mouse 
embryos. In the younger stages a hypoplastic proepicardial organ (10.5 dpc) as well as 
ventricular myocardium were observed with discontinuous epicardium, a thin layer of the 
subepicardial mesenchyme and a diminished amount of epicardium derived cells (EPDCs).22 
These hearts also presented with outflow tract abnormalities such as severe dextroposition of 
the aorta, coronary artery abnormalities, spongious myocardium of the developing 
interventricular septum and impaired formation and fusion of the atrioventricular cushions. 
At the sinus venosus region, which is the area of our focus, myocardial hypoplasia and 
morphological abnormalities were observed. In general, the sinus venosus myocardial 
abnormalities, mentioned below, were seen in the sinoatrial node, the dorsal atrial wall, the 
atrial septum as well as the myocardium of the cardinal and pulmonary veins. 
Morphology and immunohistochemical expression patterns of the sinus venosus myocardium 
will be described in the knockout embryos and compared to wildtype embryos, in subsequent 
stages of heart development.
Podoplanin expression in the heart
In wildtype mice the first expression of podoplanin can be recognized as early as 9.5 dpc in the 
coelomic mesothelium and in the proepicardial organ.13,22 Moreover, podoplanin was observed 
in the myocardium of the medial wall of the left cardinal vein shortly before entering the sinus 
venosus. At 10.5 dpc podoplanin staining in this region was more extensive and extended into 
the dorsal mesocardium. At the right side the staining is evaluated for the first time at the level 
of the future sinoatrial node, in the medial wall of the right cardinal vein. The venous valves 
showed also podoplanin positivity. At 12.5 dpc podoplanin was clearly observed in the 
pericardium, epicardium, sinoatrial node, venous valves, dorsal mesocardium, myocardium of 
the pulmonary vein, atrial septum and ventricular conduction system. Remarkably, podoplanin 
staining was also observed at the left side bordering the medial contour of the left cardinal vein. 
The pattern and intensity of this region was similar to the sinoatrial node region at the right 
side, although the left-sided region was smaller at this stage.13 
sites of epithelial-to-mesenchymal transformation  
To demarcate the coelomic mesothelium and sites of active EMT, we used WT-1 staining as 
a coelomic mesothelial marker, E-cadherin staining as a cell-to-cell adhesion marker and RhoA 
playing a crucial role in EMT at specific sites of the venous pole. WT-1 was observed in both 
the coelomic mesothelium and proepicardial organ at 9.5 dpc in the wildtype. In the mutants, 
compared to the wildtype embryos, these regions were smaller and E-cadherin was upregulated. 
At 10.5 dpc in wildtype embryos WT-1 positivity was found in the single layer of mesothelium 
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corners of the coelomic cavity at both sides adjacent to the cardinal veins, where the expression 
of WT-1 was more extensive and the cells of the coelomic mesothelium appeared to be cuboidal 
and well organized (Figure 1b). In the podoplanin knockout embryos WT-1 was also present 
in these regions (Figure 1e and f), however, the coelomic mesothelium was disorganized, the 
cells were irregular in shape and size and seemed to have maintained their epithelial 
confinement (Figure 1, compare a and b with e and f). The defective spreading of the epicardium 
at several locations was shown after WT-1 staining that followed this pattern and did not 
normally cover the myocardium in the knockout mouse embryos (Figure 1a and e). Increased 
E-cadherin staining has been observed clearly in both the epicardium and mesothelium lining 
the coelomic wall in the podoplanin knockout embryos (Figure 1g) compared to the wildtype 
mouse embryos (Figure 1c). Remarkably, in the mutants E-cadherin staining was not only 
upregulated in the epithelium of the coelomic cavity but also in the underlying mesenchymal 
cells (Figure 1c and g), supporting the observation of disturbed EMT. At 10.5 dpc in wildtype 
embryos major RhoA expression was seen in the mesenchyme and epithelium of the coelomic 
cavity and epicardium (Figure 1d). In the mutants overall expression of RhoA was 
downregulated (Figure 1h).
The sinus venosus myocardium
To evaluate the extent of sinus venosus myocardium we studied the expression of HCN4 in the 
wildtype and podoplanin knockout embryos between 9.5-14.5 dpc. The HCN4 positive region 
of the sinus venosus area (Figure 2i, k and Figure 3d, f, m, o) overlaps the Nkx2.5 negative 
(Figure 2g, j and Figure 3h-k) and MLC-2a positive sinus venosus region (Figure 2c-f and 
Figure 3c, e, l, n). Podoplanin is also expressed in these regions of the sinus venosus myocardium, 
almost completely overlapping with the Nkx2.5 negative and HCN4 positive regions. 
Figure 2. Cranio-dorsal view of 3D reconstructions (a and b) and transverse sections (c-o) showing at 12.5 dpc 
the hypoplasia of the sinoatrial nodal (SAN) region in the podoplanin knockout (podoplanin-/-) mouse embryos 
compared to the wildtype (WT) embryos. The intersection line c refers to sections (c) and (d) and the intersection 
line e refers to sections (e) and (f). In the SAN (asterisks) the expression level of MLC-2a (c-f), Nkx2.5 (g and j), 
and HCN4 (i and k) was unaltered in the WT (c, d, g and i) and podoplanin-/- embryos (e, f, j and k). Section h shows 
podoplanin (Podo) expression in the SAN of the WT heart. The SAN in the podoplanin-/- is thin and hypoplastic 
compared to WT (compare d with f). In the mutants the venous valves (VV), dorsal atrial wall (arrows in c and e) 
and primary atrial septum (AS) were also small and hypoplastic (compare c with e). Because of the deficient AS the 
mutant hearts showed a large atrial septum defect (compare c with e) and the AS myocardium was not properly 
embedded in the atrioventricular cushion (AVC, arrow heads in c and e). The AVC was not fused properly with the 
ventricular septum resulting into a ventricular septum defect (compare c with e). In WT embryos, RhoA expression 
was seen in coelomic mesenchyme, CE as well as in SAN and epicardium (EP) (l, m). In the mutants, RhoA expression 
was downregulated in SAN as well as in CE and EP (n, o). LA indicates left atrium; LCV, left cardinal vein; RA, 
right atrium; RCV, right cardinal vein. In the 3D reconstructions: atrial myocardium, light brown; cardinal veins 
lumen, transparent blue; common pulmonary vein (PV) lumen, pink; sinus venosus myocardium, purple; ventricular 
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sinoatrial node and venous valves
In the sinoatrial node the MLC-2a positive (Figure 2c-f) and Nkx2.5 negative (Figure 2g, 
j) region were identical to the HCN4 (Figure 2i, k) and podoplanin (Figure 2h) positive 
areas. In contrast to the remaining sinus venosus myocardial structures, in the sinoatrial 
node HCN4 remained positive while Nkx2.5 negative staining was maintained. In the 
knockout mice the sinoatrial node was hypoplastic (Figure 2a, b, d, f) and the venous valves 
were shorter and thinner (Figure 2c, e), however, the expression pattern of MLC2a, Nkx2.5 
HCN4 and Cx43 (not shown), was not changed compared to the wildtype (Figure 2c-k). 
Comparable to 10.5 dpc in wildtype embryos, RhoA expression was seen in coelomic 
mesenchyme and epithelium as well as in sinoatrial node and epicardium (Figure 2l, m). In 
the mutants, RhoA expression was downregulated in sinoatrial node as well as in coelomic 
epithelium and epicardium (Figure 2n, o). 
Primary atrial septum and dorsal atrial wall  
In both wildtype and podoplanin knockout embryos MLC-2a expression was present in the 
sinus venosus myocardium and the myocardium of the atrial and ventricular wall (Figure 2a-f 
and Figure 3a-c, e, l, n). Similar to the sinoatrial node and venous valves, the expression pattern 
of the mentioned markers was unchanged in the mutants compared to the wildtype embryos. 
In the mutants, myocardial hypoplasia was seen of the dorsal atrial wall (Figure 2c-f). The 
atrial septum was thin (Figure 3c-f) and deficient (Figure 2c, e) with a large secondary foramen 
(Figure 2c, e). The myocardialization process at the base of the atrial septum was almost absent 
(Figure 2c, e). Additionally in the knockout embryos, the atrioventricular cushion was not 
fused properly to the top of the ventricular septum resulting into a persisting interventricular 
communication (Figure 2c, e). There is marked dilatation of the atria in the mutant embryos 
compared to the wildtype (Figure 2c, e).   
Figure 3. Cranio-dorsal view of 3D reconstructions (a and b) and transverse sections (c-o) showing the 
myocardial hypoplasia of the common pulmonary vein (PV), atrial septum (asterisk) and the wall of the cardinal 
veins of 12.5 dpc wildtype (WT) and podoplanin knockout (podoplanin-/-) embryonic mouse hearts. The 
intersection lines c, l, e and n refer to the sections (c), (l), (e) and (n) respectively. In the MLC-2a sections (c, e) the 
hypoplasia of the myocardium around the PV in the podoplanin-/- is clearly visible. Moreover, parts of myocardium 
around the PV, which are also positive for HCN4 (d) and podoplanin (g) are missing in the podoplanin-/- (compare 
c, d with e, f). This lack of myocardium around the PV is also seen in the sections stained with Nkx2.5 (h-k) where 
the Nkx2.5 mosaic myocardium of the PV is missing in the podoplanin-/- (k, j) compared with the WT (h, i). The 
hypoplasia of the atrial septum (asterisk) is seen in the podoplanin-/- (e) compared to the WT (c). Sections (l) and (n) 
are stained with MLC-2a and sections (m) and (o) show HCN4 expression of the same region demonstrating the 
hypoplasia and the perforations (arrows in n) of the myocardium of the cardinal veins in the podoplanin-/-. LA 
indicates left atrium; LCV, left cardinal vein; LV, left ventricle; RA, right atrium; RCV, right cardinal vein; RV, 
right ventricle. In the 3D reconstructions: atrial myocardium, light brown; cardinal veins lumen, transparent blue; 
PV lumen, pink; sinus venosus myocardium, purple; ventricular myocardium, brown. Scale bars: (c), (e), (l), (n) = 
60μm; (d), (f-h), (k) = 30μm; (i), (j) = 20μm; (m), (o) = 200μm.    
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Pulmonary and cardinal veins  
In wildtype embryos the wall of the pulmonary and cardinal veins showed MLC-2a (Figure 
3c, l) and HCN4 (Figure 3a, d, m) expression while the Nkx2.5 expression pattern was mosaic 
in the myocardium lining the pulmonary vein (Figure 3h, i) and negative in the wall of the 
cardinal veins (Figure 3h). The staining for HCN4 was diminished at 15.5 dpc compared to 
earlier stages whereas the initially Nkx2.5 negative myocardium of the cardinal veins and 
Nkx2.5 mosaic myocardium of the pulmonary vein wall became positive. 
In the knockout embryos, myocardium of the pulmonary vein wall was hypoplastic and almost 
absent compared to the wildtype (Figure 3c, e). The extent of hypoplasia and lack of 
myocardium of the pulmonary vein corresponded with the regions normally expressing HCN4 
Figure 4. Sinus venosus (SV, a) and sinoatrial node (SAN, b) myocardial volume estimation of 12 wildtype (WT) 
mouse hearts of 11.5 dpc (n=3), 12.5 dpc (n=3), 13.5 dpc (n=3) and 14.5 dpc (n=3) and 12 podoplanin knockout 
(KO) mouse hearts 11.5 dpc (n=3), 12.5 dpc (n=3), 13.5 dpc (n=3) and 14.5 dpc (n=3). Podoplanin knockout embryos 
have a significant smaller SV and SAN myocardial volume (*P<0.05) compared to WT embryos.
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(Figure 3d, f) and podoplanin (Figure 3g). Comparable to the MLC-2a stained myocardium 
around the pulmonary vein as described above, the Nkx2.5 mosaic area was hypoplastic and 
almost absent in the knockout mice (compare Figure 3h, i with j, k).  
The myocardium of the cardinal veins was also hypoplastic and showed several fenestrations 
(Figure 3l-o). Both the atrial lumen and the lumen of the cardinal veins were dilated. The sinus 
venosus (Figure 4a) and separately the sinoatrial node (Figure 4b) myocardial volume, which 
was estimated by myocardial morphometry, showed a significant (P<0.05) decrease of 
myocardial volume in the knockout embryos compared to the wildtype embryos.     
DiscUssioN
This study was conducted to elucidate the role of podoplanin in the development of the sinus 
venosus myocardium derived from the specific area of the second heart field which we have 
named PHF.13,22 Previous studies have shown that mesodermal progenitor cells from the second 
heart field contribute to the formation and addition of myocardium both at the arterial and the 
venous pole of the developing heart.10,13,14,40,41 Our observations are based on the study of the 
podoplanin gene and its protein expression in different embryonic stages during cardiac 
development. We have generated podoplanin knockout mouse embryos and used several 
immunohistochemical markers to study the mutants and wildtypes. We observed that the 
mutant embryos present severe cardiac malformations and show hypoplasia of the sinus 
venosus myocardium. These findings have consequences for the development and contribution 
of the PHF to the sinus venosus myocardium. 
sinoatrial node and venous valves 
The sinoatrial node is a complex structure that plays a fundamental role in cardiac pacemaker 
activity.28 Despite its essential role in cardiac conduction the origin of the sinoatrial node is 
still not well understood. Recently the formation and differentiation of the sinoatrial node at 
the venous pole of the heart has been described from the novel Nkx2.5 negative and Tbx18 
positive precursor cells,15 which were positive for podoplanin.13 In the current study we report 
HCN4 expression in the podoplanin positive and Nkx2.5 negative sinoatrial node in accordance 
with observations in other studies.15,30,42 The specific combination of Nkx2.5 negative and 
podoplanin and HCN4 positive expression in the sinoatrial node during early heart development 
is in contrast with the expression of these markers in the primary atrial myocardium. The latter 
suggests a different precursor for the sinoatrial node and the primary atrial myocardium. In 
contrast to the primary atrial myocardium, which derives from the primary heart field, the 
sinus venosus myocardium including the sinoatrial node originates from the second heart field, 
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as concluded from Isl1, Tbx3 and Tbx18 expression at the venous pole of the heart.14,15,30,43 To 
clarify the functional role of podoplanin in the development of the sinus venosus myocardium 
we have studied podoplanin mutants and found a hypoplastic sinus venosus myocardium 
including the sinoatrial node and the venous valves. Another interesting gene involved in the 
development of the sinus venosus myocardium is Shox2.21 Shox2 mutants showed severe 
hypoplasia of the sinus venosus myocardium comparable to our observations in the podoplanin 
null mice. Moreover, the hypoplastic sinoatrial node in Shox2 mutants showed aberrant 
expression of Cx43 combined with abnormal Nkx2.5 positivity. In contrast to the Shox2 
mutants, Nkx2.5 and Cx43 expression patterns remained unchanged in the podoplanin 
knockout mouse hearts, suggesting a different role for podoplanin in sinoatrial node / 
pacemaking development than Shox2. Electrophysiological experiments will be carried out 
to investigate possible arrhythmias in these mutants to solve the mentioned neonatal death.   
Primary atrial septum and dorsal atrial wall
Lineage tracing experiments studying Isl1,14 Fgf 1010 and Tbx5,44,45 Tbx1815 and Shox221 have 
demonstrated the contribution of the second heart field at the venous pole to the formation of 
the atrial myocardium, which has a distinct molecular composition compared to the heart tube 
derived from the primary heart field.10,14,46 
Podoplanin is expressed in PHF as well and not only stains the proepicardial organ derivatives 
but also the Nkx2.5 negative myocardium in the dorsal mesocardium.13 This myocardium is 
supposed to form part of the dorsal atrial wall as well as the atrial septum. In the podoplanin 
mutant mouse this myocardium is hypoplastic, probably due to diminished PHF-derived 
myocardial contribution. Another option, is that abnormal epicardial-myocardial interaction 
plays a role in development of deficient myocardium as is seen in SP3 mutant mouse.47 We 
already described the deficient EPDC contribution in the podoplanin mutant.22,23 Therefore, 
both the hypoplasia of the atrial septum as well as the dorsal atrial wall observed in the current 
study, are related to the altered contribution of myocardial and epicardial cells from the 
PHF. 
Pulmonary and cardinal veins
A controversy regarding the development of the venous pole concerns the origin of the 
pulmonary vein. The pulmonary pit develops either in the dorsal mesocardium at the 
midline,48-50 at the left51 or the right51-53 side of the embryo as a solitary unpaired structure that 
arises from the sinus venosus51-53 or primitive atrium.46,48,54 Recently, Männer and Merkel55 
have described the pulmonary pit as a bilaterally paired structure. We have described that the 
early common pulmonary vein is surrounded by Nkx2.5 mosaic cells, which are positive for 
MLC-2a and podoplanin.13 Part of this myocardium has also been reported as mediastinal 
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myocardium.54 The Nkx2.5 mosaic area forms a myocardial sleeve around the pulmonary vein 
extending to the atrial septum and Nkx2.5 negative cardinal veins in contrast to the primary 
atrial myocardium, which is completely Nkx2.5 positive. These data support the formation of 
the wall of the pulmonary vein to be from the surrounding mesodermal precursor cells at the 
dorsal mesocardium, which is postulated to derived from the PHF.13 Concomitant with the 
higher proliferation rate of the pulmonary vein myocardium,56 the Nkx2.5 mosaic area became 
Nkx2.5 positive in contrast to the sinoatrial node and cardinal vein myocardium that remained 
Nkx2.5 negative but HCN4 positive. This suggests a distinct differentiation rate of the 
pulmonary vein myocardium compared to the sinoatrial node and cardinal vein myocardium. 
At 15.5 dpc the cardinal vein myocardium became gradually positive for Nkx2.5, whereas the 
HCN4 expression was diminished suggesting the gradual completion of the differentiation 
process at the venous pole. 
In the mutant embryos, the diminished myocardial contribution to the wall of the pulmonary 
vein and cardinal veins is evident. It is not clear whether MLC-2a and Nkx2.5 are directly 
regulated by podoplanin or whether this is due to altered addition of secondary myocardium 
from the PHF region by lack of podoplanin.      
The role of podoplanin in eMT of the coelomic epithelium 
EMT of the coelomic epithelium plays an important role in the addition of cells to the 
developing heart. An important feature of EMT is downregulation of cell-to-cell adhesion 
molecule E-cadherin,35,57,58 which is correlated with podoplanin.36 We have observed 
upregulation of E-cadherin in the coelomic cavity epithelium of the podoplanin knockout 
embryos. Regarding the addition of myocardium from the second heart field, the observed 
hypoplasia at the sinus venosus region might be caused by upregulated E-cadherin in the 
podoplanin knockout embryos, which causes abnormal EMT of the coelomic epithelium at 
specific sites of the sinus venosus myocardium.22 
Moreover, podoplanin is involved in motility of cells where it colocalizes with the ezrin, 
radixin and moesin (ERM) protein family.36,59 ERM proteins bind to the podoplanin ERM - 
binding site to activate RhoA, a member of the Rho GTPase protein family controlling a wide 
variety of cellular processes including proliferation, differentiation, cell morphology and 
motility.60,61 The increased RhoA activity leads to ‘podoplanin-induced’ EMT.37 With regard 
to this mechanism, lack of podoplanin has resulted in diminished expression of RhoA protein, 
which may prevent the ‘podoplanin-induced’ EMT with subsequent myocardial abnormalities 
of the venous pole.
Taken together, we show severe hypoplasia and myocardial abnormalities of the sinus venosus 
myocardium by lack of podoplanin. In addition, we postulate not only a common origin of 
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the sinoatrial node, dorsal atrial wall, atrial septum, pulmonary and cardinal veins deriving 
from the PHF, but also provide a link between the pulmonary vein and sinus venosus 
myocardium rather than the pulmonary vein and primary atrial myocardium. 
clinical implications 
Parts of the cardiac conduction system derive from the second heart field, which may imply 
a role in the etiology of clinical syndromes. Several transgenic mice present with sick sinus 
syndrome, occurring in a familial form, are due to the lack of Ca2+ and other ion channels as 
well as gap junctions.62 The dysfunctions include bradycardia, sinus dysrhythmia and sinus 
node exit block.62 In our mutant embryos we have observed a hypoplastic sinoatrial node. 
While podoplanin is involved in water transport,25 cationic, anionic and amino acid transport63 
and Ca2+ dependent cell adhesiveness,36 it is relevant to perform functional studies in these 
hearts in future to show dysfunctions such as bradycardia (sick sinus syndrome) comparable 
to Shox2 mutants.21 
Several studies suggested an embryonic background of atrial fibrillation originating from the 
pulmonary and caval veins, based on expression patterns of molecular and immunohistochemical 
markers.50,64,65 In the current study we observed HCN4 expression in the sinoatrial node and 
in the myocardium of the wall of the cardinal veins and the pulmonary vein. In the mutant 
mice this population of HCN4 positive cells is diminished in the sinus venosus myocardium, 
which may provide a developmental background of arrhythmias originating from this area. 
Next to disturbances in cardiac conduction the observed deficient myocardial as well as 
epicardial contribution results in atrial and ventricular septal defects in addition to the already 
observed myocardial and coronary vascular abnormalities.22 
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Atrioventricular Reentry Tachycardia (AVRT) requiring an accessory atrioventricular pathway 
(AP) is the most common type of arrhythmia in the perinatal period. The etiology of these 
arrhythmias is not fully understood as well as their capability to dissipate spontaneously in 
the first year of life. Temporary presence of APs during annulus fibrosus development might 
cause this specific type of arrhythmias. To study the presence of APs electrophysiological 
recordings of ventricular activation patterns and immunohistochemical analyses with antibodies 
specifically against MLC-2a, Periostin, Nkx2.5 and Connexin-43 were performed in embryonic 
mouse hearts ranging from 11.5-18.5 days post conception (dpc). The electrophysiological 
recordings revealed the presence of functional APs in early (13.5-15.5 dpc) and late (16.5-18.5 
dpc) post-septated stages of mouse heart development. These APs stained positive for MLC-
2a and Nkx2.5 and negative for Periostin and Connexin-43. Longitudinal analyses showed 
that APs gradually decreased in number (P=0.003) and size (P=0.035) at subsequent 
developmental stages (13.5-18.5 dpc). Expression of periostin was observed in the developing 
annulus fibrosus, adjacent to APs and other locations where formation of fibrous tissue is 
essential. We conclude that functional APs are present during normal mouse heart development. 
These APs can serve as transient substrate for AVRTs in the perinatal period of 
development. 
iNTRoDUcTioN
In the fetus and newborn Atrioventricular (AV) Reentry Tachycardia (AVRT) is a relatively 
common tachyarrhythmia. AVRT requires the presence of an accessory AV pathway (AP) that 
crosses the isolating annulus fibrosus. Initial management of AVRT can be difficult but the 
natural course is benign and most children remain symptom free without medication after the 
age of one year.1-3 
Annulus fibrosus formation plays a key role in the separation of atrial and ventricular 
myocardium in the AV canal4 and encompasses interactions between several molecular 
pathways,5,6 which have not yet been completely identified. Periostin, a member of the fascilin 
gene family,7 is highly expressed in collagen rich-fibrous connective tissue in the developing 
heart that is subjected to high mechanical stress.8,9 Recently, it has been revealed that periostin 
directly regulates collagen-I fibrillogenesis.8 The inductive role of periostin on fibrous tissue 
formation seems to be of special interest in annulus fibrosus anlage.10,11 
In mature hearts the atrial and ventricular myocardium are electrically separated in two 
myocardial compartments, which are interconnected via the AV conduction axis i.e. the AV 
node and bundle of His.5 At early embryonic stages however, the atrial and ventricular 
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myocardium are continuous in the primitive AV canal establishing a ventricular base-to-apex 
activation pattern. At later stages, ventricular conduction transforms into the mature apex-to-
base activation. The switch from ventricular base-to-apex in apex-to-base activation is 
suggested to be closely related to the completion of ventricular septation and annulus fibrosus 
development.12,13 Nevertheless, contemporary electrophysiological studies in embryonic mouse 
hearts have shown that before ventricular septation is completed a mature apex-to-base 
activation is already present, suggesting that the AV conduction axis is functional far before 
ventricular septation has finished.14,15 
It has been hypothesized that temporary persistence of the embryonic AV myocardial continuity 
during annulus fibrosus development might serve as APs. Consequently, these transient APs 
may provide the substrate for AVRT in the perinatal period and explain its self-limiting 
character. Studies in avian demonstrated that antegrade conducting APs are present at late 
post-septated stages of heart development, which gradually diminish during fetal life.12 In 
mammalian hearts,15,16 including human,17,18 APs have also been described throughout cardiac 
development. Thus far, the description of APs in mammals mainly focused on the 
electrophysiological properties of primitive AV canal myocardium in pre-septated hearts15 and 
neither late stages of fetal heart development nor the exact course of APs at the developing 
annulus fibrosus were provided.
The current study for the first time describes the presence of “functional” APs in early and 
late post-septated stages of mouse heart development. Furthermore, we show that periostin is 
highly expressed in the developing annulus fibrosus at locations where separation of atrial 
and ventricular myocardium is mandatory. 
MATeRiAL AND MeTHoDs
Animals and preparation of hearts
Animal experiments were approved by the Institutional Animal Care and Use Committee of 
the Leiden University Medical Center. Embryonic hearts were obtained from two separate 
wildtype mouse strains, C57Bl6/Jico and CD1. The presence of a vaginal plug one day after 
breeding was considered to be 0.5 days post conception (dpc). Embryos of subsequent stages 
were used, ranging from 11.5-18.5 dpc (n=48). After cervical dislocation of the pregnant 
mouse, the uterus horns containing the embryos were harvested and placed in a Petri dish 
filled with Tyrode’s solution containing in mmol/L: 130 NaCl, 4 KCL, 1.2 KH2PO4, 0.6 
MgSO4. 7H2O, 20 NaHCO3, 1.5 CaCL2. 2H2O and 10 glucose (chemicals derive from: Merck, 
Darmstad, Germany) at 37˚Celsius (˚C). Subsequently, in Tyrode’s solution of 0˚C one-by-one 




In the electrophysiology setup the embryonic hearts were attached with fine wires through 
extra-cardiac tissue in a fluid heated, temperature controlled (Physitemp instruments Inc, 
Clifton, NJ, USA) Petri dish of 35.5-37˚C onto a layer of agarose gel (Roche Diagnostics, 
Mannheim, Germany). During the 3 minute equilibration period and subsequent 
electrophysiological recordings the hearts were constantly super-perfused with Carbogenated 
(95% O2 and 5% CO2) Tyrode’s solution at 37˚C. Unipolar tungsten electrodes (tip: 1-2μm; 
impedance 0.9-1.0MΩ; WPI Inc, Sarasota, FL, USA) were positioned on the right atrium 
(RA), right ventricular base (RVB), left ventricular base (LVB) and left ventricular apex (LVA) 
(Figure 1), using microscopic guided micromanipulators (Wild Heerbrugg, M7A, Switzerland). 
An Ag/AgCl electrode in the Petri dish served as reference electrode. 
All electrograms were recorded under stable sinus rhythm with a high-gain, low-noise, direct-
current bioamplifier system (Iso-DAM8A; WPI Inc, Berlin, Germany) with 4 isolated 
preamplifier modules with an output impedance of >1012 Ω. The signals were band-passed 
(300Hz-1kHz) and notch filtered (50Hz) before being digitized at a sample rate of 1≥ kHz 
with a computerized recording system (Prucka Engineering Inc, Houston, Tex, USA) and 
stored on optical disks for offline analysis. 
Figure 1. Positioning of the unipolar electrodes for electrophysiological recordings. Four Tungsten electrodes 
were placed on the epicardial surface of the embryonic hearts, at the right atrium (RA), right ventricular base (RVB), 
left ventricular base (LVB) and left ventricular apex (LVA); AO indicates Aorta.
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The basal cycle length / Heart Rate (HR) of each heart and local depolarization time of each 
electrode, defined as maximal negative deflection on the unipolar electrogram, were 
calculated by the average of 10 consecutive beats. Subsequently, ventricular activation 
patterns of each heart were determined: base-to-apex if the RVB or LVB depolarized 1≥ ms 
prior to the LVA; apex-to-base if the LVA depolarized 1≥ ms prior to the RVB or LVB; 
concurrent if the depolarization time between the LVA and LVB or RVB was <1 ms. After 
recordings all hearts were fixed in 4% paraformaldehyde for immunohistochemical 
processing. 
immunohistochemistry and immunofluoresence
Standard immunohistochemistry was performed with: 1/2000 atrial myosin light chain 2 
(MLC-2a, gift from S.W. Kubalak, Charleston, SC, USA), 1/1000 Periostin (R.R. Markwald, 
Charleston, SC, USA) and 1/200 Connexin-43 (Cx43, Sigma, C6219, St. Louise, MO, USA) 
specific antibodies. Immunofluorescent double staining procedures were performed combining 
1/250 periostin and 1/2000 NK2 transcription factor related locus 5 (Nkx2.5, Santa Cruz 
Biotechnology, sc-8697, Heidelberg, Germany) specific antibodies. Detailed description of 
the staining procedures can be found in previous publications.10-12
Morphology and statistics
All hearts were studied for the presence of APs including their location at the developing 
annulus fibrosus using an Olympus BH-2 lighting microscope. AP-width was calculated by 
counting the number of subsequent MLC-2a stained sections through which a single accessory 
connection could be followed and multiplied by 25 μm (distance between subsequent MLC-
2a stained sections). 
Statistical analysis of HR and AV conduction time was performed with a students-t-test if 
values were equally distributed (skewness is |-1|) otherwise a Mann-Whitney U test was used. 
Analyses of AP-number and AP-width were performed with a univariate analyses of variance 
(unianova). A P value of <0.05 (2-tailed) was considered to be significant. The SPSS15.0 




Pre-septated hearts (11.5-13.5 dpc; n=6)
The mean recorded HR in pre-septated hearts was 94±24 beats per minute (bpm) with 
a mean AV interval of 84±13 ms. Comparable to previous studies,14,15 most pre- 
septated hearts (67%) already showed LVA activation prior to RVB or LVB activation, 
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indicating that the AV conduction axis is functional before ventricular septation has been 
completed. In 2 hearts concurrent ventricular apex and base activation patterns were 
observed (Table 1).
Early post-septated hearts (13.5-15.5 dpc; n=29)
In early post-septated hearts a mean HR of 115±41 bpm was recorded with a mean AV 
interval of 80±17 ms. Interestingly, only 38% of early post-septated hearts showed an apex-
to-base ventricular activation pattern, the largest group showed base-to-apex and concurrent 
ventricular activation patterns (62%). Concurrent apex and base activation was recorded in 
the majority of early post-septated hearts (48%). More detailed analyses of concurrent 
activated hearts showed that in most of these hearts (41%) concurrent activation occurred 
between the LVB and LVA. In two hearts (7%) the RVB was activated prior to the LVA and 
also in two hearts (7%) the LVB was activated prior to LVA (Table 1). Statistical analyses 
of AV conduction time showed no significant differences (P=NS) between the mean AV 
conduction time in apex-to-base (78±12 ms; n=11) and base-to-apex and concurrent (81±20 
ms; n=14) activated hearts. 







Pre-septated 94±24 (66-135) 83±13 (64-105) LVA>LVB/RVB 4 (67)
11.5-13.5dpc (n=6) Concurrent 2 (33)
LVA=RVB 2 (33)
Early post-septated 115±41 (67-246) 80±17 (44-112) LVA>LVB/RVB 11 (38)





Late post-septated 95±27 (63-146) 81±18 (56-110) LVA>LVB/RVB 6 (46)
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Late post-septated hearts (16.5-18.5 dpc; n=13)
The mean HR recorded in these hearts was 95±27 bpm with a mean AV interval of 81±18 ms. 
A mature apex-to-base activation pattern was observed in only 46% of the hearts (n=6). In a 
relatively large group of hearts activation of the LVB prior to the LVA was recorded (31%). 
Concurrent apex and base activation was observed in 15%, by which concurrent activation 
only occurred between the LVB and LVA. Furthermore, activation of the RVB prior to the 
LVA was observed in one heart (Table 1). Analyses of the mean AV conduction time showed 
no significant difference (P=NS) in apex-to-base (80±22 ms; n=6) and base-to-apex and 
concurrent (82±16 ms; n=7) activated hearts. 
Examples of unipolar-electrophysiological recordings of apex-to-base, base-to-apex and 
concurrent activated hearts are shown in Figures 2 and 3. 
APs during cardiac development
In all pre-septated hearts (n=6) the MLC-2a stained sections showed a myocardial continuity 
between the atria and ventricles over the primitive AV canal. At several locations in the left 
and right AV ring separation of atrial and ventricular myocardium by the developing annulus 
fibrosus was observed (Figure 4a, b, d). The primitive ventricular septum was already present 
at 11.5 dpc and ventricular septation was completed between 13.5-14.5 dpc. At the dorsal side 
of the heart a broad myocardial continuity between the atria and ventricles was observed i.e. 
the AV conduction axis (data not shown). 
Figure 2. Representative electrophysiological recording of an Apex-to-Base activated heart. (a) Recording of 
an early post-septated embryonic heart of 13.5 dpc with a cycle length of 703 ms (85 bpm). The left ventricular apex 
(LVA) is activated 89 ms after the right atrium (RA), followed by the left ventricular base (LVB; 90 ms) and right 
ventricular base (RVB; 92 ms). (b) Magnification of ventricular activation patterns, showing that the maximal negative 
deflection at the LVA precedes 1 ms prior to LVB and 3 ms prior to RVB activation, thereby creating a ventricular 
apex-to-base activation.    
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At 12.5 dpc expression of Cx43 was present in the working myocardium of both atria and 
ventricles, whereas Cx43 expression was absent in the myocardium of the complete AV canal 
(Figure 4c, e).
Figure 3. Representative electrophysiological recordings of concurrent Apex and Base and Base-to-Apex 
activated hearts. (a) Recording of an early post-septated heart of 15.5 dpc with a cycle length of 446 ms (134 bpm). 
76 ms after right atrial (RA) activation, first ventricular activation occurs at both the left ventricular apex (LVA) and 
left ventricular base (LVB), followed by right ventricular base (RVB) activation (81 ms). (b) Magnification of 
ventricular activation patterns, showing that the maximal negative deflection of the RVB is 5 ms after LVA and LVB 
activation. Consequently this heart shows a concurrent LVA and LVB activation pattern. (c) Recording of a late post-
septated heart of 16.5 dpc with a cycle length of 775 ms (77 bpm). First ventricular activation was observed 68 ms 
after RA activation at the LVB. Subsequently, the LVA and RVB were activated at 70 ms and 71 ms, respectively. (d) 
Magnification of ventricular activation patterns, indicating that the maximal negative deflection at the LVB precedes 
2 ms prior to LVA and 3 ms prior to RVB activation, thereby creating a base-to-apex ventricular activation.
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In all early post-septated hearts (13.5-15.5 dpc; n=29) APs were found around both the mitral 
and tricuspid orifice of the AV canal. Some of the APs consisted of a single strand of 
cardiomyocytes whereas others comprised broad myocardial continuities. At these stages Cx43 
was clearly present in the working myocardium of the atria and ventricles, however all APs 
were negative for Cx43 (Figure 4g, h). At early post-septated stages APs were more often 
located around the mitral orifice (63%; P=0.000), and analyses of the AP-width also showed 
a larger mean total AP-width at that specific region (P=0.000) (Table 2). Interestingly, in 
almost all early post-septated hearts (24/29) a broad Cx43 negative AP was present at the 
antero-lateral position of the left AV junction connecting the left atrial myocardium and left 
ventricular myocardium along its free wall (Figure 4f-h). 
In all late post-septated hearts (16.5-18.5 dpc; n=13) APs were still observed around the 
mitral and tricuspid orifice. The expressions pattern of Cx43 was similar as compared to 
earlier stages and all APs were still Cx43 negative (data not shown). Although the mean 
total AP-width at these stages was largest at the mitral orifice (P=0.028), no differences 
were found between the mean number of APs at the mitral and tricuspid orifice (P=NS). 
Compared to earlier stages the mean number of APs per heart around the mitral orifice had 
decreased significantly (P=0.000), whereas no significant decrease was observed at the 
tricuspid orifice (P=0.136) (Table 2). Furthermore, the antero-lateral AP at the left AV 
junction was present in all hearts (13/13). 
Longitudinal analyses of AP-number and AP-width in all post-septated hearts of subsequent 
developmental stages (13.5-18.5 dpc; n=42) showed significant decrease both in mean number 
of APs (P=0.003) (Figure 5) and mean total AP-width (P=0.035). 
Table 2. Summary of morphological analyses of APs in early and late post-septated hearts. 
Early post-septated Late post-septated Statistics
13.5-15.5dpc (n=29) 16.5-18.5dpc (n=13) (early vs late)
Mean number of APs 8.1 5.2 P=0.003
Mean number left sided APs 5.1 3.1 P=0.000
Mean number right sided APs 3.0 2.1 P=NS
Statistics mean AP number 
(left vs right)
P=0.000 P=NS -
Mean width (μm) of APs 347 214 P=0.035
Mean width (μm) left sided APs 238 138 P=0.000
Mean width (μm) right sided APs 109 76 P=NS





Furthermore, differences were observed in the rate by which APs disappeared around the 
mitral and tricuspid orifice, which appeared significantly faster at the left side of the AV 
junction (P=0.015). 
Periostin expression in relation to annulus fibrosus development and APs
Expression of periostin was present in all embryonic and fetal stages (11.5-18.5 dpc) and 
specifically limited to the epicardium, the endothelial lining of atrial and ventricular trabeculae, 
the subendocardial region of both outflow and AV cushions and the interstitial fibroblasts 
flanked by working myocardium in the atria and ventricles. At later stages (>14.5 dpc) strong 
expression was also observed in the AV cushion derived AV valves including their tension 
apparatus as well as in the endothelial lining of the developing coronary vessels. 
Figure 4. Connexin-43 (Cx43) expression in the AV junction in pre- and post-septated hearts. (a) Frontal MLC-
2a stained section of a pre-septated heart of 12.5 dpc. In the AV junctional area (b magnification of boxed area in a) 
Cx43 expression was absent (c consecutive section of a), whereas Cx43 was clearly present in the working myocardium 
of atria and ventricles (c). (d) And (e) magnifications of boxed areas in (b) and (c) respectively, show details of the 
right AV junctional myocardium positive for MLC-2a (asterisk in d) and negative for Cx43 (asterisk in e). (g) Frontal 
section of a 15.5 dpc MLC-2a stained heart. (g) Magnification of boxed area in (f) shows the large antero-lateral AP 
observed in n=37 of total n=42 post-septated hearts. Arrows in (g) indicate the exact locations of myocardial AV 
connections. The myocardium of the AV junction including these connections is negative for Cx43 (arrows in h). 
RV indicates right ventricle; LA, left atrium; LV, left ventricle; Scale bars: (a-c) and (f) = 300μm; (d), (e) = 30μm; 
(g), (h) = 60μm.
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Remarkably, periostin was absent in parts of the AV conduction axis, especially in the 
atrioventricular node (data not shown). Periostin expression was clearly present in the 
developing annulus fibrosus. Strongest expression was observed at the immediate border 
between the developing annulus fibrosus and AV canal myocardium (Figure 6a-c, g-i). 
Furthermore, high expression of periostin seemed to overlap with the MLC-2a positive APs 
around both the mitral and tricuspid orifice (Figure 6i). 
Immunofluorescent double stained sections with periostin and Nkx2.5 were used to study the 
developing annulus fibrosus in relation to the AP cardiomyocytes (Figure 6d-f, j-l). At all 
developmental stages periostin was strongly expressed in fibroblasts bordering AP 
cardiomyocytes (11.5-18.5 dpc), however no periostin expression could be demonstrated in 
Nkx2.5 positive cardiomyocytes themselves (Figure 6f, l). 
At early post-septated stages (13.5 dpc) low periostin expression was observed at the anterior 
side of the left AV junction in almost all hearts, corresponding to the location of the left antero-
lateral APs. These broad APs were positive for the myocardial markers MLC-2a and Nkx2.5 
but negative for periostin (Figure 6a-f). At later post-septated stages (>16.5 dpc), expression 
of periostin increased at these specific areas (Figure 6g-l). 
Figure 5. The course of APs in post-septated mouse hearts. The graph schematically represents the course of APs 
around both the developing tricuspid and mitral valve orifice in post-septated mouse hearts (n=42). Each black circle 
represents a heart in which a specific number of APs was observed as indicated on the Y-axis, at subsequent 






AVRT is a relatively common tachyarrhythmia in fetuses and neonates that appears to resolve 
in the majority of cases during the first year of life.1,2 It has been suggested that APs involved 
in these tachycardias are remnants of the primary AV canal myocardium, which disappear 
during development and maturation of the annulus fibrosus before and after birth.12,18 Although 
presence of APs has been demonstrated during normal cardiac development in human fetuses 
and neonates, their etiology and conducting properties as well as their causative role in AVRT 
are largely unrevealed.17-20 It is known that APs can be associated with congenital heart disease 
specifically with abnormal tricuspid valve development like in Morbus Ebstein.21 In a minority 
of cases genetic mutations are involved,22,23 like PRKAG2 in familial Wolff-Parkinson-White 
pre-excitation syndrome24 or in Alk3 which results in a disrupted annulus fibrosus with Cx43 
positive APs in mouse.5
Figure 6. Nkx2.5 and periostin double expression in the developing annulus fibrosus and persistent APs. (a) 
Frontal MLC-2a stained section of an early post-septated heart of 13.5 dpc. The boxed area in (a) shows a left sided 
antero-lateral AP magnified in (b). Periostin expression was observed next to the MLC-2a positive AP (c consecutive 
of a). An immunofluorescent double-stained section shows that this AP (f consecutive section of a) was positive for 
Nkx2.5 (d) and negative for periostin (e). (g) Frontal section of almost the same area in (a) of a late post-septated 
MLC-2a stained heart of 16.5 dpc. (h) Magnification of the boxed area in (g), showing an MLC-2a positive AP, which 
also is positive for periostin (i consecutive section of g). Compared to early post-septated stages (f), this AP (l 
immunofluorescent consecutive section of a) is comprised of an intermingling network of Nkx2.5 positive 
cardiomyocytes (j) and periostin positive fibroblasts (k). RV indicates right ventricle; RA, right atrium; LA, left 
atrium; LV, left ventricle; Scale bars: (a), (g) = 300μm; (b-f) = 30μm; (h-l) = 60μm.
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 AP location in relation to arrhythmias 
The conducting properties of the primitive AV canal myocardium has recently been 
demonstrated in mouse embryos.15 Here we show that annulus fibrosus development occurs 
near the Cx43 negative AV canal myocardium.25 Furthermore, the presence of antegrade 
conducting Cx43 negative APs were demonstrated, which significantly decreased in number 
and size along normal mouse heart development, but sometimes remained present at late post-
septated stages (Figure 5). 
Recently, similar APs  were demonstrated during normal quail heart development, where most 
APs were found at the postero-septal aspect of the tricuspid valve orifice.12 In contrast, we 
demonstrated the majority of APs at the antero-lateral aspect of mitral orifice in mouse. In 
quail the preferential location of right postero-septal APs might be explained by the 
physiological delay of right ventricular inflow tract formation with prolonged isolation of this 
part of the annulus fibrosus.16 This might also shed light on the observation that occasionally 
right sided APs directly penetrate through the annulus fibrosus, whereas left sided APs rather 
more frequently skirt the annulus and have a more epicardial position as observed in autopsy 
studies of human Wolff-Parkinson-White syndrome.26 It seems tempting to postulate that APs, 
which directly penetrate the isolating annulus, as observed in the current study, are related to 
normal AV junction isolation and disappear along fetal and early postnatal life.  
Interestingly, the left antero-lateral APs observed in late post-septated embryonic mouse hearts 
have been reported in studies on cardiac conduction system (CCS) development by means of 
CCS-lacZ expression. Bundles of lacZ expressing cardiomyocytes were observed at the same 
left antero-lateral position at the developing AV junction, which did not form part of the 
developing CCS. In some hearts these bundles could be traced until postnatal stages and have 
been related to Wolff-Parkison-White syndrome.14 
Differences with respect to morpho-histology and electrophysiology were noticed between 
the mitral and tricuspid valve orifice. In early post-septated hearts a significant majority of 
APs were observed around the mitral valve orifice, and also the largest total AP-width was 
found in this area both in early and late post-septated hearts. These histological findings seem 
to correlate with the electrophysiological recordings showing that in the majority of base-to-
apex activated post-septated hearts, the LVB (and not the RVB) is activated prior or concurrent 
to the LVA. However, a coincidental relationship can not be expelled, since a direct relation 
between morphologically observed APs and their individual ability to conduct could not be 
made.12 Especially at early post-septated stages multiple APs are present of which some might 
act as innocent bystanders i.e. not able to conduct.     
Recently, we demonstrated the presence of APs during human heart development, which 
also decreased along embryonic and fetal life.18 It remains to be determined whether these 
physiological APs in human are functional and can form the substrates for AVRT. 
Interestingly, APs involved in AVRT are more often located around the mitral valve orifice,27 
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which seems to correspond to the high frequency of conducting left sided APs as observed 
in the current study.
Periostin expression in relation to annulus fibrosus formation and persistent APs
Periostin is expressed in the developing annulus fibrosus,12,18 specifically at locations where 
separation of atrial and ventricular myocardium is needed. At these regions periostin might 
induce formation of isolating fibrous tissue, since it directly regulates collagen-I 
fibrillogenesis.8 
The broad Cx43 negative antero-lateral APs around the mitral orifice, which most probably 
have an imperative role in the large group of early LVB and concurrent activated hearts, were 
predominantly periostin negative at early post-septated stages. This seems to indicate that only 
APs negative for periostin are able to conduct, which correspond to recent findings of 
electrophysiological studies in neonatal mouse hearts.5 At later stages, periostin expression 
increases near the left antero-lateral APs suggesting an active process of isolation in that 
particular region. Interestingly, annulus fibrosus formation is not strictly limited to the prenatal 
stages, since contemporary studies demonstrated that formation of the fibrous structures of 
the heart extends into early postnatal development.28,29 Therefore, we postulate that periostin 
has an important role in AV junction isolation by stimulation of fibrous tissue formation, 
thereby separating atrial and ventricular myocardium, which subsequently will lead to 
regression of conducting APs pre- and postnatally. 
The regulation of periostin and the exact way it contributes in annulus fibrosus formation 
remains to be elucidated. However, it has been demonstrated that several growth factors 
including BMPs,30 TGF-β7 and PDGFs31 are involved, which are highly expressed in the 
developing AV region. In addition, state-of-art studies performed in avian hearts indicated that 
epicardium derived cells play a key role in periostin regulation involved in annulus fibrosus 
development. Inhibition of early epicardial outgrowth, resulted in a disturbed annulus fibrosus 
development coinciding with a high frequency of periostin negative antegrade conducting 
APs.10,11   
coNcLUsioN
The current study demonstrates that antegrade conducting APs, which are remnants of Cx43 
negative primitive AV canal myocardium, remain present until late fetal stages of normal 
mouse heart development. These conducting APs can act as substrate for AVRT. Ongoing 
formation and maturation of the annulus fibrosus in which periostin appears to have an 
important role, may explain spontaneous resolution of these arrhythmias in fetuses and 
neonates.
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Accessory atrioventricular myocardial connections in 







Fetal and neonatal atrioventricular reentrant tachycardias (AVRTs) can be life threatening but 
resolve in most cases during the first year of life. Transient presence of accessory atrioventricular 
(AV) myocardial connections during annulus fibrosus development may explain this 
phenomenon.
Methods and Results
45 human embryonic, fetal and neonatal sectioned hearts (4 to 36 weeks of development) were 
studied immunohistochemically. Accessory myocardial AV connections were quantified and 
categorized according to their specific location and 3D AMIRA reconstructions were made. 
Between 4 and 6 weeks of development: atrial and ventricular myocardium was continuous 
at the primitive AV canal. At 6-10 weeks: numerous accessory myocardial AV connections 
were identified at the left (45%), right (35%) and septal (20%) region of the AV junction. Most 
right sided accessory connections comprised distinct myocardial strands, left sided connections 
consisted of larger myocardial continuities. At 10-20 weeks: all accessory AV connections 
comprised discrete myocardial strands and gradually decreased in number. The majority of 
accessory connections were located at the right AV junction (67%), predominantly at the lateral 
aspect (45%). At the left AV junction 17% and at the septal region 16% of the accessory 
connections were observed. 3D reconstructions of the developing AV nodal area at these stages 
demonstrated multiple AV nodal related accessory connections. From 20 weeks until birth and 
in neonatal hearts no more accessory myocardial AV connections were observed.      
conclusions
Isolation of the AV junction is a gradual and ongoing process and particularly right lateral 
accessory myocardial AV connections are commonly found at later stages of normal human 
cardiac development. These transitory accessory connections may act as substrate for AVRTs 
in fetuses or neonates.
iNTRoDUcTioN
Atrioventricular reentrant tachycardia (AVRT) requiring the presence of an accessory 
atrioventricular (AV) myocardial pathway (AP) is the most common type of supraventricular 
tachycardia (SVT) in both the fetus and newborn.1,2 AVRT is a potentially life threatening 
problem in this young age group and these tachycardias are sometimes difficult to control with 
antiarrhythmic drug therapy.3,4,5 However, most tachycardias spontaneously resolve within the 
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first months of life and more than 60% of patients require no antiarrhythmic drug therapy and 
remain free of symptoms after the age of one year.2,4 This self-limiting character of most 
perinatal AVRTs suggests that the majority of the accessory AV pathways involved eventually 
disappear after birth. It is unknown whether APs involved in perinatal AVRT have a different 
etiology as compared to APs involved in AVRT presenting later in life. We hypothesize that 
self-limiting perinatal AVRT can be explained by the transitory presence of accessory 
myocardial connections during the normal process of isolation of the AV junction in cardiac 
development. 
Shortly after the formation of the primary heart tube, the heart is subjected to extensive 
remodelling processes.6 Previous studies have shown that around the seventh week of human 
development, the separation process of the atrial and ventricular myocardium at the primitive 
AV canal has started. As from the twelfth week of development atrial and ventricular 
myocardium are separated by a layer of fibrous tissue, the annulus fibrosus, in which the AV 
conduction axis comprises the only myocardial continuity.7 Recently, electrophysiological 
studies in avian8 and mouse models9,10 have shown that up to late stages of cardiac development 
multiple accessory AV myocardial connections were present. These accessory connections 
demonstrated retrograde10 and antegrade AV conduction and gradually decreased in number 
at subsequent developmental stages.8 In addition, an electrophysiological study in mice 
demonstrated the onset of AVRT at early stages of development.10 
In this study we investigated the presence and the specific locations of accessory AV myocardial 
pathways in relation to the process of formation of the annulus fibrosus during the different 




The human embryonic, fetal and neonatal hearts (n=45) were obtained from the collection of 
the Department of Anatomy and Embryology of the Leiden University Medical Center, The 
Netherlands. The study was approved by the local Medical Ethical Committee. All hearts were 
already sectioned either in transverse, frontal or sagittal plain and immunohistochemically 
stained with different myocardial (HHF-35, DAKO, Glostrup, Denmark; Myosin, α-MHC 
and β-MHC kindly supplied by A.F.M. Moorman) and fibrous tissue (Fibronectin, A245, 
DAKO, Glostrup, Denmark ; CollagenVI, Southern Biotechnology, Birmingham, AL ; Laminin, 
PU078, BioGenex, San Remon, USA) markers. Furthermore, histological stained sections 
were used: Haematoxylin eosin (HE), Resorcin-fuchsin-iron haematoxylin-picric acid-thiazin 
red (modified Verhoeff-Van Gieson stain) and Azan. A detailed description of staining protocols 
can be found in previous publications.11,12 
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According to pregnancy duration and Crown-Rump-Length (CRL) all embryos, fetuses and 
neonates were separated into 4 groups of subsequent gestational stages of development: Group 
1: 4 weeks / CRL5mm - 6 weeks / CRL11mm (n=2); Group 2: 6 weeks / CRL11mm - 10 
weeks /  CRL 40 mm (n=7); Group 3: 10 weeks / CRL 40mm - 20 weeks / CRL164-170mm 
(n=27); Group 4: 20 weeks / CRL164-170 -birth- neonates (n=9).
The hearts were carefully studied section by section for the presence of accessory AV 
myocardial connections at the left, right and septal area of the AV junction using an Olympus 
BH-2 light microscope. An accessory myocardial AV connection was defined as an uninterrupted 
strand of myocardium, which crosses the annulus fibrosus in addition to the AV conduction 
axis in post-septated hearts.
All accessory myocardial AV connections in the embryonic or fetal hearts were categorized 
based on their specific location in the AV junction. The accessory myocardial connections 
related to the developing atrioventricular node (AVN) were described separately.
immunohistochemistry
Additional immunohistochemical experiments were performed using MLC-2a and periostin 
specific antibodies as additional myocardium and fibrous tissue markers respectively. All 
embryonic hearts were fixed in 4% paraformaldehyde (PFA), after dehydration they were 
embedded in paraffin. The embedded hearts were 5 μm sectioned and mounted 1 to 6 onto 
protein / glycerin coated slides, so 6 different staining procedures could be performed on one 
embryo. After dehydration of the slides, inhibition of the endogenous peroxidase was performed 
for MLC-2a with a solution of 0.3% H2O2 in PBS for 20 min. For periostin antigen retrieval 
was performed in 0.01M Citric buffer of Ph 6.0 at 97˚C for 12 minutes, followed by inhibition 
of the endogenous peroxidase in a solution of 0.3% H2O2 in PBS for 20 min. Overnight 
incubation with the primary antibody was performed with the following antibodies: 1/2000 
anti-atrial myosin light chain 2 (MLC-2a, gift from S.W. Kubalak) and 1/1000 anti-periostin 
(gift from R.R. Markwald). The primary antibodies were dissolved in PBS-Tween-20 with 1% 
Bovine Serum Albumin (BSA, Sigma Aldrich, USA). The slides were rinsed between subsequent 
incubation steps: PBS (2x) and PBS-Tween-20 (1x). For both MLC-2a and periostin, a 40 min 
incubation with the secondary antibodies was performed using 1/200 goat-anti-rabbit-biotin 
(Vector Laboratories, USA, BA-100) and 1/66 goat serum (Vector Laboratories, USA, S1000) 
in PBS-Tween-20.  Thereafter a 40 minute incubation with ABC-reagent (Vector-Laboratories, 
USA, PK 6100) was performed. For visualisation, all slides were incubated with 400 μg/ml 
3-3’di-aminobenzidin tetrahydrochloride (DAB, Sigma-Aldrich Chemie, USA, D5637) 
dissolved in Tris-maleate buffer pH7.6 to which 20 μl H2O2 was added for 10 min. 0.1% 
Haematoxylin (Merck, Darmstad, Germany) was used to counter stain the slides: MLC-2a 10 
sec and periostin 5 sec, followed by rinsing with tap water for 10 minutes. Finally, the slides 
were dehydrated and mounted with Entellan (Merck, Darmstadt, Germany). 
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AMiRA reconstruction
3D reconstructions were made of the developing AVN region, as described earlier9, using the 
AMIRA software package (Template Graphics Software, San Diego, USA).  
The authors had full access to and take responsibility for the integrity of the data. All authors 
have read and agree to the manuscript as written.
 
ResULTs
4 weeks / cRL 5 mm – 6 weeks / cRL 11 mm (n=2) 
At 4 weeks (CRL 5 mm) of development the heart tube had looped and the common atrium 
was completely positioned above the primitive left ventricle. Large endocardial cushions were 
observed in the region of the common outflow tract and at the anterosuperior and posteroinferior 
luminal side of the primitive AV canal. At this stage, the atrial and ventricular myocardium 
was continuous at the region of the primitive AV junction. At 5 weeks (CRL 7 mm) the 
formation of the right ventricle had started and the future left and right ventricle were clearly 
discernible. In the AV canal region the myocardium of the primitive atria and the ventricles 
was continuous (data not shown).  
6 weeks / cRL 11 mm – 10 weeks / cRL 40 mm (n=7)
Between 6-7 weeks, the AV cushions had fused and the future tricuspid and mitral valve orifice 
of the AV junction became visible. Almost all atrial and ventricular myocardium was still 
continuous at the AV junction. Around the seventh week of development ventricular septation 
was nearly completed, thereby separating the left and right blood streams. The separation of 
atrial and ventricular myocardium had clearly commenced at the right dorsal aspect of the 
embryonic heart and to a lesser extent at the left dorsal side. At 7 to 8 weeks, ventricular 
septation was completed and formation of the partially AV cushion derived tricuspid valves 
at the right and mitral valve at the left AV junction had started. At the end of the ninth week 
AV cushion tissue was no longer observed, and well shaped mitral and tricuspid valves were 
present at the AV junction. At this stage, the atrial and ventricular myocardium was almost 
completely separated by the fibrous tissue of the developing annulus fibrosus. At the dorsal 
side of the fetal heart a distinct AV myocardial continuity was observed which corresponded 
to the developing AV conduction axis, comprising the developing AVN and the bundle of His. 
Between 6 and 10 weeks of development, many parts of the AV junction showed an incomplete 
isolation at the annulus fibrosus (Figure 1a-c). Accessory AV myocardial connections were 
found both at the left (45%), right (35%) and septal (20%) region of the AV junction (Figure 
1d). Most of the accessory myocardial connections were identified as broad accessory AV 
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myocardial continuities. At the dorsal aspect of the right AV junction accessory connections 
consisted of small single myocardial strands. 
At the right AV junction, the so-called right atrioventricular ring (RAVR) bundle could easily 
be distinguished from the atrial myocardium as a separate structure. The RAVR bundle, 
considered to be part of the embryonic AV conduction system, formed a ring of myocardium 
around the tricuspid annulus at the atrial side (Figure 2a).13
Interestingly, the majority of the right sided accessory myocardial AV connections (65%) were 
located subendocardially and made contact with the RAVR bundle. In all examined hearts the 
isolating tissue between the RAVR bundle and the ventricular myocardium was not as extensive 
Figure 1. Separation of atrial and ventricular myocardium at 6 to 10 weeks of development. In early post-septated 
hearts large myocardial continuities between atrial and ventricular myocardium were observed at the right AV junction 
(a, magnification of boxed area in b) and left AV junction (c magnification of boxed area in b), as shown in these 
frontal sections of an MLC-2a stained embryonic heart of 7 weeks of development (b). The region between the 
arrowheads in (a) and (c) show the myocardial continuity at the left and right lateral AV junction. (d) Between 6 and 
10 weeks of development 7 hearts were studied, the red numbers indicate the total number of hearts in which 
accessory myocardial AV continuities were observed at a specific location at the tricuspid and mitral orifice of the 
developing AV junction. The percentages represent the total amount of accessory myocardial AV continuities at a 
specific location, compared to the total number of accessory myocardial AV continuities at the entire AV junction. 
VS indicates ventricular septum; LA, left atrium; LV, left ventricle; LAM, left atrial myocardium; LVM, left 
ventricular myocardium; RV, right ventricle; RAM, right atrial myocardium; RVM, right ventricular myocardium. 
Scale bars: (a), (c) = 150μm; (b) = 300μm.
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as at other locations at the AV junction. Frequently, only a single layer of fibrous tissue was 
observed between the RAVR bundle and the ventricular myocardium.
10 weeks / cRL 40 mm - 20 weeks / cRL 164-170 mm (n=27)
Between 10 (CRL 40 mm) and 20 weeks (CRL 164-170 mm) of development the annulus 
fibrosus and valve formation had progressed further and cardiac development was mainly 
dominated by growth. At the left AV junction, the annulus fibrosus had become a firm 
structure with a thick layer of fibrous tissue isolating the left atrial and ventricular 
myocardium (Figure 2d-f). 
The developing AVN was positioned in the right posteroseptal region and was continuous with 
the bundle of His traversing the annulus fibrosus behind the aorta. At the right AV junction 
the annulus fibrosus was more fragile and accessory myocardial AV connections were 
Figure 2. Separation of atrial and ventricular myocardium at eleven weeks of development. The right AV junction 
(a, magnification of boxed area in d) of an eleven week old fetal heart frontally sectioned (d). Atrial and ventricular 
myocardium is separated by a layer of periostin positive fibrous annulus fibrosus tissue (asterisk in a, b and c). 
HHF-35 positive accessory AV myocardial connections (region between arrowheads in b, magnification of boxed 
area in a), negative for periostin (c adjacent section of b), were present between the right atrioventricular ring (RAVR) 
bundle and the right ventricular myocardium (RVM). (e) Magnification of dotted box in (d) shows that the left atrial 
myocardium (LAM) and left ventricular myocardium (LVM) are separated by a thick layer of periostin positive (f 
adjacent section of e) fibrous annulus fibrosus tissue (asterisk in e and f). RA indicates right atrium; RV, right ventricle; 
LA, left atrium; LV, left ventricle; VS, ventricular septum. Scale bars: (d) = 1mm; all others = 60μm.
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frequently found especially adjacent to the RAVR bundle (Figure 2a-d), which could still be 
observed in most hearts up to 20 weeks. 
Between 10 and 20 weeks broad accessory AV myocardial continuities as seen at earlier 
embryonic stages, could no longer be detected. However, up to 20 weeks of development 
numerous accessory myocardial AV connections were identified (Figure 3a-e). At these stages, 
all accessory myocardial AV connections only consisted of single strands of myocardium 
crossing the annulus fibrosus (Figure 3c-e). As expected, the majority of accessory myocardial 
AV connections were now located at the right AV junction (67%) and only 17% were located 
at the left AV junction. Furthermore, 16% of accessory myocardial AV connections were 
observed at the midseptal and anteroseptal region of the AV junction (Figure 3f). Right sided 
connections (45%) were located subendocardially at the lateral aspect of the right AV junction, 
mostly related to the RAVR bundle (Figure 3c, e). 
20 weeks / cRL 164-170 mm – birth - neonatal stages (n=9)
The annulus fibrosus of 5 fetal and 4 neonatal hearts was examined completely. In both fetal 
and neonatal hearts no accessory myocardial AV connections were observed at the left, right 
and septal area of the AV junction (data not shown). 
Accessory connections related to the developing AVN
The developing AVN and bundle of His were examined during different stages of fetal heart 
development. The cardiomyocytes of the AVN were large pale and rounded cells and could 
be well distinguished from the adjacent atrial working myocardium (data not shown). From 
10 weeks onward the developing AVN remained positioned anterior to the coronary sinus 
ostium to the mid-atrial septum, immediately adjacent to the tricuspid annulus (Figure 4a). 
Shortly after completion of ventricular septation, the bundle of His was a prominent structure 
crossing the annulus fibrosus in the midseptal region continuing at the ventricular side divided 
into a left and right bundle branch. Along fetal heart development the bundle of His was better 
isolated and could be easily identified from the surrounding structures. During subsequent 
stages of development until birth, numerous small strands of cardiomyocytes originating from 
the AVN region, penetrated the annulus fibrosus. These accessory AV nodal extensions of 
large pale rounded cardiomyocytes connected to the ventricular septal myocardium but had 
no relationship with the penetrating bundle of His (Figure 4a, b). Sections and a three 
dimensional reconstruction of the AVN region and AV nodal accessory connections of a 14,2 
week fetal heart are shown in Figure 4.
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Figure 3. Separation of atrial and ventricular myocardium at 10 to 20 weeks of development. Between 10 and 
20 weeks of development several accessory myocardial AV connections bypassing the AV conduction axis were 
present. (a) Modified Verhoeff-Van Gieson stain stained frontal section of a 15,3 week fetal heart in which myocardium 
is stained yellow-brown and fibrous tissue is stained red. (b) Represents the boxed area in (a) showing a detail of the 
annulus fibrosus of the right AV junction which is in continuity with the base of the tricuspid valve (arrows in a and 
b). (c) Detail of the boxed area in (b), showing the right atrioventricular ring (RAVR) bundle which is in continuity 
with the ventricular myocardium, thereby creating an accessory myocardial AV connection (arrow in c). (d) Shows 
a frontal section of the right AV junction of a fetal heart of 19,6 weeks of development. The arrows indicate the 
tricuspid valve in continuity with the fibrous tissue of the annulus fibrosus (red). (e) Represents the magnification 
of the boxed area in (d) showing an accessory myocardial AV connection in contact with the RAVR bundle (arrow 
in e). Between 10 and 20 weeks of development 27 fetal hearts were investigated for the presence of accessory 
myocardial AV connections at the developing AV junction (f). The red numbers indicate the total number of hearts 
in which accessory myocardial AV connections were present at a specific location at the AV junction. The percentages 
represent the amount of accessory myocardial AV connections at a specific location at the AV junction compared to 
the total number of accessory myocardial AV connections at the entire AV junction. RA indicates right atrium; RV, 
right ventricle; AO, aorta. Scale bars: (a), (d) = 1mm; (b) = 200μm; (c), (e) = 100μm.
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Figure 4. Accessory atrioventricular connections related to the developing atrioventricular node (AVN). (a) 
Shows a modified Verhoeff-Van Gieson stain stained transverse section of a 14,2 week fetal heart. The boxed area 
in (a) shows the AVN region of which a 3D reconstruction is shown in (b). During subsequent stages of development 
until birth multiple accessory myocardial connections related to the AVN were observed. (b) The 3D reconstruction 
visualizes a frontal view of these so-called nodoventricular connections (arrows in b) penetrating the annulus fibrosus 
(red transparent) and connecting the AVN with the ventricular septal (VS) myocardium. For display purpose the 
extensions have been elongated. RA indicates right atrium; LA, left atrium; RV, right ventricle; LV, left ventricle. 
In the 3D reconstruction, red indicates base of mitral valve (MV) and tricuspid valve (TV); blue, myocardium of 
the atrioventricular conduction axis, including the bundle of His (HIS). Scale bar: a = 1mm.
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DiscUssioN
SVTs affect about 0.1% of fetuses and newborns. In most cases the substrate for arrhythmia 
is an abnormal electrical conduction through an accessory AV myocardial pathway causing a 
circus movement between atria and ventricles.1 However, the majority of children presenting 
with AVRT in the fetal or neonatal period has no recurrences after the age of one year and 
show disappearance of ventricular preexcitation and non-inducibility of AVRT by 
transesophageal electrophysiological studies in approximately one third of the patients.14,15 
This self-limiting character of most AVRTs in fetuses and newborns is an intriguing clinical 
phenomenon, but the mechanism has not yet been elucidated. AVRT in this age group has 
been speculated to originate from the transient presence of conducting APs during the normal 
process of maturation of the annulus fibrosus.8,16 The development of this isolating structure 
involves several processes in which the endocardial cushions lining the luminal side of the 
primitive AV canal together with the inward migration of the epicardially located AV sulcus 
tissue have an important role.17-19 Recently, it has been shown in more detail that a combination 
of bone-morphogenetic-protein (BMP) signalling,20,21 periostin an osteoblast–specific factor22 
and epicardial derived cells, which enter the heart at the AV sulcus play a key role in this 
process.23,24 
The etiology of APs has not been elucidated. The majority of APs conduct antegradely as seen 
in patients with Wolff-Parkinson-White (WPW) syndrome (OMIM #194200; incidence in 
general population 1,5 per 1000 persons),25 the prevalence of WPW syndrome in children 
under 13 years of age is lower (0.07%).26 In adults, twenty-five percent of APs involved in 
AVRT are concealed indicating that they only have retrograde conducting properties.27 In 
infants, the percentage of concealed APs is higher, approximately 60%.28 In the majority of 
cases of WPW syndrome there is no familial involvement. However, significant minority of 
cases are inherited as a single gene disorder or occur as part of a syndrome with a strong 
genetic basis.25,29,30 Recently PRKAG2 gene missense mutations have been identified to be 
involved in familial WPW syndrome often associated with cardiac hypertrophy.30 Animal 
studies have shown that mutations in the Alk3 gene result in a disrupt formation of the annulus 
fibrosus causing ventricular preexcitation via posterior paraseptal bypass tracts.20 The 
differences in location and specific electrophysiological properties of APs as well as their 
association with structural heart disease like hypertrophic cardiomyopathy and congenital 
heart disease indicate that not all APs share the same etiological pathway. 
Previous studies have demonstrated the presence of accessory myocardial AV connections 
between atrial and ventricular myocardium during normal embryological and fetal heart 
development in humans16,31,32 and other mammals.9,10 However, the present study for the first 
time systematically describes the presence and the specific locations of gradually disappearing 
accessory AV myocardial connections crossing the developing annulus fibrosus in human 
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embryonic, fetal and neonatal hearts. We demonstrate that atrial and ventricular myocardium 
was continuous at the primitive AV canal at early stages of development. First separation of 
atrial and ventricular myocardium by the developing annulus fibrosus was observed at the 
right dorsal AV junction around 7 weeks of development and myocardial continuity persisted 
longer near the left junction. Total separation of atrial and ventricular myocardium was 
completed around ten to eleven weeks, which corresponds to other studies regarding the 
formation of the annulus fibrosus in developing human hearts.7 However, numerous accessory 
AV myocardial connections can be identified up to the end of the second trimester of pregnancy. 
Comparable to other studies16 these accessory AV myocardial connections were observed at 
the subendocardial aspect of both the right and left lateral AV junction of the heart. In the 
second and third trimester the left AV ring becomes firmly isolated by a thick layer of fibrous 
tissue followed by isolation of the right AV ring. 
Especially the isolation of the right AV ring is weak and frequently consists only of very thin 
layers of fibrous tissue. Up to 20 weeks of gestation small AV myocardial strands remain 
present near the lateral side of the tricuspid valve that are mainly located subendocardially. 
The high frequency of these right sided accessory myocardial AV connections and the weak 
isolation of especially this part of the AV junction might be associated with the normal 
developmental process of the right ventricular inflow tract. In early stages of heart development, 
as observed in the current study, the common atrium is completely positioned above the left 
ventricle. Formation of the right ventricular inflow tract starts with a groove, which is 
embedded in the myocardium of the primary fold. As a result of the expansion and outgrowth 
of this myocardial groove the right ventricular inflow tract will be formed, which eventually 
establishes the right part of the AV junction.9 Therefore, the formation of the right ventricular 
inflow tract might result in a weaker isolation and a high frequency of accessory myocardial 
AV connections, since this part of the AV junction develops subsequent to the already existent 
left AV junction.
The right sided AV myocardial connections frequently are located in close relationship with 
the RAVR bundle.13 This semicircular structure forms part of the temporary embryological 
specialized AV conduction system and is continuous with the AVN posteriorly. In the fetus it 
can be identified as a ring of node-like cells in the right atrium just above the tricuspid valve 
that obliterates later on.13,33,34 These accessory myocardial AV connections seem to correspond 
to the presumed multiple AV nodes and pathways as originally reported by Kent and reviewed 
by Anderson (1996).35 The relationship of right sided accessory myocardial AV connections 
with the RAVR bundle could explain the decremental properties as seen in some of the right 
sided APs.36 
Within the developing AVN small myocardial extensions can be identified that cross the 
annulus fibrosus and connect the developing AVN with the ventricular septal myocardium. 
These AV nodal extensions remain present until birth. The presence of the so-called 
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nodoventricular connections in fetal and neonatal hearts has been reported earlier and this 
phenomenon has been described as fetal dispersion of the AVN.37 In the first months after birth 
extensive remodelling of the fibrous heart skeleton including the AVN area takes place,31,38 in 
which the AVN becomes a more solid structure.39 AV nodal extensions appear to be a common 
finding in neonatal hearts, although it has been associated with sudden infant death syndrome 
in the past.40 In theory, nodoventricular pathways could provide the substrate for SVT, but to 
our knowledge this rare form of reentrant tachycardia has not been documented in the perinatal 
period. 
Recently, the temporary presence of functional accessory myocardial AV connections has been 
demonstrated by electrophysiological studies in avian hearts up to late stages of fetal 
development. These connections appeared to have antegrade conducting properties, which 
was demonstrated by unipolar electrogram recordings showing premature left and right 
ventricular base activation in post-septated hearts.8 Furthermore, studies performed in 
mammals9,10 showed that in normal mouse embryos conducting accessory AV pathways are 
present during cardiac development that can actually create the substrate for reentrant 
tachycardias. Some of these pathways even appeared to have decremental properties as 
observed in the Mahaim preexcitation syndrome.9 In normal human fetuses the conducting 
properties of transient accessory AV connections, depending on factors such as intercellular 
coupling remain to be elucidated as well as their capability to establish a pathway for AVRT. 
However, these accessory myocardial AV connections in human fetuses and their specific 
locations show strong similarities with the conducting accessory myocardial AV connections 
as demonstrated in avians and mice.8-10  
APs in adult patients with AVRT are mostly found around the mitral valve orifice and 
approximately 60% are located in the left ventricular free wall.27 In the pediatric age group 
the incidence of APs around the tricuspid annulus appears to be higher.41 APs around the 
tricuspid valve are usually located at the subendocardial aspect of the heart, whereas left sided 
APs can also have a more epicardial course in the AV sulcus. This implicates that the persistence 
of subendocardially located accessory myocardial AV connections as demonstrated in normal 
fetuses could only partly explain the pathogenesis of APs in patients with AVRT. However 
the delayed disappearance of fetal APs as reported in the current study offers a good explanation 
for the onset and disappearance of fetal and neonatal AVRT.  One-third of the fetuses and 
neonates with AVRT have WPW syndrome showing ventricular pre-excitation on the postnatal 
electrocardiogram, the others have concealed APs with only retrograde conduction.42 Although 
late recurrences of tachycardia after 8 to 10 years have been reported in neonates with WPW 
syndrome, the majority of these children remains free of symptoms during life.43 Recently it 
has been reported that the group of neonates with concealed APs has an even better prognosis 




In the present study we have demonstrated that accessory myocardial AV connections remain 
present up to late stages of fetal heart development, which indicates that the process of isolation 
of the AV junction is a continuous process not finished by the time of birth. The temporary 
presence of these accessory myocardial AV connections could serve as substrate for perinatal 
AVRT.
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cLiNicAL PeRsPecTiVe
Atrioventricular reentrant tachycardias presenting in fetal or neonatal life can be life threatening 
but also tend to resolve in the majority of patients in the first year of life. The etiology of 
accessory pathway mediated tachycardias in the perinatal period has not been elucidated. In 
early embryonic development the atrial and ventricular myocardium are continuous in the 
primitive atrioventricular canal. The atrioventricular conduction axis will then develop, which 
coincides with separation of the atrial and ventricular myocardium by formation of the annulus 
fibrosus. Annulus fibrosus development involves several processes in which the endocardial 
atrioventricular cushions lining the luminal side of the primitive atrioventricular canal together 
with the inward migration of the epicardially located atrioventricular sulcus tissue have an 
important role. In post-septated human hearts we demonstrated the presence of numerous 
accessory atrioventricular myocardial connections around both the mitral and tricuspid annulus 
during normal cardiac development. At the end of the second trimester the connections 
gradually decreased in number and size, and were located mostly around the tricuspid annulus. 
The persistence of fetal atrioventricular connections may serve as substrate for atrioventricular 
reentrant tachycardia in the fetus and newborn. The self-limiting character of most of these 
tachycardias could be explained by loss of the substrate due to the ongoing development of 
the annulus fibrosus, a process not completely finished by the time of birth. 
1 Department of Pediatric Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
2 Division of Neonatology, Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.
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Cardiac arrhythmias are commonly observed in the fetus, however, may have major 
consequences for fetal development and post natal life.
Aims
To evaluate the perinatal management and cardiac outcome of fetuses with tachy- or 
bradyarrhythmia.
study design
Perinatal management, outcome and long-term cardiac follow-up were evaluated retrospectively 
in consecutive fetuses with cardiac arrhythmias.
Results
Forty-four fetuses were diagnosed: supraventricular tachycardia (SVT, n=28), atrial flutter 
(AF, n=7) and atrioventricular block (AVB, n=9). The overall incidence of cardiac anomalies 
was 18% mainly in the AVB group; hydrops was present in 34%. Direct or trans-placental 
fetal anti-arrhythmic medication was given in 76%. Mortality was 6% in SVT / AF and 78% 
in the AVB group, respectively. AF resolved in all patients. In the SVT group, Wolff-Parkinson-
White (WPW) syndrome was present in 21%, diagnosed at birth or later in life. After the age 
of one year about 90% of patients in the SVT group remained asymptomatic and free of drugs 
(median follow-up 76 months).
conclusions
Mortality rate is low in patients with fetal SVT and AF but high in patients with AVB. Related 
morbidity includes WPW syndrome and congenital cardiac anomalies. Electrocardiographic 
screening is recommended in all fetal SVT cases before adolescence since WPW syndrome 
may occur later in life.
 
iNTRoDUcTioN
Fetal arrhythmias are common in clinical practice with a frequency ranging from 1% to 3% 
of all pregnancies. Most of these arrhythmias reflect transient, isolated atrial ectopic beats. 
However, sustained episodes of tachy- or bradyarrhythmia do occur and can lead to congestive 
heart failure, hydrops, fetal or neonatal demise, or severe neurologic morbidity in 
survivors.1-7
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The most common forms of fetal tachycardias are supraventricular tachycardia (SVT) and 
atrial flutter (AF). The majority of fetal SVTs are atrioventricular reentry tachycardias (AVRT) 
caused by the presence of an accessory atrioventricular myocardial pathway.8 If indicated, 
anti-arrhythmic drugs can be given transplacentally or directly to the fetus. In SVT and AF, 
various anti-arrhythmic drugs are used, including digoxin, flecainide, sotalol and 
amiodarone.9
More than three quarters of fetal bradycardia cases are caused by complete atrioventricular 
block (AVB). AVB in the absence of structural heart disease is mostly auto-immune mediated 
by maternal anti-Ro (SS-A) or anti-La (SS-B) antibodies.10 In AVB, transplacental steroid 
treatment may reduce the effects of inflammation and fibrosus of the conduction system caused 
by maternal antibodies.11 Complete AVB  in the presence of complex congenital heart disease 
(CHD) has a poor prognosis.12,13 
Elective delivery by cesarean section can be performed in the third trimester of pregnancy to 
start direct neonatal therapy (anti-arrhythmic drugs, radiofrequency catheter ablation or 
pacemaker therapy). The goal of pre- and postnatal treatment of tachycardia is to achieve sinus 
rhythm or to reduce the fetal heart rate in order to prevent heart failure or death. In most cases 
of fetal tachycardia, medication can be stopped within the first year after delivery. However, 
in cases of fetal and neonatal SVT recurrences can be expected in approximately 30% of patients 
later in life.14 The aim of this study was to evaluate the perinatal management and long-term 




We searched both our antenatal and neonatal databases for infants with in-utero cardiac 
arrhythmia, diagnosed between January 1990 and December 2005 at the Leiden University 
Medical Center, which is a tertiary fetal referral center. Arrhythmias included both tachy- and 
bradyarrhythmias. Sinus tachycardias, transient sinus bradycardias, premature atrial or 
ventricular contractions and ventricular tachycardias were excluded. In this time period the 
management protocol included complete work up with ultrasound examination and consultation 
of the pediatric cardiologist. Fetal ultrasound included detailed anatomic imaging of the fetal 
heart to diagnose or exclude cardiac defects. Routine karyotype was obtained in fetuses with 
suspected structural heart disease. 
Fetal Diagnosis and Therapy
SVT as a result of AVRT was diagnosed if there was a 1:1 atrioventricular conduction 
observed at a rate of 200-400 beats / min. AF was diagnosed when the atrial rate was 
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300-450 beats / min. Ventricular rates in AF depended on the degree of atrioventricular 
conduction block, usually 200-250 beats / min. The highest (peak) fetal heart rate was noted 
to give an indication of the severity of the tachycardia. AVB was classified as second degree 
or complete AVB based on M-mode evaluation and Doppler-flow measurements. Fetal 
hydrops was defined as a fluid collection visible on ultrasound in two or more cavities of the 
fetal body.15 Maternal serum antibody titers (anti-cardiolipin antibodies, anti-Ro (SS-A) and 
anti-La (SS-B) were obtained in case of a heart block. 
Anti-arrhythmic therapy was started when arrhythmias were sustained or associated with 
hemodynamic compromise prior to 34 weeks’ gestation. After 34 weeks’ gestation, such cases 
were delivered. A baseline electrocardiography (ECG) of the mother was obtained before the 
treatment started and maternal cardiac monitoring was conducted during the loading period 
to detect early signs of toxicity. During the study period, the following drugs were used: 
digoxin, sotalol, flecainide, amiodarone and adenosine. Digoxin was administered to the 
mother in adjusted oral doses to maintain a maternal serum therapeutic level of 1-2 ng/mL 
(loading dose 2x0.75 mg, maintenance 0.25-0.5 mg, maximum 0.75 mg/daily). Flecainide 
(oral dose 200-400 mg daily) and sotalol (oral dose 2x80-160 mg daily) were used as secondary 
agents. Amiodarone was administered by combined direct fetal intravenous and maternal oral 
and intravenous route. Direct fetal amiodarone therapy consisted of amiodarone on the basis 
of estimated fetal weight (10 mg/kg). In some cases adenosine was given intravenously (0.1 
mg/kg) as direct fetal therapy just before amiodarone therapy. Drugs to treat AVB were given 
to the mother included ritodrine (intravenously 9 mg / hour), dexamethasone (4 mg daily) and 
fenoterol (intravenously 150 μgram/hour).
After birth, if tachycardia or AVB was present, ECGs were made to confirm antenatal diagnosis. 
In all SVT and AF cases, ECGs were made during sinus rhythm to detect ventricular 
preexcitation (deltawave) caused by anterograde conduction through an accessory pathway 
(WPW syndrome). 
Long-term cardiac follow-up
With approval of the protocol by the institutional review board of the Leiden University 
Medical Center, family physicians were contacted by letter to explain the aims and nature of 
the study. After consultation with the family physician, parents were sent an explanatory letter 
asking their permission to review all medical records and their cooperation for testing the 
children. All cases were evaluated by a pediatric cardiologist and included medical history, 
physical examination and ECG. Additional studies, i.e. 24 hour-Holter monitoring, exercise-
test and ECG were performed if children were symptomatic. Long-term neurodevelopmental 
outcome was also assessed and has been reported separately.16
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During the 16-year study period, 44 pregnancies were referred to our center because of 
sustained fetal tachy- or bradyarrhythmia. Figure 1 shows the overall outcome of the 44 fetuses 
with arrhythmia. Perinatal characteristics of the study population are presented in Table 1. 
The mechanism of SVT was AVRT in all cases. One infant in the SVT group with 
cardiomyopathy and encephalopathy due to hydroxyglutaric aciduria died at the age of 5 
months. The AVB cases consisted of complete AVB (n=7) and second degree AVB (n=2). Two 
of 9 cases had auto-immune associated AVB, 5 had complex congenital heart malformations 
and 2 had a severe form of long QT syndrome (LQT8 or Timothy syndrome). In the AVB 
group were 3 fetal deaths and 4 postnatal deaths (Table 2). One case of infant death in the 
AVB group (LQT8) occurred after follow-up. 
 
Fetuses with arrhythmia 
n = 44 
Supraventricular Tachycardia 
n = 28 
Atrial Flutter 
n = 7 
Atrioventricular Block 
n = 9 
Termination of pregnancy 
n = 0 
Termination of pregnancy 
n = 1 
 
Termination of pregnancy 
n = 2 
 
Intrauterine fetal death 
n = 0 
Intrauterine fetal death 
n = 0 
 
Intrauterine fetal death 
n = 1 
 
Neonatal death 
n = 0 
Neonatal death 
n = 0 
 
Neonatal death 
n = 2 
 
Infant death 
n = 1 
Infant death 
n = 0 
 
Infant death 
n = 2 
 
Figure 1. Flowchart showing the outcome of the 44 studied fetuses with tachy- or bradyarrhythmias.
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Prenatal drug therapy 
Clinical data and details in all 19 cases of tachyarrhythmia treated prenatally with anti-
arrhythmic medication are presented in Table 3. During anti-arrhythmic therapy, sinus rhythm 
was achieved in 77% (7/9) non-hydropic and in 75% (6/8)  hydropic tachycardia fetuses. There 
was a trend towards multidrug therapy in the more recent years. Clinical data and details in 
the 3 cases of prenatally treated bradyarrhythmia are presented in Table 4. 
short-term follow-up
Neonatal management and outcome in live-born infants is presented in Table 5. The overall 
incidence of cardiac anomalies in the study population was 18% (8/44). In the SVT group 1 
infant had a ventricular septal defect and 1 infant had cardiomyopathy, polyvalvular disease 
and pulmonary stenosis. In the AF group, 1 infant was found to have coarctation of the aorta. 
In the AVB group, 5 of 9 infants had complex CHD (congenitally corrected transposition of 
the great arteries (cc-TGA), n=2; left atrial isomerism, n=1; ventricular septal defect, pulmonary 
stenosis, cardiomyopathy, n=1; endocardial fibroelastosis, n=1). Postnatally, AVB block 
remained present in all survivors (n=6) and 5 patients received pacemaker therapy immediately 
after birth.
In 67% of AF-fetuses and 78% of SVT-fetuses episodes of tachycardia or incessant tachycardia 
remained present after birth. Nineteen of the 28 children in the SVT group were treated with 
medication after birth. SVT was self-limiting in 74% (14/19), and treatment could be stopped 
within the first year of life. Five of 28 fetal SVT (AVRT) cases had WPW syndrome, as 
Table 1. Characteristics of the study population by type of arrhythmia.








Maternal age – yearsa 28 (20 – 39) 31 (24 – 39) 32 (28 – 36)
Male fetus – % (n) 61 (17) 43 (3) 44 (4)
Gestational age at  
diagnosis of arrhythmia – weeksa 29 (18 – 40) 30 (24 – 38) 23 (12 -37)
Peak/slowest fetal heart rate – beats/mina 247 ( 200 – 400) 237 (200 – 250) 55 (45 – 70)
Fetal hydrops – % (n) 39 (11) - 44 (4)
Antenatal therapy – % (n) 57 (16) 43 (3) 33 (3)
Duration of antenatal therapy – daysa 56 (12 – 95) 49 (43 – 96) 33 (12 – 93)
Gestational age at birth – weeksa 38 (30 – 42) 37 (36 – 38) 36 (30 – 40)
Birth weight – gramsa 2993 (1547 – 3965) 3282 (2530 – 4726) 2704 (2300 – 3470)
 aValue given as median (range).
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demonstrated by the presence of ventricular preexcitation on the ECG at birth. In 2 cases, 
radiofrequency catheter ablation of an accessory pathway was performed in the first months 
of life due to drug-refractory tachycardias. AF was treated with anti-arrhythmic therapy (n=4) 
or cardioversion (n=2). After initial conversion to sinus rhythm, AF did not recur in all 6 cases. 
Interestingly, in two AF cases the presence of an accessory pathway was demonstrated. One 
AF case showed WPW syndrome on ECG after cardioversion, another AF case developed 
recurrent AVRT requiring anti-arrhythmic therapy. 
Long-term cardiac follow-up
Long-term follow-up was obtained from 28 infants of the 36 survivors. Eight of the 36 
surviving infants could not be followed due to declined consent or lack of contact address. At 
the time of cardiac assessment the median age of the children was 76 months ranging from 6 
months to 15 years of age. 
Twenty-three children were examined in the SVT-group. No cases still required drug therapy, 
and no cases were treated with catheter ablation after the first year of life. Twenty-two of 23 
patients were still asymptomatic and only one child (six year old) with self-limiting SVTs after 
birth complained of short episodes of palpitations. Three of 5 cases of postnatal WPW syndrome 
showed normalization of ECG on follow-up with disappearance of ventricular preexcitation. 
Interestingly, a new case of asymptomatic WPW syndrome was found in a 9 year old child who 
had a normal ECG and self-limiting SVTs at birth. In cases of WPW syndrome follow-up ECGs 
were recommended and instructions were given on how to act when symptoms occur.
Table 2. Details on cases of tachy- or bradyarrhythmias leading to fetal or infant death.
Arrhythmia Complementary Diagnosis Outcome
SVT D2 – hydroxyglutaric aciduria induced 
cardiomyopathy
Died at age of 5 months
AF Trisomy – 21 Termination of pregnancy
AVB - Termination of pregnancy
AVB Left isomerism Termination of pregnancy
AVB Corrected transposition of the great arteries, 
pulmonal stenosis
Intrauterine fetal death
AVB Maternal Sjögren syndrome Pacemaker, died at age of 20 months
AVB Endocardial fibroelastosis Pacemaker, died at age of 2 days
AVB Long QT – syndrome Pacemaker, died at age of  29 days
AVB Long QT – syndrome Pacemaker, implantable cardioverter 
defibrilator, surgery,  died at the age of 2 years
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In the AF group, 5 of 6 cases remained free of arrhythmia symptoms. Four of 6 underwent 
neurological and cardiac examination. The ECG was normal in 3 of 4. One 2 year old AF case 
with postnatal WPW syndrome had remained asymptomatic but the ECG still showed 
ventricular preexcitation. A 9 year old AF case had developed drug refractory AVRT after birth 
and underwent successful catheter ablation at the age of 4 years. One 4-year old child with 
AF had coarctation of the aorta and self-limiting AF. The patient underwent coarctectomy and 
remained asymptomatic after surgery. 
Morbidity and mortality rate in the AVB group was extremely high. One infant with cc-TGA 
received a DDD pacemaker at the age of 6 years and was in good clinical condition at the age 
of 9 years. Echocardiographic follow-up showed good function of the systemic right ventricle. 
One autoimmune mediated AVB case developed cardiomyopathy and died unexpectedly during 
a period with fever and pneumonia at 1.5 years of age. Another AVB case with fetal hydrops 
received a pacemaker immediately after birth but died on day 2 after birth. Postmortem analysis 
showed extensive endocardial fibroelastosis. There were two cases of functional 2:1 AV block 
associated with a severe form of long QT-syndrome, LQTS 8 or Timothy-syndrome. In one 
case a pacemaker was placed, but the infant died 29 days after birth because of uncontrollable 
ventricular arrhythmias. The other case also received a pacemaker followed by implantation 
of an implantable cardioverter defibrillator (ICD) at the age of three months. The ECG showed 
extreme QT-prolongation and T-wave alternans. He had recurrent ICD shocks for torsade des 
pointes and died at the age of 2 years of ventricular arrhythmia and cardiomyopathy after 
stellectomy of the left ganglion stellatum (Table 2).
 
Table 4. Clinical data on 3 AVB cases in which drug therapy was applied.
Year Fetal heart rate Fetal 
hydrops
Maternal and direct fetal drug 
therapy
Outcome
1996 45 beats/minute 
(3o- block)
no DXM → DXM + R → cs 
at 37 weeks
Died at 1.5 years of age
2001 48 beats/minute 
(3o- block)
yes R → cs at 30 weeks Died 2 days after birth
2005 45 beats/minute 
(2o- block)
yes F → cs at 34 weeks Cardiomyopathy, 
pacemaker, severe 
developmental delay




We studied perinatal management and long-term cardiac outcome of a consecutive cohort of 
fetuses with tachy- and bradyarrhythmias. 
In the SVT and AF group mortality was remarkably low (6%) and limited to one postnatal 
death due to severe metabolic disease and one case of termination of pregnancy due to trisomy 
21. In contrast to other studies,2,5 there was no tachycardia-related mortality despite presence 
of fetal hydrops, young gestational age and the need for maternal or direct fetal drug therapy 
in a significant number of cases. There is a broad experience in management of fetal SVT and 
AF, although studies in literature remain limited to retrospective case series.17,18 In general, 
maternal drug therapy is opted if tachycardia is intermittent or incessant before 32 to 35 weeks 
of gestation. Digoxin is often used for SVT and AF in non-hydropic fetuses, although many 
centers nowadays prefer sotalol or flecainide as drug of choice. Sotalol appears to be more 
effective than digoxin for treatment of AF.19,20 In the presence of fetal hydrops, flecainide or 
amiodarone has become the therapy of choice for SVT.5
 In 2006, Cuneo et al. reviewed literature with regard to the outcome of fetal tachyarrhythmias. 
They report conversion rates in SVT cases in the range from 23-62% with standard 
transplacental therapy with relative low mortality in this group.  If second-line agents were 
indicated, mortality rates of 19% with flecainide and 25-30% with sotalol were reported. The 
combined mortality rate for hydropic and non-hydropic fetuses with AF was 8%.21 There was 
no tachycardia-related mortality in the present series, which may be explained by relatively 
Table 5. Management and neonatal outcome in live-born infants (n=40).








Neonatal arrhythmia – % (n) 78 (22) 67 (4) 100 (6)
Neonatal ward admision – % (n) 89 (25) 100 (6) 100 (6)
Admission duration – daysa 6 (1 – 61) 6 (4 – 21) 22 (2 – 42)
Mechanical Ventilation at birth – % (n) 14 (4) 33 (2) 83 (5)
Neonatal anti-arrhythmic therapy – % (n) 86 (19) 67 (4) 100 (6)
Anti-arrhythmic medication – % (n) 61 (17) 17 (1) -
+ electric cardioversion – % (n) - 33 (2) -
+ accessory pathway ablation – % (n) 7 (2) 17 (1) -
+ pacemaker implantation – % (n) - - 83 (5)
+ implantable cardioverter – defibrillator – % (n) - - 17 (1)
aValue given as median (range).
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aggressive treatment strategies with timely switch to alternative transplacental therapies or 
direct fetal drug therapy after failure of first or second line therapy especially in young and 
hydropic fetuses. 
Thus far, there are very limited data on long-term postnatal outcome of fetal tachycardias.1 
Similar to other studies, AF resolved spontaneously or after cardioversion in all fetal AF cases. 
Interestingly, we found the presence of an accessory pathway in 2/6 fetal AF cases, which has 
been reported previously.22 In the present study the majority of SVT cases remained 
symptomatic and required drug therapy after birth and two neonates even underwent 
radiofrequency catheter ablation in the first months of life. Twenty-one percent of SVT cases 
had WPW syndrome, which corresponds to the incidence of WPW syndrome in neonates with 
SVTs.14 In the present series none of the SVT group required medication at median age of 72 
months and only one child had mild symptoms. These findings indicate that around 90% of 
the fetal SVT group, including those with WPW syndrome, becomes asymptomatic without 
medication after the age of one year. These findings slightly differ with series on AVRT in 
neonates showing a low recurrence rate in AVRT cases without WPW syndrome but a high 
recurrence rate in AVRT cases with WPW syndrome.14 
In this cohort, ventricular preexcitation (WPW syndrome) disappeared in 3 of 5 patients but 
also newly appeared in one patient on follow-up. There is a risk of sudden cardiac death in 
approximately 1% of patients with WPW syndrome, caused by atrial fibrillation and a fast 
ventricular response through the accessory pathway.23 Therefore, we advocate to perform 
ECGs at around 8-12 years of life in all children with fetal AVRT to identify possible cases 
of WPW syndrome. Curative treatment by catheter ablation has become first line therapy in 
older symptomatic children and adults with WPW syndrome and should be considered in older 
asymptomatic children after episodes of fetal AVRT.24
In the present series the outcome of the group of fetal AVB was disappointing and 7/9 AVB 
cases died, including one of the two cases with auto-immune mediated AVB due to 
cardiomyopathy. The poor clinical outcome of this small series can be explained because the 
majority of AVB cases had either severe CHD (n=5) or LQTS8 (n=2), a severe type of LQTS 
with poor postnatal prognosis due to lethal ventricular arrhythmias. Previous reports have 
shown that fetal AVB has relatively poor prognosis and mortality rates are high during the 
first 12 months of life.25 Jaeggi et al. described clinical outcome in large series of AVB cases. 
In cases of autoimmune mediated AVB the rates of live birth and 1-year survival were 88% 
and 75% respectively as compared to rates of only 56% and 19% in cases associated with 
major structural CHD (P<0.0001). They conclude, like in earlier reports, that AVB associated 
with major structural heart disease other than cc-TGA has an extremely poor outcome.26 In 
fetuses with AVB and left atrial isomerism survival rates between 0 and 22% have been 
reported.21 The use of dexamethasone as therapy for auto-immune-mediated AVB remains 
controversial. Several studies have reported improved survival rate after introduction of 
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dexamethasone treatment for fetal auto-immune AVB.11 In contrast, a recent study by Lopes 
et al. described the clinical outcome of 116 fetuses with autoimmune-mediated AVB (49%) 
and CHD related AVB (51%), mainly left atrial isomerism. They showed high survival rate 
(>90%) in untreated fetuses with autoimmune-mediated AVB, questioning the rationale for 
steroid therapy in this group. This study further confirmed that poor outcome is highly 
associated with CHD, fetal hydrops and a slow ventricular rate (<55 bpm).27 
In conclusion, fetal SVT and AF has low mortality and excellent long-term prognosis, although 
in some cases aggressive treatment strategies, including direct fetal therapy and radiofrequency 
catheter ablation in the first year of life, are required. Furthermore, we recommend ECG 
screening before adolescence to detect WPW syndrome in this patient population. Fetal AVB 
in the presence of CHD or long QT-syndrome has a dismal prognosis with high pre- and 
postnatal mortality. 
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For several decades researchers all over the world, driven by curiosity and in their way to 
discover new treatment modalities for cardiovascular disease, tried to unravel unexplored 
processes within cardiovascular development. Although knowledge significantly increased 
on certain mechanisms underlying this complicated developmental process other questions 
automatically occurred, creating the basis for future (ongoing) research.       
In this thesis we focused on normal and abnormal cardiac development in relation to congenital 
heart disease and supraventricular arrhythmias. In Part I of this thesis we described the 
development of the posterior heart field (PHF) derived venous pole of the heart specifically 
in correlation to the role of Shox2 (Chapter 2 and 3)1 and podoplanin (Chapter 4 and 5)2,3 
in that particular area. Furthermore, the developmental processes in this region seem to have 
an important role in the anlage of the cardiac conduction system (CCS) and epicardial lineage 
development of the heart. In the second part (Part II) the aetiology of a specific subtype of 
supraventricular tachycardias (SVTs) i.e. atrioventricular (AV) re-entry tachycardias (AVRTs) 
are related to normal heart development in mammals (Chapter 6 and 7).4 Finally, Chapter 
8 demonstrates the late outcome of fetal brady- and tachyarrhythmias.5       
 
PART i   THe PosTeRioR HeART FieLD
9.1 cARDiAc DeVeLoPMeNT AND THe HeART FoRMiNG FieLDs
In the early tri-laminar embryonic body the up-regulation of specific genes i.e. GATA-46 and 
Nkx2.57,8 in the splanchnic mesoderm already demarcates the heart forming regions. At the 
present time it is well accepted that the cardiomyocytes forming to the heart derive from two 
progenitor areas, the so-called first and second heart fields (or lineages).9-11 As mentioned in 
Chapter 1, it is still unclear whether the contribution of these progenitor areas / fields occurs 
in a strictly separate manner or that it may be regarded as a continuum during cardiogenesis.
The first heart field gives rise to the primary heart tube by fusion of the two laterally located 
cardiac mesodermal primordia. This primary heart tube mainly encompasses the AV canal and 
the future left ventricle, which is connected to the inflow and outflow tract. Lineage tracing 
and immunohistochemical expression studies indicated that these first heart field derived 
cardiomyocytes of the primary heart tube express Nkx2.5 and become negative for Isl1 after 
differentiation.9,12 Subsequently, at the venous as well as the arterial pole second heart field 
(SHF) derived cardiomyocytes are added to this primary heart tube.9,10,13-16 At the arterial pole 
the contribution of the SHF has been divided into two sub-lineages i.e. the anterior16,17 and 
secondary heart fields15 contributing Isl1 positive cardiomyocytes to the proximal and distal 




and maturation is a highly complicated and an appealing cardiac structure, it lays outside the 
scope of the current thesis. Here, we specifically studied the contribution of the SHF to the 
venous pole of the heart i.e. the PHF due to the conserved expression of Shox2 (Chapter 2 
and 3)1 and podoplanin (Chapter 4 and 5)2,3 in that particular area. 
In contrast to the Nkx2.5 positive myocardium from the first heart field, we observed an 
addition of Nkx2.5 negative cells that were positive for Shox2 and podoplanin as well as the 
myocardial marker MLC-2a at the venous pole of the heart.1,2 This population of cardiomyocytes 
is considered to be derived from the PHF and highly resembles the SHF derived Isl1 positive 
cardiomyocytes that are added to both poles of the primary heart tube.9,13 Moreover, Isl1 mutant 
mouse embryos fail to extend their primary heart tube at the arterial as well as venous pole.9 
Similar developmental abnormalities were also observed at the venous pole of Shox2 and 
podoplanin mutants where there is hypoplasia of the Nkx2.5 negative / MLC-2a positive 
myocardium, which can be studied in Chapter 2, 3 and 5. 
9.2 THE PHF IN CARDIO-MORPHOGENESIS WITH RESPECT TO THE ROLE 
oF SHOX2 AND PODOPLANIN
The contribution of the PHF to the venous pole of the heart is suggested to start around 8.5 
days post conception (dpc) of mouse heart development shortly after looping of the heart tube 
has started. In chick however, addition of PHF derived cardiomyocytes occurs already in the 
tubular heart stage, since in avian the configuration of a tubular straight heart remains present 
longer as compared to mammals. The signaling pathways and specific genes involved in the 
development of the PHF partially do have overlap with the SHF derived cardiomyocytes at 
the outflow tract of the heart: Isl1,9 Id2,18 Mesp-1,19 Pitx2,20,21 SP3,22 T-box genes 2 and 3 (Tbx2, 
Tbx3)23,24 and the bone morphogenetic genes 2 and 4 (Bmp2, Bmp4).15,25 Furthermore, a subset 
of transcription factors has been identified to be solely responsible for PHF anlage i.e. 
Tbx18,12,26 Tbx527 as well as the genes described in this thesis: Shox2 (Chapter 2 and 3)1,28 
and podoplanin (Chapter 4 and 5).2,3 
In Chapter 4 and 5 we demonstrate a common gene expression pattern within the PHF derived 
cardiomyocytes in the podoplanin mouse model. In early mouse heart development the 
expression of podoplanin in the cuboidal-shaped epithelium of the coelomic cavity and the 
adjacent MLC-2a positive sinus venosus myocardium stimulates the possibility that the dorsal 
coelomic cavity encompasses the area where the PHF derived cardiomyocytes originate from.2,3 
A cuboidal-shape of the epithelium is related to an active Epithelial-to-Mesenchymal 
Transformation (EMT) process, which can also be observed in other areas during cardiogenesis, 
like the developing AV cushions29,30 and the epicardium.31,32 Interestingly, for podoplanin a 
role in cell migration and invasion in EMT has been established in several cancer types.33 
188
chapter 9
In this thesis we were able to demonstrate that during cardiogenesis a similar podoplanin 
mediated EMT processes in the coelomic epithelium occurs via interactions with E-cadherin 
and Rho-A (Chapter 5).3 For Shox2 a functional link with regard to the EMT process has not 
yet been demonstrated. Moreover, it is not expressed in the cuboidal-shaped coelomic 
epithelium so that a contributory role in EMT remains to be investigated.
The first impression of the important role of the PHF in heart development became obvious 
by studying the expression patterns of podoplanin and Shox2 in the developing heart. Both 
genes showed to have a highly restricted spatio-temporal expression pattern that largely 
overlaps at the developing venous pole of the heart. These areas include the myocardium in 
which the sinus horns are embedded, the pulmonary veins, the venous valves and parts of the 
developing CCS including the sinoatrial node (SAN), AV node (AVN) region, common bundle 
(CB) and primitive bundle branches.1,2 Moreover at the venous pole expression of podoplanin 
and Shox2 was also observed in the pro-epicardial organ (PEO) from which the epicardium 
derives (Chapter 9.2.1 “PHF and epicardial development”).1,2,34 The abrogated development 
of the sinus venosus myocardium and epicardial lineage in Shox2 as well as podoplanin 
knockout mouse embryos confirmed the important role of the PHF in cardiogenesis. 
Interestingly, mutations in several other genes that have a critical role in PHF anlage show a 
comparable abnormal cardiac phenotype including: hypoplasia of the sinus venosus 
myocardium leading to a diminished incorporation of the sinus horns in the developing heart; 
hypoplasia of the venous valves, the atrial myocardium, the atrial septum and abnormal 
development of the dorsal mesenchymal protrusion as was demonstrated recently in the Pdgfr-α 
knockout mouse.35 Furthermore, abnormal pulmonary vein development has been described 
in podoplanin mutants.36    
Shox2 not only has a role in the anlage of the sinus venosus but also in differentiation of the 
PHF derived cardiomyocytes.1,28,37 The PHF derived sinus venosus myocardium is characterized 
by expression of MLC-2a and the pacemaker channel HCN4 and absence of Nkx2.5, Cx40, 
Cx431 and Nppa at early stages of development.28 At later stages (>14.5 dpc) except for the 
SAN, the sinus venosus myocardium attains an “atrial differentiation program” becoming 
positive for Nkx2.5, Cx40, Cx43 and Nppa and loosing expression of HCN4.38 As from that 
moment expression of Shox2 becomes limited to the SAN region. Therefore, Shox2 is postulated 
to have an essential role in differentiation of PHF derived myocardium. This is further 
substantiated by the fact that the hypoplastic SAN and sinus venosus myocardium in Shox2 
mutants shows an aberrant expression pattern resembling to that seen in normal atrial working 
myocardium.1,28 The exact signaling pathways via which Shox2, most likely in combination 
with other genes, regulates differentiation of the sinus venosus myocardium remain to be 
elucidated. However, some strong candidates are Tbx3,39 Tbx5,37 Pdgfr-α35 and Pitx2c,40 which 
all show a specific spatio-temporal expression pattern in the PHF derived sinus venosus 




9.2.1 PHF and epicardial development
The epicardium covering the outer layer of the heart derives from the PEO, a cauli-flower like 
structure located near the sinus venosus area of the developing heart. From the PEO, epicardial 
cells start to migrate to cover the complete surface of the heart.41 The epicardium, covering 
the outflow tract of the heart derives from a separate region.42 After spreading of the epicardium 
subsequent EMT of these cells leads to formation of the EPDCs, which enter the heart to fulfill 
several roles within cardiac development.41 The significant role of the epicardium in 
cardiogenesis is largely demonstrated in avian hearts with mechanical / chemical inhibition 
of the epicardial outgrow from the PEO, leading to several cardiac malformations, including: 
myocardial non-compaction, abnormal development of the coronary arteries,43 AV valves,44 
Purkinje fibers45 and a disturbed anlage of the annulus fibrosus resulting in accessory pathways 
(APs) causing ventricular pre-excitation.44,46 Furthermore, abrogated epicardial lineage 
development may also result in an aberrant cardiac looping process as observed in Sp3 mutant 
mouse embryos.22
Several genes including, Shox2 (Chapter 3), podoplanin,34 Pdgfr-α,35 Tbx527,47 and Tbx1848 
involved in sinus venosus / PHF anlage also seem to have an imperative role in epicardial 
lineage development. A postulated common pool of progenitor cells from which both the PHF 
and the PEO derive may explain why abnormal PHF and epicardial lineage development 
frequently coincide. Interestingly, recent studies demonstrated a specific region in the dorsal 
mesocardium characterized by Tbx18 positive and Nkx2.5 negative cells, which contributes 
to both the sinus venosus and PEO in developing hearts.12,49 Although in these studies this 
specific area located in the dorsal mesocardium was not referred to as the PHF-region, we 
truly consider that with respect to the role of this specific area in heart development, it perfectly 
matches with the definition of the PHF.  
In Chapter 3 the disturbed epicardial lineage development in Shox2 mutants was demonstrated. 
The spreading and migration of the epicardium in these mice seemed not to be as abnormal 
as observed in podoplanin and Pdgfr-α knockout mouse embryos, which also showed severe 
epicardial blebbing and multiple myocardial perforations in the ventricles.34,35 These phenotypic 
differences may be related to the observation that unlike Shox2, podoplanin and Pdgfr-α are 
expressed in the complete epicardium covering the heart where both are suggested to be 
involved in local EMT processes. Moreover, Pdgfr-α has recently been demonstrated to be 
involved in regulation of Wt1,35 which has a major role in regulation of snail and E-cadherin, 
representing two key factors in the EMT process.50 Similarly, podoplanin (as was demonstrated 
in Chapter 5)3 also contributes in the regulation of EMT mediators. Consequently, we postulate 
that especially the local involvement of factors like podoplanin and Pdgfr-α in EMT leads to 
a more severely abrogated epicardial lineage development as compared to those who are only 
expressed in the PEO during cardiogenesis, like Shox2 (Chapter 3).   
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9.2.2 The PHF in relation to development of the ccs 
Two theories have been put forward regarding the development and origin of the cardiomyocytes 
contributing to the CCS (Chapter 1.4.1 “The origin and development of the CCS”). In short, 
the “specification and ballooning theory” state that the CCS derives from pre-specified 
cardiomyocytes in the primary heart tube. During cardiogenesis, these cardiomyocytes will 
retain their primitive phenotype by expression of specific genes / transcription factors that 
will prevent these cardiomyocytes to attain a working myocardium phenotype.51-53 The second 
theory, the “recruitment theory” states that the CCS derives from a pool of multi-potent 
undifferentiated cardiomyogenic cells.54-56 
As discussed in Chapter 4,2 the second theory is more in line with the contribution of the PHF 
to the formation of the CCS, since it does not exclude other cell lineages to be involved i.e. 
the NCCs57,58 and the PHF (including the epicardium). Moreover, with respect to our 
observations in the Shox2 (Chapter 2 and 3)1 as well as podoplanin (Chapter 5)3 mouse 
model, we conclude that the CCS is not a completely primary heart tube derived structure, 
which argues to the first theory. However, in our opinion the concept of the heart fields 
including the PHF, demonstrated that overlap exists between the two main theories. Recently, 
Christoffels and Moorman59 also did an attempt to link both theories. They suggested that 
cardiomyocytes that are recruited according to the “recruitment theory” can be considered as 
the precursor cells, which via the “specification and ballooning theory” will contribute to the 
definitive structures of the CCS.59 Unfortunately, the place of second heart field derived 
structures was not specifically included in these considerations.
Our data indicated that newly added PHF derived cardiomyocytes to the venous pole, which 
can be recognized by their unique expression pattern (i.e. positive for MLC-2a, HCN4 and 
negative for Nkx2.5, Cx40 and Cx43), contribute to major parts of the CCS (Chapter 2, 3 
and 5).1,3 In the embryonic heart areas similar in expression pattern and location have also 
been described in the “specification and ballooning theory” that contribute to the mature CCS 
and are referred to as primitive myocardium.51-53 Interestingly, as mentioned in Chapter 1.4.1 
“The origin and development of the CCS”, the areas of primitive myocardium also show 
overlap with the transitional zones i.e. the sinu-atrial transition, AV transition, primary ring 
and ventriculo-arterial transition (Chapter 1 - Figure 5c).60 These transitional zones can be 
discriminated based on the expression patterns of several markers involved in CCS 
development.61-64 Therefore, we may speculate that the primitive myocardium at the venous 
pole, which largely resembles to the sinu-atrial transitional zone, is PHF derived. The spatio-
temporal expression of specific transcription factors / genes like: Tbx2, Tbx559 and Shox2 
(Chapter 2 and 3)1 may regulate the differentiation of the PHF derived primitive myocardium 
so that it partially forms the CCS, whereas others parts will attain a working myocardial 
differentiation program. Most likely, comparable differentiation processes occur at other 




zones. Finally, with respect to the role of the heart fields in CCS development, it can not be 
excluded that some parts of CCS might have a contribution from the first (i.e. primary heart 
tube) as well as the second heart field.
In this thesis we mainly focused on development of the SAN a structure that can easily be 
discriminated in early stages of mouse heart development.65 In Shox2 and podoplanin knockout 
embryos the SAN is severely hypoplastic. Although it is now well established that the SAN, 
like the complete sinus venosus myocardium, is a PHF derived structure the exact signaling 
pathways involved in differentiation of this highly complex region remains largely unknown. 
Moreover, contemporary studies demonstrated that different regions within the SAN i.e. solid 
head (or node) and tail along the terminal crest, show distinct expression patterns of genes,39 
which has been related to the even more complex SAN electrophysiological properties.66 
However, we were able to unravel a small part of this complicated issue, by showing aberrant 
differentiation of SAN (and sinus venosus) cardiomyocytes in Shox2 mutants.1,28 In the SAN 
an up-regulation of Nkx2.5, Cx40, Cx43 and Nppa that normally encode for an atrial 
differentiation program was observed. This of course suggests an abnormal pacemaking 
function in Shox2 mutant hearts. Most strikingly, the Shox2 morpholino injections in Zebra 
fish embryos in Chapter 2 as well as the electrophysiological recordings in embryonic Shox2 
mutant mouse hearts in Chapter 3, indeed confirmed a decreased / bradycardic heart rate.1 
The lowered heart rate in Shox2 mutants has been related to a decreased expression or absence 
of the pacemaker channel HCN4 due to up-regulation of Nkx2.5.28 This of course seems to 
be a reasonable explanation since bradycardia has been reported in patients with mutations in 
the HCN4 gene.67 Remarkably, in our studies we did not find absence of HCN4 in Shox2 
mutant embryos. Moreover, the intensity of HCN4 expression in the hypoplastic SAN was 
comparable to that observed in embryonic wildtype hearts. So, what then could be the 
underlying mechanism of the lowered heart rate in mutants? 
In our opinion the hypoplasia of the SAN itself might explain its deteriorated function, since 
electrophysiological mapping studies in human68 and animal69-71 largely demonstrated that 
pacemaking occurs in a widely distributed area in the SAN creating a pacemaking complex. 
Under physiological circumstances, as cycle length decreases, the leading pacemaker area 
shifts towards the upper region in the SAN (head / solid node).71 On the other hand, an increase 
in cycle length leads to an inferior shift of the leading pacemaker area. In line with that, it 
seems reasonable to speculate that in case of hampered SAN anlage the physiological shift of 
the leading pacemaker-site through the pacemaking complex fails. Consequently, this might 
underlie the observed bradycardic heart rate in Shox2 mutant embryos. 
Besides the important role of the PHF in development of the SAN, the contribution of the 
PHF to others parts of the CCS was not studied in detail in this thesis. However, in embryonic 
hearts the expression of Shox21 and podoplanin2 highly overlap with other components of the 
developing CCS i.e. AVN, CB and primitive left and right bundle branches. Furthermore, 
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expression was observed in the myocardium of the atria that comprise the location of the 
internodal pathways. Notably, Espinoza-Lewis et al. did not find Shox2 expression in the CB 
and primitive bundle branches, so that the exact role of Shox2 in that particular part of the 
heart remains doubtful.28 Nevertheless, a more extensive role of the PHF in CCS development 
is strengthened by the observation that expression patterns of Shox2 and podoplanin highly 
resembles to that of other markers, which have been used to study CCS development like: 
CCS-LacZ,62 MinK-LacZ,64 Hnk-1,61,72 Leu773,74 and PSA-NCAM.75 In the near future lineage 
tracing studies most probably will have an essential role in unraveling the exact contribution 
of the PHF in development of the more peripheral regions of the CCS. 
9.2.3 The PHF in congenital heart malformations and clinical implications
In Part I of this thesis, we demonstrated that the PHF has a major role in heart development, 
as indirectly can also be appreciated by the high mortalities rates of Shox2 (Chapter 2 and 
3)1 and podoplanin (Chapter 5)3 mutant mouse embryos. Similar mortality rates have been 
reported in other mouse models for PHF development.35 
The PHF is involved in formation and differentiation of the sinus venosus myocardium but 
also has an important role in CCS and epicardial lineage development. Consequently, abnormal 
PHF anlage may encompasses a broad variety of cardiac malformations ranging from structural 
heart defects to certain types of cardiac arrhythmias, or combination of events like: the 
association between SAN dysfunction and atrial septal defects (ASD) in patients with mutations 
in the Tbx5 gene causing Holt-Oram syndrome;76 or mutations in Nkx2.5 that leads to disturbed 
AV conduction and ASD and / or ventricular septal defects (VSD).77,78
With respect to cardiac arrhythmias related to abnormal PHF development, we postulate that 
they may either occur secondarily to the structural cardiac malformations, or be due to abnormal 
myocardial differentiation of the PHF derived myocardium i.e. by the maintenance or re-
expression of the characteristic expression pattern (positive for MLC-2a, HCN4 and negative 
for Nkx2.5, Cx40 and Cx43) pre- or postnatally. Therefore, it seems tempting to speculate 
that the preferential location of arrhythmias like atrial ectopic tachycardia (AET) that are 
occasionally observed at fetal stages of development, is rendered by areas of abnormal 
differentiated PHF derived myocardium. However, to our knowledge a clear link has not yet 
been demonstrated.
Table 1 summarizes the cardiac abnormalities, which are postulated to be related to abnormal 




Table 1. Schematic representation of congenital heart defects that can be related to abnormal development of 
the Posterior Heart Field (PHF) derived myocardium. The PHF contributes cells to the sinus venosus / atrium 
and pro-epicardial organ from which the epicardial lineage develops, the congenital heart defects are separated in 
two columns correspondingly. Whether the PHF also contributes to the atrioventricular (AV) conduction axis remains 
uncertain, therefore this text is indicated in grey. The numbers in this table refer to the individual references that can 
be obtained from the reference list of this chapter. AVB indicates AV block; AVRT, AV reentry tachycardia; AVNRT, 




PART ii  NoRMAL HeART DeVeLoPMeNT iN ReLATioN To AVRT
The development of the mature impulse propagation through the heart not only involves 
formation of the CCS, proper isolation of specific areas within the heart is extremely important 
as well. “Leakage” of the cardiac impulse might occur via so-called accessory AV myocardial 
pathways (APs) at locations where the isolating layer between the atria and ventricles, the 
annulus fibrosus, is absent. APs are involved in AVRTs, a sub-group of SVTs, which represent 
the largest group of tachy-arrhythmias within the pediatric age group.79 Strikingly, almost 
two-thirds of fetuses diagnosed with SVT based on AP-pathology remains free of arrhythmia 
before the age of one year without further medical treatment.80,81 
In Part II of this thesis we have related the process of normal heart development, including 
that of the CCS, AV junction and annulus fibrosus, to spontaneous disappearance of AVRTs 
at fetal and neonatal stages of development.        
9.3 DeVeLoPMeNT oF THe AV JUNcTioN iN ReLATioN To TeMPoRARY 
PReseNce oF APs
9.3.1 Development of the AV junction - Morphology
The AV junction is a complex region in the heart that harbors several important cardiac 
structures. Imagine that you are facing towards a mature heart from a superior view, from 
which the atria are cut-off in a transverse plane at the level of the AV junction. Then, two 
separate orifices including their valvular-apparatus can be discriminated; The mitral valve 
orifice at the left and at the tricuspid valve orifice at the right side. The fibrous tissue of 
the mitral and tricuspid valves is in continuity with the annulus fibrosus, surrounding both 
orifices (Chapter 1- Figure 7). In the septal region a single myocardial continuity i.e. the 
AV conduction axis can be discriminated that penetrates through the annulus fibrosus, to 
interconnect the atrial with the ventricular (septal) myocardium. This part of the CCS 
connects superiorly (atrial level) to the AVN and inferiorly (ventricular level) to the bundle 
branches. 
It is noteworthy, with respect to the developmental process underlying the AV junction, that 
at the very early embryonic stages the heart only consists of a single heart tube. This primary 
heart tube solely comprises the myocardium contributing to the future left ventricle and AV 
canal (first heart field derived) and directly connects to the cardiac in- and outflow tract. 
So, at these stages there is neither presence of an AV junction with two separate AV orifices 
nor a specialized AV conduction axis.82 Due to the addition of SHF-derived cardiomyocytes 
(Part I) and complex remodeling processes of the heart, including cardiac looping and 




independent AV orifices has been demonstrated by our group in a study on the development 
of the right ventricular inflow tract in CCS-LacZ transgenic mice.83 Shortly after looping 
of the heart tube, the contours of the primitive left and right ventricles can be discriminated, 
which are interconnected via the primary interventricular foramen. At these stages (mouse 
10.5 dpc; human ≈ E28), the atrial part of the heart still connects to the ventricular part via 
a single orifice, the primitive AV canal, which by then is mainly positioned above the future 
left ventricle (Chapter 1 - Figure 5). Subsequently, due to outgrowth of the right ventricle, 
a remodeling of the primary fold will occur, that will eventually form the right ventricular 
inflow tract.83 Eventually, by completion of ventricular septation and remodeling of the 
endocardial located AV cushions, which mainly contribute to formation of the mitral and 
tricuspid valves, the two individual AV orifices including their valvular apparatuses will 
appear.
More or less subsequent to formation of the mitral and tricuspid valve orifice, the separation 
of the AV myocardial continuity in the AV canal is initiated. This process of annulus fibrosus 
formation, as was already mentioned in Chapter 1.5.1 “Annulus fibrosus: The isolating 
system”, involves interaction between epicardially located AV sulcus tissue and endocardial 
located AV cushion tissue.84-88 In Chapter 6 and 7,4 we demonstrated that formation of the 
annulus fibrosus in mouse as well as in human already starts at pre-septation stages of 
development, by formation of fibrous tissue near the primitive AV canal. Around the twelfth 
week of human development, as was also demonstrated by others,84 the complete atrial and 
ventricular myocardium are separated by the annulus fibrosus through which the AV conduction 
axis forms the only myocardial continuity between the atria and ventricles.  
In this thesis we mainly focused on the role of periostin, primarily known as osteoblast-
specific factor 2,89 in the formation of the annulus fibrosus. Periostin was postulated to 
have an important role within this particular process because of its proven ability to directly 
regulate collagen-I fibrillogenesis.90 In human (Chapter 7),4 mouse (Chapter 6) and 
quail44,46,91 hearts we did observe high expression of periostin in the developing annulus 
fibrosus especially at locations where isolation is mandatory, all the way through cardiac 
development. Intriguingly, state-of-the-art stem cell studies demonstrated that 
cardiomyocytes-like cells can be newly generated by reprogramming fibroblasts.92 With 
respect to that, it is thrilling to speculate whether a sort of natural differentiation mechanism 
occurs in an opposite direction near the AV junction so that cardiomyocytes become 
isolating fibroblasts that contribute to the annulus fibrosus. In this thesis, we did however 
not find a link that substantiates that hypothesis. Our periostin expression data in mouse 
showed that in the developing AV junction periostin is never co-expressed in cardiomyocytes 
(Chapter 6). For now we may only put forward that periostin is in someway involved in 
fibrous tissue formation given its proven role in collagen-I fibrillogenesis.90 Whether 
periostin is the key factor in AV isolation remains doubtful, since recent studies in periostin 
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mutant mice showed that periostin null mutants are largely normal and do not show an 
abnormal cardiac phenotype.93 
Other known factors involved in formation of the annulus fibrosus are bone-morphogenetic 
proteins (BMP) signaling94,95 and epicardial cells.44,46,96 The contributory role of BMPs and the 
epicardium is substantiated by the fact that disturbed BMP signaling in Alk3 knockout mice94 
as well as hampered epicardial outgrowth in quail44,46 leads to defects in annulus fibrosus 
formation with multiple abnormal myocardial AV connections (i.e. APs) between the atria and 
ventricles that are electrophysiological functional.44,46 The role of the epicardium / EPDCs in 
annulus fibrosus formation is substantiated by the observation that in vitro cell cultures of 
human and quail EPDCs express periostin so that they subsequently may have an important 
role in collagen-I fibrillogenesis.44 The contribution of especially the epicardium insinuates 
that the PHF (Part I) also has a role in annulus fibrosus development (Table 1). 
Nevertheless, there are still numerous unidentified signaling pathways involved in the 
anlage of the annulus fibrosus. Furthermore, it remains highly fascinating why formation 
of AV isolation especially does not occur in the AV conduction axis leading to complete 
AV block (AVB). 
     
9.3.2 Development of the AV junction - electrophysiology
The main purpose of annulus fibrosus development is to prevent “leakage” of the cardiac 
impulse from the atria to the ventricles (or the other way around) via APs that bypass the AV 
conduction axis including the AVN and His-Purkinje-system (HPS). Consequently, APs can 
only be identified once the AV conduction axis has become functional at a specific moment 
in cardiac development. Before the presence of this axis, the complete primitive AV canal 
myocardium itself renders the area for normal AV conduction. Fascinatingly, in a looped heart 
tube the primitive AV canal myocardium was already demonstrated to have slow conducting 
properties in chick.97 These conducting properties might be explained by a restricted expression 
pattern of certain gap junction proteins in that specific area.98,99 We for instance demonstrated 
that during development Cx43, involved in rapid impulse conduction through the atria and 
ventricles, is never expressed in the primitive AV canal / AV junction.99 (Chapter 6) In 
someway, these slow conducting properties of the primitive AV canal myocardium at the early 
stages of development resemble the decremental properties of the mature AVN that will reside 
in this specific area. Therefore, it is tempting to postulate that the AVN, at least partially, 
derives from this slow conducting primitive AV canal myocardium. 
During cardiac development the transition of the ventricular activation pattern from base-to-
apex into the mature apex-to-base activation coincides with a functional AV conduction axis 
mainly with respect to maturation of the HPS. Furthermore, studies in chick and quail hearts 
demonstrated that this process highly correlates with completion of ventricular 




developing heart”). However, as demonstrated in Chapter 6, the majority of normal developing 
embryonic mouse hearts already show a mature apex-to-base activation pattern far before 
completion of ventricular septation. This observation is substantiated by several optical 
mapping studies performed in pre-septated embryonic mouse hearts, which also demonstrated 
a functional AV conduction axis at these stages of development.63,102 These observations might 
indicate that: (1) the transition to a mature apex-to-base ventricular activation patterns in 
mouse hearts is not related to completion of ventricular septation as is suggested to be the case 
in avian hearts; (2) pre-septated embryonic mouse hearts may already have a functional and 
/ or preferential pathways for fast AV impulse propagation, which primarily activates the apex 
before the base in the developing ventricles. 
9.3.3 APs during normal heart development
The incidental presence of APs during normal heart development has already been reported 
in human,103-105 mouse83 and chick.106 Our group was the first that studied the presence and 
course of APs during subsequent stages of normal heart development. The initial studies 
performed in quail demonstrated the presence of electrophysiological functional APs, which 
appeared to be remnants of the early embryonic primitive AV canal myocardium. These 
APs were located around both the developing mitral and tricuspid valve orifice and 
decreased in number and size at subsequent stages of development.91 This thesis for the 
first time describes the presence and course of APs during normal mammalian heart 
development. In both mouse (Chapter 6) and human (Chapter 7)4 APs, more or less similar 
to those observed in quail, could be observed until late stages of fetal life, which gradually 
decreased in number and size.
Between species, some differences were observed in the preferential location of APs at the 
annulus fibrosus. At late stages of human heart development most APs were observed sub-
endocardially at the lateral aspect of the tricuspid valve orifice.4 Fetal quail hearts also 
demonstrated the majority of APs around that orifice, however in quail the APs were positioned 
to a more septal position in the AV junction.91 On the other hand, in fetal mouse hearts most 
APs were located at an antero-lateral position near the mitral valve orifice (Chapter 6).
The persistence of especially right sided APs at later stages of development, as observed in 
human and quail, might be related to the process that is involved in the formation of the right 
ventricular inflow tract. In contrast to the left ventricular inflow tract, the right inflow tract is 
a newly formed orifice which originates from a groove in the primary fold.83 In addition, the 
concept of the “transitional zones” (Chapter 1.4.1. “The origin and development of the 
CCS”), which describes the presence of four transitional zones in the looped embryonic heart 
tube based on the expression of CCS developmental markers, contributes to this idea. Especially 
the dorsal side of the right AV junction may be formed by a myocardium of three transitional 
zones: the sinu-atrial transition, the AV transition and the primary fold, as can also be 
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appreciated in Figure 5d in Chapter 1.60 The left AV junction however, only receives a 
contribution from the sinu-atrial transition and the AV transition. Consequently, we postulate 
that both the physiological delay and a far more complicated developmental process of the 
right AV junction explains the higher incidence of persistent right sided APs at late fetal stages 
of development. Furthermore, we may comment that the preferential location of persistent 
APs (in human) is not related to the location where annulus fibrosus formation initiates during 
heart development, since Chapter 7 describes that formation of this isolating structure starts 
near the right AV junction / future tricuspid valve orifice.4,84
As was demonstrated in Chapter 6, the majority of APs during fetal stages of mouse heart 
development are located near the mitral valve orifice. The mean AP-width also appeared larger 
at the left AV junction. Remarkably, unlike in avian and human,4,91 in all fetal mouse hearts a 
broad AP could be observed at an antero-lateral position near the mitral valve orifice. The 
presence of more or less identical pathways at this specific location in the developing AV 
junction has been reported before. Rentschler et al. demonstrated in their study on CCS 
development by means of LacZ expression several APs that interconnected the left atrium and 
ventricle along the free wall. These LacZ expressing APs, which were not part of the mature 
CCS, were observed at subsequent stages of development including neonatal mouse hearts 
and have been related to WPW-syndrome.63 Thus far, it remains unclear what exactly causes 
the high incidence of especially left sided APs in mouse fetuses, at least an interspecies 
differences can not be excluded.    
  
9.3.4 APs  - specialized tissue or ordinary working myocardium?
The APs studied in normal heart development in human (Chapter 7),4 mouse (Chapter 6) 
and avian91 are all supposed to be remnants of the early primitive AV canal myocardium. 
However, from electrophysiological studies we do know that not all APs share similar 
electrophysiological characteristics. In Mahaim tachycardia the APs have decremental 
properties resembling that of the AVN,107 which might indicate that some APs are composed 
of specialized conducting tissue. Furthermore, it is well known that APs involved in Mahaim 
tachycardia have a morphological-relation with the specialized CCS and interconnect the AVN 
or His bundle to the fascicles or ventricular muscle.108 Nevertheless, the question remains 
whether the presence of APs with decremental properties can also be related to the normal 
process of cardiac development. 
Contemporary studies by Jongbloed et al. related right ventricular inflow tract development 
to be one of the underlying mechanisms for atrio-fasciculair tracts. In that study functional 
APs were observed at the right AV junction, which connected to the right bundle branch via 
the moderator band.83 Interestingly, in Chapter 7 we demonstrated multiple APs between the 
developing AVN and the ventricular septal myocardium in human fetal hearts. These APs 




indicate that they have specialized conducting properties. Furthermore, we observed that the 
majority of APs at the tricuspid valve orifice are related to the right AV ring bundle (RAVRB). 
This ring of specialized cells located around the developing tricuspid valve orifice is believed 
to be a remnant of the more extensive embryonic CCS that deteriorates during fetal life. The 
RAVRB can be detected by expression of various markers for the developing CCS, like: HNK-
1,61,109 Leu7,73 CCS-LacZ.62,83 In several species a similar structure can also be recognized 
around the developing mitral valve orifice, which has been referred to as the left AV ring 
bundle (LAVRB).2,110,111 In young animals these ring bundles have also been found and tend 
to express a specific subset of markers, which also demarcate the CCS.110 The fact that these 
ring bundles make contact with the AVN via the AV nodal extensions might suggest a role in 
normal AV conduction, however at present there are no electrophysiological studies which 
support to this idea.110  
It seems tempting to postulate that APs with decremental properties (i.e. in Mahaim 
tachycardia) are those that are related to the embryonic CCS i.e. RAVRB or LAVRB located 
at the AV junction. The exact mechanism by which these ring bundles deteriorate remains 
unknown. However, we may speculate that ongoing myocardial differentiation as observed 
in other parts of the developing CCS has an important role so that these ring bundles (and 
if present the related APs) loose their specialized (decremental) properties and become 
ordinary working myocardium. 
9.4  AVRT IN THE FETUS AND THE YOUNG – CLINICAL IMPLICATIONS
The AVRTs represent the largest group of tachy-arrhythmias pre- and postnatally and can be 
potentially life-threatening.80,81 From fetal life up to adolescence, the APs underlying AVRT 
can present at the tricuspid as well as mitral valve orifice. The incidence of APs tends to be 
higher at the left / mitral valve orifice.112-114 The etiology of the APs underlying this specific 
type of arrhythmia is largely unknown. In a minority of cases genetic mutations are involved, 
like PRKAG-2 (in familiar WPW-syndrome)115,116 and ALK3 (in mice).94 Furthermore, high 
numbers of APs are found in combination with other forms of congenital heart disease i.e. 
Ebstein anomally117,118 and congenital corrected Transposition of the Great Arteries (ccTGA).119 
In rare cases, an intra-cardiac tumor has been reported to serve as substrate for AVRT.120,121 
Intriguingly, the majority of otherwise healthy fetuses and neonates that initially suffer from 
AVRT remain free of symptoms before the age of one year without additional anti-arrhythmic 
therapy (Chapter 8).5,79,81 A prolonged cardiac maturation during the first year of life might 
cause APs to spontaneously disappear, so that AVRT automatically resolves. This is supported 
by the observation that especially the development of the fibrous structures of the heart that 
includes the annulus fibrosus, extends into post-natal life.122,123   
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This thesis fully supports the theory that APs are remnants of the early primitive AV canal and 
that prolonged cardiac maturation leads to disappearance of AVRT during the first year of life. 
This theory is best substantiated by the observation that: (1) Functional accessory AV myocardial 
connections are present during normal mouse heart development that might serve as APs 
(Chapter 6);4 (2) These APs, which can be found around the tricuspid as well as mitral valve 
orifice, decrease in number and size at subsequent stage of heart development and accordingly 
might explain the self limiting character of AVRT (Chapter 6 and 7);4 (3) In human hearts many 
APs were related to the RAVRB that encompasses a part of the embryonic CCS that deteriorates 
later on, which might explain why some APs have specialized properties (Chapter 7). 
The ongoing maturation of the annulus fibrosus offers a good explanation for spontaneous 
AVRT disappearance. However, it remains uncertain why approximately one-third of patients 
have a recurrent episode of AVRT later in life.124 In line with that, it is still unknown why the 
incidence of certain forms of tachy-arrhythmia like AVNRT increases with age.81,125 At the 
moment there are no studies giving answers to those specific questions. It seems however 
interesting to state in general that cardiac development is not a process that is completed at 
the time of birth. Especially, for cardiac arrhythmias in the paediatric age group it might be 
speculated that postnatal cardio-morphogenesis has an important role. 
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This thesis consists of two parts: Part I (Chapter 2 - 5) illustrates the role of the posterior 
heart field (PHF) in cardiac development, mainly with respect to formation of the venous pole 
and parts of the cardiac conduction system (CCS). Furthermore, abnormal PHF development 
is related to congenital heart disease including conduction disturbances. 
Part II (Chapter 6 - 8) correlates the process of heart development with the etiology of 
atrioventricular reentry tachycardias (AVRTs) that are frequently observed during perinatal 
stages of development. 
Chapter 1 – The first chapter provides an extensive overview concerning the processes 
involved in heart development, which are studied and referred to in Part I and Part II of this 
thesis. In general it can be stated that the heart develops from two independent lineages of 
cardiomyocytes, the first (i.e. primary) and second heart field (SHF) respectively. The first 
heart field gives rise to the primary heart tube. Subsequently, newly generated SHF derived 
cardiomyocytes are added at the outflow as well as the inflow tract of the developing heart. 
The contribution of the SHF to the outflow tract is distinguished in an anterior and secondary 
heart field. At the venous pole we refer the contribution of the SHF as the PHF. The first 
chapter also describes the important contribution of the epicardium and cardiac neural crest 
cells in heart development. During cardiogenesis the cardiac conduction system is formed. 
The theories explaining the development of this highly specialized system, the individual 
components and the emerging impulse propagation are discussed. Furthermore, an introduction 
is provided on the formation of the isolating layer between the atria and ventricles: the annulus 
fibrosus. This structure has an imperative role in the strictly regulated impulse propagation 
through the heart. Defects in the annulus fibrosus lead to accessory atrioventricular (AV) 
myocardial pathways (APs) between the atria and ventricles, which may result in abnormal 
impulse propagation and AVRTs. This chapter concludes by discussing the different types of 
brady- and tachyarrhythmias including the current treatment modalities in fetuses and 
neonates.
PART i
Chapter 2 – The important role of the Short stature homeobox gene 2 (Shox2) is demonstrated 
in heart development. Shox2 is crucial for the anlage of the PHF derived myocardium at the 
venous pole of the heart including the sinus venosus myocardium, the sinoatrial node (SAN) 
and the venous valves as was shown by severe hypoplasia of these structures in Shox2 mutant 
mice. Shox2 null mutants furthermore, demonstrated marked atrial dilation and embryonic 
lethality between 12.5 and 13.5 dpc. A functional link between Shox2 and the early myocardial 
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marker Nkx2.5 was established. Absence of Shox2 leads also to aberrant differentiation of the 
PHF derived myocardium including up-regulation of Nkx2.5, Cx43 and Cx40 in the SAN, 
which suggests a disturbed pacemaking function. Shox2 antisense morpholino injections in 
Zebrafish embryos indeed confirmed presence of SAN dysfunction. 
Chapter 3 – In addition to the previous chapter, here electrophysiological experiments were 
performed in Shox2 mutant embryonic mouse hearts. Compared to wildtype, Shox2 mutants 
showed a decreased heart rate despite the presence of the pacemaker channel HCN4 in the 
hypoplastic SAN. Furthermore, a role for Shox2 in epicardial lineage development was 
demonstrated. Shox2 mutants have a smaller size of the pro-epicardial organ (PEO), normal 
epicardial spreading and decreased numbers of epicardium derived cells (EPDCs) at locations 
of a thin ventricular myocardial wall. Furthermore, abnormal ventricular morphology and 
trabecularization were observed, both possibly related to abnormal epicardial lineage 
development. These data substantiate the hypothesis that the sinus vensosus myocardium and 
the epicardium derive from a common pool of progenitor cells (i.e. the PHF). Both abnormal 
pacemaker and epicardial lineage development may contribute to the early embryonic death 
of Shox2 mutant mice.     
Chapter 4 – In this chapter the derivatives of the PHF were studied further by the expression 
of transmembrane protein podoplanin, a novel marker in heart development. Podoplanin not 
only stains the characteristic MLC-2a positive and Nkx2.5 negative PHF derived sinus venosus 
myocardium, but also the adjacent cuboidal-shaped coelomic epithelium near the sinus 
venosus. It was speculated that this podoplanin positive cuboidal-shaped coelomic epithelium 
represents the area from which the PHF derived cells originate via a process called epithelial-
to-mesenchymal transformation (EMT). Furthermore, podoplanin expression was present in 
the wall of the developing pulmonary vein and CCS including the SAN and the AV conduction 
axis. These data support the hypothesis that major parts of the CCS share PHF 
characteristics.
Chapter 5 – By using podoplanin mutant and wildtype mouse embryos, the role and possible 
mechanism of podoplanin in PHF development was further evaluated. Podoplanin null 
embryos demonstrated hypoplasia of the PHF myocardium including the SAN, the primary 
atrial septum, dorsal atrial wall and the myocardium lining the cardinal and pulmonary veins. 
An abnormal differentiation by up-regulation of Nkx2.5 and Cx43 in the hypoplastic SAN as 
demonstrated in Shox2 mutants (Chapter 2 and 3), was not observed. Chapter 5 confirms 
that the coelomic epithelium near the sinus venosus contributes to the PHF derived myocardium. 
In podoplanin mutants the epithelium lining the coelomic cavity showed an aberrant expression 
of E-cadherin and Rho-A, which are normally controlled by podoplanin. Therefore, it might 
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be concluded that podoplanin mutant mice suffer from a disturbed EMT process since both 
E-cadherin and Rho-A are key factors in EMT.
PART ii
Chapter 6 – This chapter describes the presence and course of functional APs at subsequent 
stages of normal mouse heart development. Electrophysiological unipolar electrode recordings 
in embryonic and fetal mouse hearts demonstrated the presence of multiple antegrade (atrium-
to-ventricle) conducting APs up till late stages of fetal life. Morphological analysis of these 
hearts clearly demonstrated and confirmed the presence of multiple APs crossing the isolating 
annulus fibrosus directly connecting the atrial and ventricular myocardium. These APs were 
all composed of primitive, Cx43 negative AV canal myocardium and could be observed around 
the developing mitral as well as tricuspid valve orifice. At subsequent developmental stages 
these APs significantly decreased in number and size around both AV orifices. The transient 
persistence of these APs could explain the high incidence of AVRTs in the perinatal period of 
human development.     
 
Chapter 7 – In this chapter the developing annulus fibrosus was studied in human embryonic 
fetal and neonatal hearts, to investigate whether APs are also present in normal human heart 
development as is the case in mouse (Chapter 6). Approximately up till six weeks of 
development the myocardium in the AV canal is continuous between atrium and ventricle. In 
the period thereafter the formation of the annulus fibrosus starts at the AV junctional area. APs 
were detected around the developing mitral as well as tricuspid valve orifice. Initially, these 
APs consisted of broad myocardial continuities crossing the annulus fibrosus. At later stages 
the APs only comprised single myocardial strands. Most APs around the tricuspid valve orifice 
were related to the right AV ring bundle (RAVRB), which is a remnant of the more extensive 
embryonic CCS. APs could be detected up till 20 weeks of pregnancy. From that moment and 
in neonatal hearts no APs were detected anymore. Reconstructions of the AV node area 
demonstrated multiple APs that directly interconnect the AV node with the myocardium at the 
top of the ventricular septum. These APs related to the AV node could be observed until 
birth. 
Chapter 8 – This chapter evaluates the perinatal management and cardiac outcome of fetuses 
that suffer from severe tachy- or bradyarrhythmia. A retrospective data analysis demonstrated 
a low mortality rate in fetuses with supraventricular tachycardia (including AVRT) and atrial 
flutter, although in some cases aggressive treatment strategies, including direct fetal therapy 
and radiofrequency catheter ablation in the first year of life, were mandatory. Furthermore, 
for detection of Wolff-Parkinson-White (WPW) syndrome, ECG screening before adolescence 




based on an AV block (AVB) coincides with high mortality rates especially in the presence of 
congenital cardiac anomalies and long QT-syndrome. 
Chapter 9 – The final chapter encompasses the general discussion of this thesis and discusses 
the contents of Part I and Part II. Part I describes the important role of the PHF in cardiac 
development including the sinus venosus myocardium, the epicardial lineage and parts of the 
CCS. We specifically shed new light on the anlage of the SAN. Although our data also 
insinuates a role for the PHF in formation of the more peripheral part of the CCS (i.e the AV 
node, bundle of His and bundle branches), lineage tracing studies are still mandatory to unravel 
the true contribution of the PHF to those parts of the CCS. Furthermore, abnormal PHF anlage 
is related to congenital heart malformations, including supraventricular arrhythmias. Part II 
discusses the normal development of the annulus fibrosus at the AV junction in relation to the 
persistence of myocardial continuities between the atria and ventricles, which might serve as 
an AP for abnormal AV conduction. Our data illustrates that the temporary persistence of these 
APs during heart development, might explain the presence and spontaneously disappearance 
of AVRTs in fetuses and neonates. However, question remains why some patients have a 
recurrent (or a de novo) episode of AVRT later in life, morphological as well as 
electrophysiological changes postnatally might be involved but ought to be studied in more 
detail in the future.                               
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sAMeNVATTiNG 
Dit proefschrift bestaat uit twee delen. Deel I (Hoofdstuk 2 – 5) beschrijft de rol van het 
“posterior heart field” (PHF) in de ontwikkeling van het hart, daarbij ligt de focus voornamelijk 
op de aanleg van de veneuze pool en delen van het cardiale impuls geleidingssysteem. Tevens 
wordt een gestoorde aanleg van het PHF gerelateerd aan congenitale hartafwijkingen inclusief 
hartritmestoornissen. In deel II (Hoofdstuk 6 – 8) wordt het proces van hartontwikkeling 
gerelateerd aan de oorzaak van atrioventriculaire (AV) reentry tachycardieën (AVRTs) die 
vaak rond de geboorte voorkomen.
Hoofdstuk 1 – Het eerste hoofdstuk omvat een uitgebreid overzicht van de verschillende 
processen die betrokken zijn bij de aanleg en ontwikkeling van het hart. In deel I en deel II 
van dit proefschrift zal naar deze processen worden gerefereerd, daarnaast zullen sommige 
van deze processen ook ten dele verder worden bestudeerd. Globaal kan worden aangenomen 
dat het hart is opgebouwd uit twee afzonderlijke hartspiercel vormende gebieden, te weten 
het “first heart field” en het “second heart field” (SHF). De hartspiercellen die het primaire 
hartbuisje vormen zijn afkomstig van het “first heart field.” Zowel aan de in- als de uitstroom 
van dit primaire hartbuisje worden nieuwe hartspiercellen toegevoegd, deze zijn afkomstig 
van het SHF. De bijdrage van het SHF aan de uitstroom van het hart kan worden onderscheiden 
in een “anterior heart field” en een “secondary heart field.” De toevoeging van de SHF 
afkomstige hartspiercellen aan de instroom van het hart hebben wij het PHF genoemd. Het 
eerste hoofdstuk laat ook de belangrijke bijdrage van het epicard en de cardiale neurale lijst 
cellen zien in de ontwikkeling van het hart. Tijdens het hartontwikkelingsproces vindt de 
aanleg van het cardiale impuls geleidingssysteem plaats. De hedendaagse theorieën betreffende 
de ontwikkeling van dit gespecialiseerde systeem, de afzonderlijke componenten van dit 
systeem, en de geleiding van de cardiale impuls door het ontwikkelende hart komen aanbod. 
Ook wordt een inleiding gegeven over de aanleg van de laag isolatie tussen de atria en de 
ventrikels: de annulus fibrosus. Deze isolerende structuur heeft een belangrijke rol in een 
gecoördineerde impulsgeleiding door het hart. Een defect in de annulus fibrosus leidt tot extra 
hartspiervezelverbindingen tussen atria en ventrikels, de zogenaamde “accessory pathways” 
(APs). De aanwezigheid van deze APs kan leiden tot een abnormale cardiale impulsgeleiding 
en het ontstaan van AVRTs. Tot slot wordt in het laatste deel van dit hoofdstuk ingegaan op 
de verschillende vormen van brady- en tachyaritmieën, inclusief de huidige behandelstrategieën 
bij foetussen en neonaten.
DeeL i
Hoofdstuk 2 – Dit hoofdstuk beschrijft de rol van het Short stature homeobox gen 2 (Shox2) 
in de aanleg en ontwikkeling van het hart. Shox2 heeft een essentiële rol in de aanleg van de 
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PHF afkomstige hartspiercellen aan de veneuze pool van het hart, inclusief de sinoatriale 
knoop (pacemaker) en de veneuze kleppen. Het belang van Shox2 in de aanleg van deze 
structuren wordt bevestigd door ernstige onderontwikkeling (hypoplasie) van deze structuren 
in muizen embryo’s met mutaties in het Shox2 gen. Daarnaast vertonen Shox2 gemuteerde 
embryo’s een ernstige vergroting (dilatatie) van de atria en gaan dood tussen dag 12.5 en 13.5 
van de ontwikkeling. Ook wordt in dit hoofdstuk een functionele link gelegd tussen Shox2 en 
de vroege hartspiercel marker Nkx2.5. De afwezigheid van Shox2 leidt tot een abnormale 
differentiatie van de PHF afkomstige hartspiercellen, onder andere resulterend in een verhoogde 
expressie van Nkx2.5, Cx43 and Cx40 in de sinoatriale knoop van het hart. Deze abnormale 
differentiatie van de sinoatriale knoop impliceert een gestoorde functie welke middels Shox2 
antisense morpholino injecties in Zebravis embryo’s wordt bevestigd. In de geïnjecteerde 
Zebravis embryo’s wordt een abnormale pacemakerfunctie waargenomen.
Hoofdstuk 3 – In navolging van het voorgaande hoofdstuk worden hier de resultaten besproken 
van de elektrofysiologische experimenten in harten van Shox2 gemuteerde muizen embryo’s. 
Ondanks de aanwezigheid van HCN4, het belangrijkste pacemaker kanaal, in de hypoplastische 
sinoatriale knoop van de Shox2 gemuteerde embryo’s vertonen deze harten tragere 
hartfrequenties vergeleken met de hartfrequenties van normale embryonale harten. In dit 
hoofdstuk wordt ook de rol van Shox2 in de ontwikkeling van het epicard beschreven. Shox2 
mutanten hebben een kleiner pro-epicard orgaan (PEO), laten normale epicardiale verspreiding 
zien, en hebben minder epicardium derived cells (EPDCs) met name op de plaatsen waar de 
wanden van de hartkamers dun zijn. Tevens wordt in Shox2 gemuteerde harten een abnormale 
morfologie van de ventrikels en het trabekelsysteem waargenomen, beide afwijkingen zijn 
mogelijke gerelateerd aan een abnormale aanleg en signalering van het epicard. Het feit dat 
Shox2 mutanten zowel epicardiale afwijkingen als een gestoorde aanleg van de hartspiercellen 
van de veneuze pool laten zien, draagt bij aan de hypothese dat beiden vanuit dezelfde 
hartvormende regio ontstaan, het PHF. De abnormale epicardiale ontwikkeling en de gestoorde 
pacemaker functie in Shox2 mutanten dragen mogelijk beiden bij aan de embryonale 
letaliteit.
Hoofdstuk 4 – In dit hoofdstuk worden de structuren van het hart die afkomstig zijn van het 
PHF verder bestudeerd aan de hand van de expressie van het transmembraan eiwit podoplanine, 
een nieuwe marker binnen het hartontwikkelingsonderzoek. Podoplanine kleurt niet alleen de 
karakteristieke MLC-2a positieve en Nkx2.5 negatieve sinus venosus hartspiercellen aan die 
allen afkomstig zijn van het PHF, maar ook het aanliggende kubische epitheel van de coeloom 
holte dat direct naast de sinus venosus harstpiercellen gelegen is. Gepostuleerd wordt dat dit 
kubische podoplanine positieve coeloomholte epitheel de regio representeert van waar de PHF 
hartspiercellen ontstaan door een proces genaamd: “Epithelial-to-Mesenchymal Transformation” 
Samenvatting
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(EMT). Expressie van podoplanine wordt ook waargenomen in de wand van de ontwikkelende 
pulmonaal venen en in het ontwikkelende cardiale impuls geleidingssysteem, onder andere 
in de sinoatriale knoop en de atrioventriculaire geleidingsas. Deze data draagt bij aan de 
hypothese dat belangrijke delen van het cardiale impuls geleidingssysteem en het PHF 
overeenkomstige eigenschappen vertonen.
 
Hoofdstuk 5 – Met behulp van normale muizen embryo’s en muizen embryo’s met een 
mutatie in het podoplanine gen, wordt in dit hoofdstuk de rol van podoplanine in de 
ontwikkeling van het PHF verder onderzocht. Podoplanine gemuteerde embryo’s laten een 
onderontwikkeling (hypoplasie) zien van de PHF afkomstige onderdelen van het hart, te 
weten: de sinoatriale knoop, het primaire atrium septum en de hartspiercellen gelegen rond 
de ontwikkelende cardinaal en pulmonaal venen. In deze embryo’s wordt echter geen 
abnormale differentiatie van hartspiercellen gezien zoals in Shox2 gemuteerde embryo’s 
met een verhoogde expressie van Nkx2.5 en Cx43 (Hoofdstuk 2 en 3). In hoofdstuk 5 
wordt bevestigd dat het epitheel van de coeloomholte grenzend aan de sinus venosus 
bijdraagt aan de PHF afkomstige hartspiercellen. In podoplanine gemuteerde embryo’s 
wordt in het epitheel van de coeloomholte een abnormale expressie van E-cadherin en Rho-A 
gezien, welke normaliter beiden door podoplanine worden gereguleerd. Gezien E-cadherin 
en Rho-A belangrijke factoren in het EMT proces zijn mag geconcludeerd worden dat dit 
proces in podoplanine mutanten verstoord is.
DeeL ii
Hoofdstuk 6 – Dit hoofdstuk beschrijft de aanwezigheid en het beloop van APs in 
opeenvolgende stadia in normale muizen hartontwikkeling. Elektrofysiologische experimenten 
middels unipolaire elektrode opnames in embryonale en foetale harten, tonen de aanwezigheid 
van vele in antegrade richting (van atrium naar ventrikel) geleidende APs tot op late foetale 
stadia van de ontwikkeling. Morfologische analyse van deze harten bevestigen de aanwezigheid 
van multipele APs die direct door de isolerende annulus fibrosus heen de hartspiercellen van 
de atria met de die van de ventrikels verbinden. Al deze extra verbindingen rond zowel de 
ontwikkelende mitralis als de tricuspidalis hartklep openingen bestaan uit hartspiercellen van 
het primitieve AV kanaal gekenmerkt door de afwezigheid van Cx43 expressie. Tijdens 
opeenvolgende stadia van de ontwikkeling vindt een significante afname van zowel het aantal 
als de omvang van de APs rond beide AV hartklep openingen plaats. Het tijdelijk persisteren 
van deze APs kan een verklaring zijn voor de hoge incidentie van AVRTs in de perinatale 
stadia van de ontwikkeling bij de mens.
Hoofdstuk 7 – In dit hoofdstuk wordt de ontwikkeling van de annulus fibrosus bestudeerd 




specifiek gelet op de aanwezigheid van APs zoals aangetoond tijdens normale muizen 
hartontwikkeling (Hoofdstuk 6). Tot ongeveer 6 weken van de ontwikkeling vormen de 
hartspiercellen van de atria en ventrikels een continuïteit via het primitieve AV kanaal. In de 
opeenvolgende periode start de formatie van de annulus fibrosus in het AV overgangsgebied. 
APs worden dan zowel rond de ontwikkelende mitralis als tricuspidalis hartklep opening 
waargenomen. Initieel omvatten deze APs brede AV continuïteiten van hartspiercellen, op 
latere stadia bestaan de APs slechts uit individuele bundels van hartspiercellen die door de 
annulus fibrosus direct de atria met de ventrikels verbinden. De meeste APs gelegen rond de 
tricuspidalis hartklep opening zijn gerelateerd aan de rechter AV ring bundel (RAVRB), een 
overblijfsel van het meer uitgebreidere embryonale cardiale impuls geleidingsysteem. APs 
werden tot 20 weken van de zwangerschap waargenomen, vanaf dat moment en in de neonatale 
harten konden geen APs meer worden geïdentificeerd. De reconstructies van het AV knoop 
gebied laten multiple APs zien die direct de AV knoop met de top van het ventrikel septum 
verbinden, deze APs werden tot aan de geboorte waargenomen.
Hoofdstuk 8 – Dit hoofdstuk evalueert de behandelstrategieën en de klinische uitkomsten 
van foetussen die in-utero gediagnosticeerd zijn met ernstige vormen van tachy- en 
bradyaritmieën. Middels retrospectieve data analyse wordt aangetoond dat foetale 
supraventriculaire tachycardieën (inclusief AVRTs) en atriumflutter gepaard gaan met een lage 
mortaliteit. Desondanks waren bij sommige patiënten wel agressieve behandelstrategieën 
noodzakelijk, zoals directe foetale therapie en radiofrequency katheter ablatie in het eerste 
levensjaar. Tevens wordt aangeraden om bij kinderen die een foetale supraventriculaire 
tachycardie hebben doorgemaakt nog voor de adolescentie een ECG screening te verrichten 
voor het Wolff-Parkinson-White syndroom, ook in die gevallen waarbij geen ventriculaire 
pre-excitatie aanwezig was op het postnatale ECG. De foetale bradyaritmieën die veroorzaakt 
worden door een atrioventriculair blok (AVB) hebben een hoge mortaliteit, specifiek wanneer 
deze gepaard gaan met andere congenitale hartafwijkingen of het lange QT-syndroom. 
Hoofdstuk 9 – Het laatste hoofdstuk omvat de algemene discussie van dit proefschrift, waarin 
afzonderlijk de inhoud van Deel I en Deel II wordt bediscussieerd. Deel I beschrijft de 
belangrijke rol van het PHF in hartontwikkeling inclusief de sinus venosus hartspiercellen, 
het epicard en delen van het cardiale impuls geleidingssysteem. Specifiek worden nieuwe 
inzichten getoond met betrekking tot de aanleg van de sinoatriale knoop. Ondanks het feit dat 
de resultaten beschreven in dit proefschrift ook een rol voor het PHF in de aanleg van de 
perifere delen van het cardiale impuls geleidingssyteem (AV knoop, bundel van His en 
bundeltakken) suggereren, zijn in de toekomst lineage tracing studies vereist om de ware 
bijdrage van het PHF aan die delen van het cardiale impuls geleidingssysteem te bevestigen. 
Tot slot wordt in Deel I een abnormale aanleg van het PHF gerelateerd aan congenitale 
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hartafwijkingen inclusief supraventriculaire hartritmestoornissen. Deel II bediscussieert de 
normale ontwikkeling van de annulus fibrosus in het AV overganggebied in relatie tot het 
persisteren van hartspiervezel continuïteiten tussen atria en ventrikels die kunnen fungeren 
als APs voor abnormale AV geleiding. Onze data illustreert dat het tijdelijk persisteren van 
APs tijdens de hartontwikkeling een verklaring kan zijn voor het optreden en het spontaan 
verdwijnen van AVRTs in foetussen en neonaten. Het blijft echter tot op heden onduidelijk 
waarom sommige patiënten een herhaalde (of een eerste episode) van AVRT doormaken op 
een later stadium van het leven. Mogelijk liggen postnatale elektrofysiologische en 
morfologische veranderingen in het hart hieraan ten grondslag, dit dient in ieder geval nog 
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